


# Exploring the Interdependencies of Research Funders in the UK

March 2014

OHE: K. Shah, J. Sussex, K. Hernandez-Villafuerte and M. Garau  
SPRU: D. Rotolo, M. Hopkins, N. Grassano, P. Crane, F. Lang,  
J. Hutton, C. Pateman, A. Mawer, C. Farrell and T. Sharp



# EXPLORING THE INTERDEPENDENCIES OF RESEARCH FUNDERS IN THE UK

REPORT BY THE OHE AND SPRU

Prepared for

CANCER RESEARCH UK

March 2014<sup>1</sup>

## Authors

OHE: Shah, K., Sussex, J., Hernandez-Villafuerte, K. and Garau, M.

SPRU: Rotolo, D., Hopkins, M.M., Grassano, N., Crane, P., Lang, F., Hutton, J., Pateman, C., Mawer, A., Farrell, C. and Sharp, T.

For further information please contact:

Jon Sussex

[jsussex@ohe.org](mailto:jsussex@ohe.org)

Office of Health Economics

Southside, 105 Victoria Street

London SW1E 6QT

United Kingdom

Tel: +44 207 747 1412 or +44 7789 435855

---

<sup>1</sup> The report was released to the public in June 2014.

## CONTENTS

Executive summary and key findings .....	1
1. Introduction and context .....	4
References for Chapter 1.....	5
2. Economies of scale in medical research .....	6
2.1 Introduction.....	6
2.2 Method .....	7
2.3 Literature review findings .....	8
2.4 Cost data .....	10
2.5 Additional findings from the interviews .....	12
2.6 Summary of economies of scale.....	13
References for Chapter 2.....	14
3. Funding interdependencies in neoplasms research .....	16
3.1 Introduction.....	17
3.2 Research methods .....	19
3.2.1 Limitations of the dataset construction for analysis and interpretation.....	20
3.2.2 Method for analysis of research funding schemes.....	21
3.2.3 Method for case studies of leading researchers .....	21
3.3 Scientometric analysis results: Contextual descriptive statistics.....	22
3.3.1 Publication numbers and outlets.....	22
3.3.2 Publications by UK research host organisations.....	23
3.4 Scientometric analysis: Interdependencies in neoplasm research.....	26
3.4.1 Collaborations among authors and interdependent host organisations.....	26
3.4.2 The interdependence of funding organisations .....	34
3.5 Scientometric analysis: Complementarities in neoplasms research .....	42
3.5.1 Complementarities across regions.....	42
3.5.2 Funder complementarities at research host organisation level.....	46
3.5.3 Complementarities across MESH codes within neoplasms .....	46
3.5.4 Complementarities across funding schemes.....	63
3.5.5 Researchers use of complementary funding schemes over time.....	71
3.6 Scientometric analysis: Diversity in neoplasm research .....	77
3.6.1 Diversity of funders and host organisations across scientific disciplines .....	77
3.6.2 Diversity of funders and host organisations across medical areas .....	81
3.7 Scientometric analysis: Additional perspectives.....	86
3.7.1 Funder, host organisations and highly-cited publications .....	86
3.7.2 Funder, host organisations and intensity of international collaboration .....	888

3.9 Future research .....	92
References for Chapter 2 .....	91
4. Complementarity/substitutability of government and charity funding of cancer research in the UK.....	95
4.1 Introduction.....	95
4.2 Updated literature review.....	96
4.2.1 Objectives and scope .....	96
4.2.2 Method .....	96
4.2.3 Findings.....	98
4.3 Stated preference survey.....	101
4.3.1 Objective .....	101
4.3.2 Methods.....	102
4.3.3 Results .....	106
4.3.4 Discussion.....	116
References for Chapter 4.....	118
Appendix to Chapter 3 .....	121
Appendix to Chapter 4 – Screenshots from survey .....	122

## EXECUTIVE SUMMARY

Investment in medical research is vital to the continuing improvement of the UK's health and wealth. It is through research that we expand our understanding of disease and develop new treatments for patients. Medical research charities currently contribute over £1 billion annually to medical research in the UK, of which over £350 million is provided by Cancer Research UK. Many charities, including Cancer Research UK, receive no government funding for their research activity.

Cancer Research UK is engaged in a programme of work in order to better understand the medical research funding environment and demonstrate the importance of sustained investment. A key part of that is the Office of Health Economics' (OHE) 2011 report "*Exploring the interdependency between public and charitable medical research*". This study found that there are substantial benefits, both financial and qualitative, from the existence of a variety of funders and that reductions in the level of government financial support for medical research are likely to have broader negative effects.

This contributed to other evidence which found that the activities and funding of the charity, public and private sectors respectively are complementary, i.e. mutually reinforcing, rather than duplicative or merely substituting for one another.

*"Exploring the interdependencies of research funders in the UK"* by the Office of Health Economics (OHE) and SPRU: Science and Technology Policy Research at the University of Sussex, represents a continued effort to build the evidence base around the funding of medical research.

**This report uncovers the extent to which funders of cancer research are interdependent, nationally and internationally. Key figures show that two thirds of publications acknowledging external support have relied on multiple funders, while just under half benefited from overseas funding, and almost a fifth are also supported by industry. In addition the analysis shows that the general public would not want tax funding of cancer research to be reduced, but would not donate enough to charities to compensate for any such reduction.**

Exploring the interdependencies between different medical research funders, particularly in cancer, provides us with a striking picture of the extent to which research funders contribute together to produce world class research. The findings provide a compelling case for why investment - by all sectors - is needed to allow the UK to continue to punch above its weight in terms of research outputs.

## KEY FINDINGS

### ECONOMIES OF SCALE IN MEDICAL RESEARCH

**A cut in research funding by a research funder might cause a slightly disproportionate fall in research activity, demonstrating a small effect of economies of scale.**

- However, beyond the short term, economies of scale appear to be exhausted at small sizes of research teams and research projects.
- There are exceptions of a few projects that entail expensive and highly specific equipment, IT systems or buildings that demonstrate the existence of economies of scale.

### FUNDING COMPLEMENTARITIES AND INTERDEPENDENCIES IN NEOPLASMS RESEARCH

**The UK produced almost 7% of global research publications on neoplasms<sup>2</sup> in 2011. To achieve this, scientists' host organisations and their funders worked in an interdependent and complementary way.**

- Over 1,000 UK organisations contributed to neoplasms research papers, and in doing so collaborated with co-authors in over 5,000 non-UK organisations.
- Funding acknowledgements appear in half of all publications and reveal that these papers by UK researchers benefited from the support of over 650 distinct UK funders and over 1,500 non-UK funders, as well as over 300 private organisations (many of them multinational).
- These publications were supported by an average of more than three funders per publication.
- Major funders strongly focus on pathology and genetics while surgery is relatively neglected.
- Minor UK funders are complementary to major UK funders as they focus on distinct neoplasm types.

### COMPLEMENTARITY/SUBSTITUTABILITY OF GOVERNMENT AND CHARITY FUNDING OF CANCER RESEARCH IN THE UK

**Most of the public's decisions about how much to donate to cancer research or other medical research charities are unaffected by government decisions on funding cancer or other medical research.**

- The vast majority of respondents stated that their out-of-pocket donations to cancer research and other medical research charities would not be

---

<sup>2</sup> Neoplasms are abnormal masses of tissue arising from an abnormal proliferation of cells. This term covers all forms of cancer research.

affected by changes in government funding levels or by being given the opportunity to allocate £100 of their income tax to these charities.

## 1. INTRODUCTION AND CONTEXT

The UK makes a disproportionately strong and successful contribution to the global medical research effort. An important element of this is the role of medical research charities alongside the public sector and private industry. Charities currently contribute over £1 billion annually to medical research in the UK (AMRC, 2013), about one third of which is provided by Cancer Research UK.

The public, charity and private sectors bring different strengths and emphases. The evidence is that the three sectors' activities and funding are complementary, i.e. mutually reinforcing, rather than duplicative or merely substituting for one another (Cancer Research UK, 2011; HERG et al., 2008; OHE, 2009; OHE, 2011). Taken together, this combined medical research effort generates not only health benefits to people all over the world, but also important economic gains to the UK (HERG et al., 2008).

The Government's June 2013 Spending Round maintained public funding of science research, including medical research, in cash terms until 2015/16, implying a gradual squeeze in real terms given expected inflation (as measured by the GDP deflator) of 2% per year (HM Treasury, 2013). The period of austerity and consequent pressure to constrain public expenditure is likely to continue beyond then.

Cancer Research UK was interested in gaining further understanding of the following:

- a) What is the difference between the diverse research activities supported by funders in the UK? Do these research activities complement one another? How interdependent are these research activities?
- b) If there was a cut in government funding for life sciences would other funders (private and public) be able to continue to support research activities? What would be the impact on the life sciences output in the UK?

In March 2013 Cancer Research UK awarded a grant to the Office of Health Economics (OHE) and SPRU: Science and Technology Policy Research at the University of Sussex to help answer these questions. This report sets out our work and has the following main elements:

- A high level investigation of the likely extent of economies of scale in charity- and publicly-funded medical research in the UK. It is based on a review of academic and grey literature on economies of scale in medical research, and a programme of interviews with major UK medical research funders plus analysis of cost data provided by them. This part of our work is reported in Chapter 2.
- Scientometric analysis (that is the science of measuring scientific research) was undertaken to establish the interdependencies and the differences between the diverse research activities supported by different funders of cancer research in the UK. This is reported in Chapter 3. We looked at research publications and tracked back to the funders identified



through these outputs. Our strategy made no *a priori* judgements on where UK researchers obtain funding and the results show the relative importance of all funders named or acknowledged in papers, including non-UK funders and industry.

- A study of the complementarity or substitutability of government and charity funding of cancer research in the UK, including a literature review. The main focus of this strand of our research is an internet survey of a sample of the UK general population. We use a stated preference design, informed by a prior focus group workshop, to assess how a change in Government funding of cancer research might affect public willingness to donate to cancer research charities. This part of our work is presented in Chapter 4.

## References for Chapter 1

AMRC (Association of Medical Research Charities). (2013) *Charity funded research. AMRC member research expenditure for 2012*. London: AMRC.

Cancer Research UK. (2011) *Building the ideal environment for medical research*. London: Cancer Research UK.

HERG, OHE, RAND Europe. (2008) *Medical research: what's it worth?* London: Medical Research Council, Wellcome Trust, Academy of Medical Sciences.

HM Treasury. (2013) *Spending round 2013*. Cmnd 8639. London: Her Majesty's Treasury.

OHE (Office of Health Economics). (2009) *Forward together: complementarity of public and charitable research with respect to private research spending*. Cambridge: Alzheimer's Research UK.

OHE (Office of Health Economics). (2011) *Exploring the interdependency between public and charitable medical research*. London: Cancer Research UK.

## 2. ECONOMIES OF SCALE IN MEDICAL RESEARCH

### Key Points

- There is some evidence in the literature of the existence of economies of scale in research but it is from a nearly 20-year old US study and is not specific to medical research.
- In the short term, cost data from UK medical research funders suggests a hypothetical 1% cut in research funding might initially cause an approximately 1.3% fall in research activity, but in the medium to long term the impact would be more proportionate.
- Beyond the short term, economies of scale appear to be exhausted at small sizes of research teams and research projects, with the exception of a few projects that entail expensive and highly specific equipment, IT systems or buildings.
- But even temporary cuts in funding can have long lasting consequences: reduced funding means less work for researchers in the UK, meaning that some will either leave the country or change careers, and not all would return to the UK or to research were funding to be increased again later.

### 2.1 Introduction

The impact on the output of medical research in the UK of a hypothetical cut in government funding depends on the answers to two questions:

- would changes in government funding affect the general public's donations to medical research charities?
- to what extent are there economies of scale in medical research? If economies of scale are significant then a 1% cut in medical research spending would reduce the outputs from that research by more than 1%.

We address the first of these questions in Chapter 4. Answering the second question is the subject of the remainder of the present chapter.

The presence (or not) of economies of scale is detected by measuring marginal costs relative to average costs. If marginal costs are below average costs then there are economies of scale: increasing the amount of activity would reduce the average cost of that activity; and conversely, reducing the amount of activity would raise the average cost of that activity.

Economies of scale are generated by the existence of fixed costs. In the short run, e.g. within a year, many costs may be 'fixed': not only the costs of buildings and equipment used but also overhead costs such as those of IT and information services, finance, personnel and general management staff. Over time many of the costs that are fixed in the short term become variable: overheads can be

scaled down or up; buildings and equipment can be turned to other uses, sold off, or simply not replaced when they wear out. Some costs may never be variable though. These are the 'sunk costs' associated with highly specific capital: physical capital such as specialised buildings or equipment (e.g. a synchrotron may have no other use than medical research, or no use that is nearly as valuable as medical research); and human capital, i.e. the specialised training and experience embodied in researchers that would not be nearly so valuable if those people had to find other employments.

Thus the existence and magnitude of economies of scale is dependent on the timescale under consideration. In the absence of sunk costs, all costs are ultimately variable and in that case economies of scale are a short to medium term phenomenon. We have attempted, therefore, to distinguish between short and long term effects.

To quantify precisely the magnitude of economies of scale in medical research would require access to, and detailed discussion and analysis of, disaggregated cost data from a representative range of organisations and individuals undertaking medical research in the UK. It is not clear that such data are currently available. RCUK and UUK noted in their review of the impact of 'full economic costing' of research that "The absence of robust cost data had led many institutions to underestimate the costs of research" (RCUK and UUK, 2009).

Separately identifying the costs of medical research is far from straightforward given that research is usually jointly produced (in higher education institutions) with teaching undergraduate and graduate students, and (in hospitals) with provision of health care services to patients. Allocating costs, e.g. between undergraduate education, postgraduate education and research at a university, is to some extent arbitrary. Plus there are very many different areas of research, which may share costs. Thus in a 'multi-product enterprise' such as a university there is a distinction between 'ray economies of scale' and 'product-specific economies of scale'. Ray economies of scale assume that the composition of output remains constant, while its scale is allowed to expand or contract. This gets round the multi-product nature of the enterprise by assuming that the quantity of teaching, say, is increased pro rata with the quantity of research. But a multi-product enterprise may expand outputs of different products non-proportionally, in which case ray economies of scale are not applicable. In such an environment, estimation of product-specific economies of scale allows a better understanding of the organisation's cost structure.

A further complication is that empirical studies of economies of scale need to measure not only the quantity of research outputs (which is itself not straightforward but is commonly proxied by numbers of research publications), but also should allow for the quality of those outputs (which is very difficult in practice), as a 1% cut in funding might lead to lower quality research as corners are cut, not just to less research.

## 2.2 Method

Thus, an empirical analysis of economies of scale in medical research would be a major undertaking. It would, furthermore, depend on the willingness of research

organisations (i.e. the recipients of research funding) to open their books to scrutiny of their costs. Such a study would have been well beyond the scope of the budget available for the current project. We therefore agreed with Cancer Research UK to undertake instead a high level assessment of the magnitude of economies of scale in medical research, based on:

- a review of economic and grey literature on economies of scale in medical research outside industry. There is a considerable literature on R&D in industry, especially in pharmaceutical companies, but our focus was rather on that research which is funded by the Government and/or charities. The review comprised: (a) a search (as at 6<sup>th</sup> August 2013) by title and (if warranted by the title) abstract of the first 100 hits found via Google Scholar and Google respectively using the search terms "economies of scale" AND ("medical" AND "research"); (b) obtaining grey literature on the subject of medical research funding in the UK, including literature recommended by interviewees; and (c) checking apparently relevant references in the bibliographies of relevant publications;
- interviews with senior representatives of the MRC, NIHR and OSCHR, the Wellcome Trust and Arthritis Research UK. The interviewees provided an overview of the fixed versus variable costs of the research funded by their organisations and indicated how their organisations might be expected to respond to reduced or increased funds for medical research;
- a group interview with five managers at Cancer Research UK with responsibilities related to allocation of funds to different types of research activity;
- analysis of cost data provided by interviewees on the balance between fixed and variable costs in medical research.

### 2.3 Literature review findings

All of the handful of relevant references found among the first 100 hits of the Google Scholar search were summarised in a book chapter by Cohn and Cooper (2004). These references discuss economies of scale in the production of university research, including medical research, in the context of empirical studies of economies of scale in higher education institutions. They are all econometric analyses and have as their main focus the measurement of economies of scale in university teaching but they also offer evidence (or appear to) on economies of scale in research as one of the products of universities seen as multi-product enterprises.

Dundar and Lewis (1995) examined econometrically the production of hours of student teaching and the number of research publications of 118 departments of 18 public research universities in the USA. They report finding, at the department level, both ray and product-specific economies of scale in undergraduate teaching, graduate teaching and research publications. In other words, the cost per research publication fell the larger the scale/funding of the university department, both when teaching and research are increased together in constant proportions and when research is increased by itself.

The only UK studies were by Johnes (1997 and 1998) and Izadi et al. (2002). Johnes (1997 and 1998) used academic year 1994/95 data for 99 UK universities to estimate a multi-product cost function with research as one of the products. 'Research' was not limited to medical or natural sciences research but covered all areas including humanities and social sciences. 'Research' was measured as the value of research grants. The results appear to show significant unexploited economies of scale in research overall at the then current average scale of UK universities. Izadi et al. (2002) analysed the same data as Johnes but used a different econometric approach. They also appeared to find economies of scale in research. Each of the UK studies concerns 'product-specific' economies of scale where the 'product' is the *value of research grants won*. In other words, larger universities win disproportionately more research grants, and smaller universities disproportionately few. Unfortunately, however, these UK studies say nothing about the outputs of the research carried out with those grants and hence nothing about what happens to the cost per research output as research funding is increased or reduced.

The Google review revealed two references of interest from the grey literature.

Vonortas and colleagues (2011) undertook an analysis for DG Research and Information of the European Commission of the economies of scale and scope at the project level in European Commission funded research. They analysed econometrically survey data from 1,172 organisations participating in 676 research projects funded by the 5<sup>th</sup> and 6<sup>th</sup> Framework Programmes for Research and Technological Development of the EU. This includes medical research but along with much non-medical research. The complex econometric analysis showed no statistically significant relationships between project size and outputs for publicly and charity funded research. Economies of scale were exhausted at small project sizes "well below the ... average project sizes that we observe". In summary they found that: "Taken overall, the econometric results indicate that increasing scale does not seem to improve project performance, with the notable exception of firms which seem to benefit from increasing scale in terms of their own funding, showing a positive effect mainly on commercial impacts." (Vonortas et al., 2011; both quotes taken from page 4).

In a review for the UK Government Office of Science and Technology, von Tunzelmann et al. (2003) looked at the impact of the size of research units on their research performance. The review was not limited to medical research. The studies they reviewed included the Dundar and Lewis (1995) and Johnes (1997) articles discussed above. Von Tunzelmann and colleagues concluded overall that:

"the key unit would appear to be the group or team, rather than the department or the university"

and

"there is reasonably convincing evidence of a size effect in the form [of] a 'critical mass' threshold. In many scientific fields, productivity seems to rise as the team size increases to about six or eight persons, above which there is usually little or no extra gain per capita."

This suggests that if a hypothetical cut in research funding were met by cutting discrete small teams rather than shaving resources from many more of them, the loss of research output would be proportionate to the funding cut rather than disproportionate.

Finally, one of the interviewees identified a 2009 report by the management consultants McKinsey (2009) of being of some relevance to the discussion of economies of scale. McKinsey sought to identify the distinguishing characteristics of high productivity medical research laboratories, based on interviews with "12 world-class academic innovators" and their own analysis of practices in 15 research laboratories in industry with different levels of performance and "several more academic laboratories". They identified five areas that distinguished high productivity labs: strategy decisions, talent management, portfolio and project management, problem solving, collaboration. The inclusion of portfolio and project management in the list implies a possible role for economies of scale, though more so for economies of scope: "The top labs design their portfolios of projects to be interlinked, so that they are both additive, in that the lab reaps benefits from their intellectual scale, and synergistic, in that each project might uncover insights that prove valuable to another." (McKinsey & Company, 2009).

Overall the literature is largely unhelpful about identifying the existence or not of economies of scale in medical research, in terms of research output per research pound spent. Such economies of scale as there are appear to be exhausted at small scales of research units. Consequently, if a hypothetical cut in medical research spending were met by closing down whole, albeit small, research teams rather than by squeezing across the board, the loss of research output might only be proportionate to the funding cut, rather than disproportionately damaging.

## 2.4 Cost data

Medical research in the UK is funded, indirectly as well as directly, from a variety of sources. This, plus the previously noted tendency for research to be conducted in institutions that are jointly producing research and teaching (and sometimes health care), from some or all of the same people and facilities, makes it problematic to determine the balance between variable and fixed costs incurred in the production of medical research. However, a review of literature on UK research funding arrangements, combined with information obtained in the interview programme, allows the following impressionistic picture to be constructed.

Some of the infrastructure necessary for universities to conduct medical research is paid for by "Quality Related (QR)" funding that UK universities receive from the higher education funding councils of the four countries of the UK in recognition of the quality and quantity of the research they achieve across all subject areas (UKCRC, 2012). Some of the infrastructure, including some staff costs, is also in effect paid for out of non-research funding streams received by universities. The 2010 Wakeham Report found that UK higher education institutions were reporting in 2008/09 a deficit of £2.187billion (24%) of research funding versus research costs.

The funding arrangements currently in place in the UK assume that 20% of full economic costs of research (whether medical research or any other kind) are met from QR and other underlying funding streams. The remaining 80% of full economic costs are supposed to be funded by research council and NIHR grants, and by grants from charities topped up by the tax-funded Charity Research Support Fund. Charities generally fund around 60% of full economic costs of research at universities. The interviewees from MRC and NIHR confirmed that this 20/80 split of funding of full economic costs was not based on any assessment of the split between fixed and variable costs of research, but was rather a political agreement.

The Wakeham Report recommended incentivising universities to improve efficiency in indirect costs, which are essentially overhead costs and which across all research councils (not just the Medical Research Council) were estimated to represent 30% of total research project costs. Direct costs were estimated at 61% of total research project costs, with estates costs making up the remaining 9%. (Estates costs are more usually included under the heading of indirect or overhead costs, but the Wakeham Report treated them separately as it explicitly did not propose cutting spending on that part of total research costs).

Information provided by Cancer Research UK implies a rather higher percentage of medical research costs are direct, i.e. short-term variable, costs than the Wakeham Report states for all (not just medical) research councils. An analysis of data provided by Cancer Research UK, of £155million of research grants (110 grants) awarded by them with start dates between June 2012 and May 2013 inclusive, shows that the costs of those projects have the following average split:

- directly incurred costs = 54% (min 20%; max 93%)
- directly allocated costs = 22% (5%; 56%)
- indirect costs = 24% (2%; 45%)

Thus there is wide variation from project to project but overall, short term variable costs (i.e. the direct costs) appear to average 76% of the total and indirect costs (overheads etc.) 24%.

Other data provided by Cancer Research UK shows the annual budgets of the five research institutes they fund. Out of total costs of £122million, 78% are identified as research staff costs and other research running expenses, which may be thought of as broadly equivalent to 'variable' costs. The other 22% were overhead costs, including administrative and support staff (e.g. information systems staff) and corresponding operating expenses, plus the annuitised costs of property and capital equipment.

Data provided by the MRC showed that of the total of £372million that the MRC committed in 2012/13 to fund grants and fellowships, 78% went on 'direct costs' (including 'exceptions', which are direct costs funded at 100% of 'full economic costs') and 22% on 'indirect costs'.

In summary, the 78/22 direct/indirect cost split for the MRC grants and fellowships matches the 78/22 direct/indirect split for Cancer Research UK's institutes, and is similar to the 76/24 direct/indirect split for Cancer Research UK's grants.

Taking a 78/22 or 76/24 split to represent the balance of variable versus short term fixed costs: a hypothetical 1% cut in research funding falling entirely on direct/variable costs would imply an approximately 1.3% cut in the short term in the amount of research activity.

However, in the medium to long term it would be possible to reduce the scale of infrastructure slightly so that research capacity and use of that capacity are once more brought into balance. To the extent that resources have been invested in highly specific human capital – specialist trained and experienced researchers – and highly specific fixed capital, meaning that the specialised skills/experience and equipment have much higher value in their current uses than in their next best alternative uses, then those economies of scale will persist even in the long run. Those costs are ‘sunk’, meaning that if that human and physical capacity is used less than fully then there will be irrecoverable waste. However, it is not possible on the basis of the information we found to determine what percentage of costs fall into the ‘sunk’ category.

## 2.5 Additional findings from the interviews

We asked the interviewees at Arthritis Research UK, MRC, NIHR, OSCHR and the Wellcome Trust how significant, if at all, they would expect short run and longer run economies of scale to be, and how they would expect a marginal reduction or increase in funds available for medical research to be allocated.

Three of the four interviewees who felt able to comment considered that although there might be economies of scale in medical research in the short run – because research capacity and overhead support functions cannot be created or abandoned immediately – in the longer run capacity could and would be adjusted in response to sustained increases or cuts in funding. The fourth interviewee largely agreed with this view but with the qualification that a minority of medical research in the UK is capital intensive, and furthermore that the physical capital involved was highly specific, implying substantial sunk costs and hence some long lasting economies of scale. Examples are: the Diamond Light Source synchrotron at Harwell; cancer biobanking; and research requiring high cost IT and imaging equipment.

When considering the likely impact of marginal reductions or increases in funding, an essential distinction is whether the changed funding level is expected to be a temporary aberration or a permanent feature. Temporary increases in funding would be expended on short duration projects, to avoid creating commitments that might not be sustainable beyond the current year. Temporary reductions would be met by delaying the starts of new projects or by attempting to squeeze efficiencies out of research activity already under way.

One particular issue, raised by two of the interviewees, was that temporary cuts in funding can have long lasting negative consequences. The fixed costs of educating and training researchers, combined with the international nature of labour markets for highly trained and expert people, mean that the funding ‘tap’ causes problems immediately it is turned off and these problems take time to be overcome even if the tap is turned back on again subsequently. When reduced funding means less work for researchers to do, they leave the country or leave



research for other careers. If funding were then to be increased again, not all of them would return to the UK or to research. Thus even temporary funding cuts cause long term damage. In general, planned cuts with advance warning (giving time to plan for them) are less damaging than sudden unexpected cuts.

Changes to funding levels that are expected to persist would generally prompt qualitatively different responses by research funders. The initial response to a cut in funds available might still involve attempting to squeeze efficiencies from research units and projects already being funded. One interviewee said that their organisation would not push too hard for further efficiencies for fear of the damage that might cause. A more general short term response would be to raise the quality 'bar' for funding new projects: i.e. fewer projects would be initiated. This would in effect mean less research produced from the existing research capacity. Given the earlier discussion of fixed/indirect and variable/direct costs, a 1% cut in funds might in the short term therefore be expected to have the effect of a greater than 1% cut in the amount of research activity funded.

However, over the medium to longer term a sustained cut in funds would lead to reduced capacity too, bringing research capacity and use of that capacity back into balance. In other words, capital would be sold off or not replaced and overhead staff and costs would also be cut. Thus over a period of a few years a 1% cut in funding would imply, broadly speaking, a 1% reduction of research activity. This view is borne out by the literature on economies of scale in medical research, as discussed earlier.

The response to a sustained increase in funds available might, even in the short term, be to increase research capacity as well as to make more use of such capacity. A common theme in the interviews was that capacity for medical research is issue/field specific. Consequently, funders' decisions about how much of any increase to invest in capacity would depend on which fields were considered to be the highest priorities for more research and whether they already had sufficient capacity or whether they were high priorities to build up.

## 2.6 Summary of economies of scale

The published academic literature offers little evidence on whether there are economies of scale in medical research outside industry. A study of 18 public research universities in the USA found that the cost per research publication produced (not specifically medical research, but all types of research) fell as the scale/funding of the university department increased, both when teaching and research are increased in step together and when research is increased by itself (Dundar and Lewis, 1995). Studies using data for 99 UK universities for the academic year 1994/95 also appeared to find economies of scale in research (again not specifically medical research), but they used research grants won as their measure of 'research', which begs the question what happened to the scale of outputs from research (Johnes, 1997 and 1998; and Izadi et al., 2002). An EU study found economies of scale in research projects (again, not specifically medical research) to be exhausted at small project scales (Vonortas et al., 2011) and von Tunzelmann and colleagues concluded that further economies of scale

would not be realised once research teams went beyond eight or so members (von Tunzelmann et al., 2003).

Data from Cancer Research UK and the MRC show direct (arguably short term variable) costs to be around 76%-78% of total costs, and indirect costs (arguably more fixed costs in the short term) around 22%-24% of total costs. This suggests that in the first year or so after a change in funding, when only direct costs can be varied, a hypothetical 1% cut in funding would lead to a 1.3% reduction in medical research activity.

The views of the interviewees imply that this short term consequence would not last in the medium to longer term as over a period of a few years it would be possible to adjust research capacity too. Thus economies of scale appear to be only short term. The one exception to that is a minority of medical research that involves high cost and highly specialised equipment, IT or biobanks. Furthermore, temporary cuts in funding can have long lasting negative consequences: reduced funding means less work for researchers in the UK, meaning that some will either leave the country or change careers, and not all would return to the UK or to research if funding were to be increased again later.

Thus, in summary, there is some evidence of the existence of economies of scale in research but it is from a nearly 20-year old US study and is not specific to medical research. Beyond the short term, economies of scale appear to be exhausted at small sizes of research teams and research projects, with the exception of the small number of projects that entail expensive and highly specific equipment, IT systems or buildings.

## References for Chapter 2

Cohn, E. and Cooper, S.T. (2004) Multi-product cost functions for universities: economies of scale and scope. In Johnes, G. and Johnes, J. eds. *International handbook on the economics of education*. Cheltenham: Edward Elgar Publishing Ltd. 579-612.

Dundar, H. and Lewis, D.R. (1995) Departmental productivity in American universities: economies of scale and scope. *Economics of Education Review*. 14(2), 119-144.

Izadi, H., Johnes, G., Oskrochi, R. and Crouchley, R. (2002) Stochastic frontier estimation of a CES cost function: the case of higher education in Britain. *Economics of Education Review*. 21(1), 63-71.

Johnes, G. (1997) Costs and industrial structure in contemporary British higher education. *The Economic Journal*. 107, 727-737.

Johnes, G. (1998) Corrigendum. *The Economic Journal*. 108, 1275.

McKinsey & Company. (2009) *Pharma R&D compendium. The secret of high productivity in the research lab.* London: McKinsey & Company.

RCUK (Research Councils UK) and UUK (Universities UK). (2009) *RCUK/UUK review of the impact of full economic costing on the UK higher education sector.* Swindon: RCUK.

UKCRC (UK Clinical Research Collaboration) (2012) *UK health research analysis 2009/10.* London: UKCRC.

Vonortas, N., Polt, W., Fisher, R., Spanos, Y., Dinges, M., Ipektsidis, B. and Pateraki, M. (2011) *Economies of scale and scope at the research project level.* Report for the European Commission Directorate-General for Research and Innovation. Brussels: European Commission.

von Tunzelmann, N., Ranga, M., Martin, B. and Geuna, A. (2003) *The effects of size on research performance: a SPRU review.* Report for the Office of Science and Technology, Department of Trade and Industry. Brighton: SPRU Science and Technology Policy Research, University of Sussex.

Wakeham, W. (2010) *Financial sustainability and efficiency in full economic costing of research in UK higher education institutions.* Report of the RCUK/UUK Task Group chaired by Sir William Wakeham. Swindon: RCUK.

## 3. FUNDING INTERDEPENDENCIES IN NEOPLASMS RESEARCH

### Key Points

#### Descriptive statistics

- The UK produced 6.9% of global research publications on neoplasms in 2011.
- This research was produced by authors from 1,159 UK organisations and co-authors from 5,077 non-UK research host organisations.
- Publications by UK authors acknowledged financial support from 2,621 organisations, of which 663 were UK based, excluding 307 private sector organisations.
- 26 host organisations (2% of the total) contribute to 72% of the publications output.

#### Interdependency – Strong interdependencies exist among research hosts and among research funders

- 67% of publications relied on collaboration among research hosting institutions and 43% involved international collaborators.
- The 113 leading UK research organisations collaborate in publications more with international partners than with their UK neighbours.
- Where publications acknowledge funding, multiple funders are acknowledged 64% of the time, with a mean of 3.3 funders acknowledged per publication.
- Industry contributed to over 14% of UK neoplasm publications in 2011 and 18% of those acknowledging funders acknowledge industry support. These papers were more highly cited than expected.

#### Complementarity – The research funding of different organisations is complementary, particularly between large funders and small funders

- The major funders of research on neoplasms support scientific publications that have co-authors across almost the entire UK, but centre their efforts in the Cambridge, London and Oxford areas.
- Smaller funders focus primarily on London but often have a secondary and focus on other regions, which makes them complementary to the major funders in geographic terms.
- The top-three UK funders of neoplasms research – Cancer Research UK, the UK Departments of Health and MRC – focused mainly on “Neoplasms, Glandular and Epithelial”, “Digestive System Neoplasms” and “Urogenital Neoplasms”, while smaller funders are complementary as they often focus on other neoplasm types.
- Funding schemes provided by the major charity and government funders provide UK researchers with a broad choice of grants, making the UK an attractive funding environment for leading scientists who rely on multiple grants simultaneously to build their groups and sustain promising new research lines.

**Diversity – The major research funders and host organisations differ considerably in terms of supported scientific disciplines and research domains**

- Of the major funders, Cancer Research UK and the Departments of Health (including NHS and NIHR) BBSRC and EPSRC support the broadest range of research.
- Major funders strongly focus on pathology and genetics, while surgery is relatively neglected.

**Additional Perspectives – Research quality and international collaborations**

- Major UK funders support a higher proportion of highly cited publications than minor UK funders. Papers with more funders also have higher citations.
- Publications supported by industry are significantly more highly cited than those without industry support.

### 3.1 Introduction

The UK biomedical research community benefits from a broad range of public sector, private sector and charitable funders that play a key role in supporting their work. Yet, the extent to which funders play complementary roles in this support is less understood. The analysis undertaken for this project provides evidence of a highly interdependent and complementary funding system, based on an in-depth study of the portion of the UK's research base focused on neoplasms.

Prior studies that attempt to ascertain the nature of funding landscapes have often begun by exploring the stated funding activities of selected, large UK-based funders (e.g. HERG et al. 2008; Morgan-Jones and Grant 2011, OHE 2011). Our approach complements the established ones with an additional 'search mode'. Specifically, starting from the one of the main outputs of research activity, that is publications, we map the funders as they are acknowledged in publications. This empirical approach has an advantage in that it makes no *a priori* judgements on which funding bodies supported the UK researchers. It allows a comprehensive picture to be produced of the diverse and complex constellation of all funders that supported publications in the selected domain, i.e. the approach is not biased towards the large funding bodies. Publications and the relative databases containing the bibliographic data of these publications can be analysed to reveal much about the way researchers make use of their funding environment. Publications can be used as a starting point to explore questions such as:

- a) How interdependent are the research activities that funders support?
- b) How do funders support research activities in ways that complement one another?
- c) How is the broad and diverse range of research activities in the UK supported by the different funders?

From an analytical perspective these are broad questions. Using scientometric analysis, terms such as interdependence, complementarity, and diversity can be

explored from a number of different informative perspectives (Rotolo et al. 2013). The analysis therefore has to begin by addressing even more fundamental questions concerning the involvement of funders in supporting biomedical research:

- Which public and private bodies fund UK researchers in cancer and which support more publications?
- What are the differences in the geographic and institutional coverage of each funder's investments?
- Which funders support rapidly cited works, or works in high quality journals?
- Which funders support international collaborations or public/private collaborations?
- Which funders support more interdisciplinary research?
- Which funders support particular approaches such as clinical trials of therapeutics and diagnostics? (These are derived from the Medical Subject Headings (MeSH) classifications).
- What is the diseases focus (within cancer) of different funders?

Additional insights into the complementarities of funders are provided by a qualitative analysis of the types of award schemes offered by grant funders and their characteristics.

Finally, the interdependency of research funded through different means and complementarities between funders is explored using case studies drawn from interviews with four leading UK researchers to illustrate how researchers working in diverse areas of biomedicine have used funding schemes funding in order to achieve significant research milestones.

The data analysis is arranged in sections according to address questions A, B and C above, with additional sections discussing further findings, distributed according to the following working definitions of key terms:

- **Research host organisations** – Primarily undertake research
- **Major UK host organisations** – UK research host organisations that contribute to at least 2% of the UK research output in neoplasms in 2011
- **External funding organisations** – Primarily sponsor research undertaken externally
- **Major UK funders** – UK funders that supported at least 2% of the UK research publications in neoplasms in 2011
- **Interdependency** – Where two or more research hosts or external funders support a single output (i.e. publication)
- **Complementarity** – Where different research hosts and external funders support activities that collectively address a wider range of activities than individual organisations contributing to more potential synergies across the research system.
- **Diversity** – Variety in the characteristics, scope and balance of research activities that individual research hosts undertake or that individual external funders support

### 3.2 Research methods

Two systematic approaches are possible to undertake a comprehensive analysis of a research funding landscape over a given time period. One starts upstream with the funders and then traces the research outputs they have supported (the 'top down' approach). The other starts with the research outputs and traces the funders that supported these (the 'bottom up' approach). Both approaches have limitations and so with limited resources, analysts must be aware of these and make pragmatic choices (McLean et al. 1998).

Collection of data from funders requires that, *inter alia*, all relevant funders can be identified and that these organisations are transparent about the research they support, use common definitions and similar reporting styles to ensure relevant inputs, and their outputs, can be identified (Hopkins and Siepel 2013). Efforts to develop a 'top down' approach have been advanced by UK research funders and are becoming increasingly sophisticated (for example see UKCRC 2012). However many smaller funders are not included in such funding statistics, nor are international funders.

The 'bottom up' approach requires that all relevant research outputs can be identified and that authors of outputs are transparent about who has funded their research, with funding data reported in a style that is accessible and amenable to analysis. Although much research is published and accessible through highly indexed and structured databases which aids searching, some organisations, particularly in industry, do not publish all of their research (Rafols et al. 2012, Goldacre 2012). This is a substantial limitation because in the UK at least, estimates suggest industry funds the majority of biomedical research (Morgan-Jones and Grant 2011) However this limitation is also likely to be a problem for the top down approach (Hopkins and Siepel 2013).

This study develops a 'bottom up' strategy to map all papers written by authors working in the UK and related to the neoplasms domain in order to map the funding landscape. The required information is not readily available from one database and so a multi-stage process is required to identify relevant papers and collect data across the required fields for a broad analysis. Full details of the steps undertaken to create the dataset are provided in the Appendix to this chapter. The following paragraphs provide just a summary of this more detailed account.

For the purposes of identifying a sample of UK papers from which to generate a 'snapshot' of the UK research system a search was undertaken of PubMed/MEDLINE using the Medical Subject Headings (MeSH) code 'Neoplasms'. This is a broad term encompassing cancerous and pre-cancerous growths. All papers with at least one UK author on neoplasms published in 2011 were identified. Of the 7,922 records identified, electronic access was possible for 94.8% of the sample (7,510 publications).

These 7,510 publications were scanned for acknowledgements to funders, with 3,914 publications disclosing at least one funder. Robustness checks confirmed that those publications not acknowledging funders were more likely to be shorter, less cost intensive categories of publication (such as editorials or comments) and

that those not acknowledging funders were most often funded only by their employer (already captured for this analysis through identification of all author affiliated host organisations). These findings are consistent with prior research on UK biomedical publications data which found that 39% of papers did not acknowledge funders, with the primary reason being that the papers were funded by the organisation or organisations that the authors were affiliated with (Lewison et al. 1995).


As discussed in Chapter 2, most grants by UK research councils and charities do not fully reimburse organisations hosting research for their costs. Therefore in identifying the funders of neoplasm research in the UK it is appropriate to discuss the research host organisations and their external funders. These are considered as two distinct perspectives in the analysis presented here – a single combined approach being problematic because of heterogeneity in the origin of funding supporting research host organisations that not externally grant funded.

### **3.2.1 Limitations of the dataset construction for analysis and interpretation**

A key limitation is that although publications record author affiliations and in many cases report funding sources, it is frequently the case that publications do not disclose which authors or affiliated organisations have benefitted from specific funders. Figure 3.1 illustrates the structure of the data records under ideal and actual conditions, and shows how the resulting data analysis focuses on either the publications host organisations produce, or the publications funders support.



**Figure 3.1: Ideal and actual funding disclosure reconstruction**



### 3.2.2 Method for analysis of research funding schemes

In order to understand how the major research funders provide complementary or overlapping funding schemes for the research community it was necessary to identify the leading funders, using the data from publication acknowledgements sections. Those funders contributing to >1% of publications were selected for investigation (10 UK-based funders and three non-UK based funders). Funders' websites and key documents such as annual reports for the most recent period were examined to determine whether these schemes were open to researchers working in the UK. A qualitative comparative analysis based on similarities and differences between the funders' different schemes was then undertaken.

### 3.2.3 Method for case studies of leading researchers

The scientometric analysis of publications in 2011 and the description of the top funders funding schemes both provide system-wide snapshots of the landscape of UK biomedicine in the neoplasms field. To explore how researchers navigate through this landscape and also to give a dynamic view of how different funding

schemes may be complementary or interdependent, case studies of leading researchers were undertaken.

Case study subjects were selected from a sample of convenience provided by Cancer Research UK and so cannot be described as scientifically selected. Five individuals were approached in mid 2013 with four responding and contributing. The case study sample over-selects highly successful scientists funded by Cancer Research UK, but with this bias understood these cases can be used to inform the scientometric analysis by providing insight into the writing of acknowledgement sections and the role of international partners. These case studies also to provide some (non-comprehensive) illustrations of the ways in which different funding sources funding can be used over time to advance an avenue of research.


### **3.3 Scientometric analysis results: Contextual descriptive statistics**

#### **3.3.1 Publication numbers and outlets**

Of the 115,101 publications in 2011 classified as related to neoplasms according to the MeSH coding system, 7,922 had at least one UK-based author. The UK was therefore involved in the generation of 6.9% of the global output of publications on neoplasms in 2011. These papers are distributed across 1,480 journal titles. The analysis focuses on a sample of 94.8% of these papers, based on 7,510 publications across 1,350 journal titles.

Concentration is low with only 13 journals containing >1% of these publications and the top 17 journals accounting for just 20% of total publications (see Figure 3.2). The most frequently targeted journals within the sample are the British Journal of Cancer (2.9%), highlighted in green, the European Journal of Cancer (1.6%), highlighted in blue, joint in third place, highlighted in orange, the International Journal of Cancer (1.5%) and the Journal of Clinical Oncology (1.5%).

**Figure 3.2: Leading journals of 2011 UK publications on neoplasms and distribution journal-number of publications**



### 3.3.2 Publications by UK research host organisations

Table 3.1 reports the top-50 UK organisations publishing in neoplasms (62 host organisations are listed). It is notable that a large proportion of the organisations contributing to more than 100 publications per year are clusters of institutions linked by association to a university hospital or NHS Trust. This makes direct comparisons to smaller organisations somewhat problematic, but pragmatically is necessary as staff in these clusters will frequently work between sites and have dual affiliations.


Figure 3.3 shows the distribution of publishing output in the field of neoplasms across the population of host organisations, dividing these into three groups according to their contribution to the publication output: (i) less than 0.1%, (ii) from 0.1% to 1%, and (iii) more than 1%. These three groups accounts for 951, 182, and 26 organisations that contributed respectively to 1,433, 2,933, 5,394 publications,. This suggests that although neoplasm research in the UK was undertaken in a large number of organisation (1,159 organisations), a core of 26 host organisations (~2%) contributed to ~72% of the publication output.

**Table 3.1: Top-50 ranking of UK organisations (62 organisations listed) publishing on neoplasms research**

Organisation	Number of publications
1) Institute of Cancer Research, <a href="#">London</a> <i>(including the following organisation or name variations: Royal Marsden NHS Foundation Trust)</i>	699
2) University College London, <a href="#">London</a> <i>(including the following organisation or name variations: University College London Hospitals NHS Trust, UCL Cancer Institute, National Hospital for Neurology and Neurosurgery, Royal Free Hampstead NHS Trust)</i>	630
3) Imperial College, <a href="#">London</a> <i>(including the following organisation or name variations: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross Hospital)</i>	567
4) University of Cambridge, <a href="#">Cambridge</a> <i>(including the following organisation or name variations: Cancer Research UK Cambridge Research Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research Centre, Addenbrooke's University Hospital, Cambridge University Hospital NHS Trust)</i>	556
5) Oxford University, <a href="#">Oxford</a> <i>(including the following organisation or name variations: Gray Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, United Kingdom)</i>	548
6) King's College London, <a href="#">London</a> <i>(including the following organisation or name variations: King's College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's Hospital, Western General Hospital)</i>	529
7) University of Leeds, <a href="#">Leeds</a> <i>(including the following organisation or name variations: Leeds Cancer Research UK Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary)</i>	395
8) University of Manchester, <a href="#">Manchester</a> <i>(including the following organisation or name variations: Cancer Research UK Paterson Institute, Christie Hospital)</i>	389
9) Queen Mary University of London, <a href="#">London</a> <i>(including the following organisation or name variations: St Bartholomew's Hospital)</i>	323
10) University of Edinburgh, <a href="#">Edinburgh</a> <i>(including the following organisation or name variations: Edinburgh Cancer Research Centre, Western General Hospital)</i>	282
11) University of Glasgow, <a href="#">Glasgow</a> <i>(including the following organisation or name variations: NHS Greater Glasgow and Clyde, Gartnavel General Hospital, Glasgow Royal Infirmary, Western Infirmary)</i>	278
12) University of Newcastle, <a href="#">Newcastle Upon Tyne</a> <i>(including the following organisation or name variations: Northern Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Freeman Hospital)</i>	243
13) University of Birmingham, <a href="#">Birmingham</a>	219
14) University of Sheffield, <a href="#">Sheffield</a> <i>(including the following organisation or name variations: Weston Park Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals NHS Trust)</i>	212
15) Cardiff University, <a href="#">Cardiff</a> <i>(including the following organisation or name variations: Velindre NHS Trust)</i>	191
16) University of Southampton, <a href="#">Southampton</a> <i>(including the following organisation or name variations: Southampton General Hospital)</i>	170
17) University of Liverpool, <a href="#">Liverpool</a>	166
18) St George's Hospital NHS Trust, <a href="#">London</a> <i>(including the following organisation or name variations: St George's Hospital, St George's, University of London)</i>	132
19) Queen's University, <a href="#">Belfast</a> <i>(including the following organisation or name variations: Belfast City Hospital)</i>	128
20) University of Nottingham, <a href="#">Nottingham</a>	115
21) University of Aberdeen, <a href="#">Aberdeen</a>	104
22) University of Bristol, <a href="#">Bristol</a>	100
23) University of Leicester, <a href="#">Leicester</a>	87
24) Mount Vernon Hospital, <a href="#">Northwood</a>	81
25) London Research Institute, <a href="#">London</a>	79
26) Ninewells Hospital and Medical School, <a href="#">Dundee</a>	77
27) AstraZeneca, <a href="#">Macclesfield</a>	75
27) Royal Liverpool and Broadgreen University Hospitals NHS Trust, <a href="#">Liverpool</a>	75
28) Great Ormond Street Hospital for Children, <a href="#">London</a>	72
28) Queen's Medical Centre, <a href="#">Nottingham</a>	72
29) Churchill Hospital, <a href="#">Headington</a>	70
29) Nottingham University Hospitals NHS Trust, <a href="#">Nottingham</a>	70
30) London School of Hygiene and Tropical Medicine, <a href="#">London</a>	69
30) University of Dundee, <a href="#">Dundee</a>	69
31) Royal Surrey County Hospital, <a href="#">Guildford</a>	58
32) Queen Elizabeth Hospital, <a href="#">Birmingham</a>	57
33) Nottingham City Hospital, <a href="#">Nottingham</a>	56
34) University Hospital of Wales, <a href="#">Cardiff</a>	54
35) Leicester Royal Infirmary, <a href="#">Leicester</a>	52
35) University of Sussex, <a href="#">Brighton</a>	52
36) Medical Research Council, <a href="#">London</a>	49
37) University of Warwick, <a href="#">Warwick</a>	48

Organisation	Number of publications
38) University Hospital Southampton NHS Trust, <a href="#">Southampton</a>	46
39) Beatson Institute for Cancer Research, <a href="#">Glasgow</a>	44
40) University of York, <a href="#">York</a>	42
40) Wellcome Trust Sanger Institute, <a href="#">Cambridge</a>	42
41) Aberdeen Royal Infirmary, <a href="#">Aberdeen</a>	41
41) St. Mary's Hospital, <a href="#">London</a>	41
42) Queen Alexandra Hospital, <a href="#">Portsmouth</a>	40
42) Royal Infirmary of Edinburgh, <a href="#">Edinburgh</a>	40
43) University of East Anglia, <a href="#">Norwich</a>	39
44) St Mary's Hospital, <a href="#">Manchester</a>	38
45) Birmingham Women's Hospital, <a href="#">Birmingham</a>	36
46) Birmingham Children's Hospital, <a href="#">Birmingham</a>	35
46) Royal Hallamshire Hospital, <a href="#">Sheffield</a>	35
46) Royal National Orthopaedic Hospital, <a href="#">London</a>	35
47) Norfolk and Norwich University Hospital, <a href="#">Norwich</a>	34
48) Royal Brompton Hospital, <a href="#">London</a>	33
48) University of Surrey, <a href="#">Guildford</a>	33
49) University Hospitals Bristol NHS Trust, <a href="#">Bristol</a>	32
50) Manchester Royal Infirmary, <a href="#">Manchester</a>	31
50) Royal Devon and Exeter Hospital, <a href="#">Exeter</a>	31

**Figure 3.3: Number of organisation by contribution to the 2011 UK publications in neoplasms**



### 3.4 Scientometric analysis: Interdependencies in Neoplasm Research


This section aims to address the question 'How interdependent are these research activities that funders support?'. In this context, interdependency is understood as situations where two or more research hosts or external funders support a single research output (publication).

Host organisations may therefore be seen as interdependent when they work with other host organisations to produce research publications. Funders can be described as interdependent on other funders when the publications that their mission depends on are produced in conjunction with those funders. Analysis of these two perspectives (illustrated in Figure 3.1) form the basis of this section with the analysis of the authors' affiliations on 7,510 publications and the analysis of external funders based on acknowledgements in 3,914 publications. It is a presumption that in most cases publications produced with charitable funding or funding from research councils are the result of interdependencies between hosts and external funders due to the practice of not funding 100% of full economic costs (as discussed in Chapter 2). However, the analysis presented here does not explore this third perspective.

#### 3.4.1 The interdependence of research host organisations

Analysis of the sample of 7,510 publications reveals that neoplasms research is a highly collaborative enterprise between research host organisations. Figure 3.4 shows the distribution of publications by authorship, revealing that very few (<6%) publications are sole authored, and of these fewer are cost intensive 'articles'. Figure 3.5 shows the distribution of publication by number of authors' affiliations per paper, revealing that 67% of publications result from cross-organisational collaboration, indicating that research host organisations are highly interdependent on each other to produce research publications.

**Figure 3.4: Number of authors per publication and types of publications**



**Figure 3.5: Number of affiliations per publication and types of publications**




Table 3.2 shows that publications have a mean of 7.7 authors (although Figure 3.5 shows the mode is 3 for all publications and 4 if considering just the more cost intensive articles) and involves a mean of 3.8 host organisations (although Figure 3.6 shows the mode is 1, even for the cost-intensive research articles, this is because of the wide distribution of the data).

Overall, Table 3.2 shows that the sample of 7,510 publications has 1,159 UK host organisations publishing on neoplasms and co-authoring with researchers at 5,077 non-UK host organisations.

Research on neoplasms involves much international collaboration with 43.3% of publications having at least one co-author based outside the UK. This implies that over two fifths of the UK neoplasms publication output is dependent on international host organisations, with the average international 'publication' relying on a mean of 2.1 non-UK organisations. Table 3.3 reveals the top-50 ranking (containing 68 organisations) non-UK host organisations (excluding industry) that contribute co-authors to publications with UK co-authors. The high proportion of US collaborators in this list (18/68), implies that UK research on neoplasms is most interdependent on the US funding system for co-author funding. Other strong ties are evident with Italian and Dutch (both 8/68), German (6/68), Swedish (5/68) and Spanish (5/68) research systems.

**Table 3.2: Descriptive statistics on the publication sample (N=7,510)**

<b>Number of author-publication pairs</b>	57,988
<b>Number of authors per publication</b>	
<i>Mean</i>	7.7
<i>Standard Deviation</i>	11.4
<i>Min</i>	1
<i>Max</i>	303
<b>Number of affiliation-publication pairs</b>	
<i>before names' harmonisation process</i>	34,732
<i>after names' harmonisation process</i>	28,834
<b>Number of distinct affiliations</b>	6,402
<i>UK</i>	1,159
<i>Non-UK</i>	5,077
<b>Number of affiliations per publication</b>	
<i>Mean</i>	3.8
<i>Standard Deviation</i>	5.9
<i>Min</i>	1
<i>Max</i>	141
<b>Number of UK affiliations per publication</b>	
<i>Mean</i>	1.7
<i>Standard Deviation</i>	1.5
<i>Min</i>	1
<i>Max</i>	30
<b>Number of publications involving</b>	
<i>at least one non-UK affiliation</i>	3,253
<i>only UK affiliations</i>	4,257
<b>Number of non-UK affiliations per publication</b>	
<i>Mean</i>	2.1
<i>Standard Deviation</i>	5.3
<i>Min</i>	1
<i>Max</i>	111
<b>Number of countries per publication</b>	
<i>(excluding UK)</i>	
<i>Mean</i>	1.1
<i>Standard Deviation</i>	1.1
<i>Min</i>	0
<i>Max</i>	24



**Table 3.3: Top 50 Ranking of non-UK organisations (68 organisations listed) collaborating with UK organisations**

	Organisation	Number of publications
1)	Karolinska Institutet, Sweden	164
2)	National Institutes of Health, United States	146
3)	University of California, United States	144
4)	University of Texas, United States	129
5)	Umea University, Sweden	124
6)	Fondazione IRCCS Istituto Nazionale dei Tumori, Italy	123
7)	Harvard University, United States	122
8)	International Agency for Research on Cancer, France	120
9)	Utrecht University, Netherlands	116
10)	University of Toronto, Canada	114
11)	German Cancer Research Center, Germany	113
12)	Erasmus University Medical Center, Netherlands	103
13)	Paris South University, France	98
14)	Mayo Clinic, United States	97
15)	Catalan Institute of Oncology (ICO), Spain	96
16)	AMC Amsterdam, Netherlands	91
17)	Leiden University Medical Center, Netherlands	89
18)	Lund University Hospital, Sweden	85
19)	Aarhus University, Denmark	83
20)	Danish Cancer Society, Denmark	82
21)	Katholieke Universiteit Leuven, Belgium	82
21)	Memorial Sloan-Kettering Cancer Center, United States	82
21)	Radboud University, Netherlands	82
22)	Dana Farber Cancer Institute, United States	81
23)	CIBER-BBN, Spain	76
23)	University of Montreal, Canada	76
24)	University of Copenhagen, Denmark	74
25)	Queensland Institute of Medical Research, Australia	72
26)	University of Melbourne, Australia	71
27)	University of Pennsylvania, United States	70
28)	Istituto Toscano Tumori, Italy	69
28)	University of Washington, United States	69
29)	University of Heidelberg, Germany	68
30)	University of Sydney, Australia	65
31)	Federico II University, Italy	64
32)	University of Athens, Greece	63
33)	Netherlands Cancer Institute, Netherlands	61
34)	University of Torino, Italy	60
35)	University of Southern California, United States	58
35)	Uppsala University, Sweden	58
36)	Azienda Ospedaliera Civile MP Arezzo, Italy	55
37)	National Institute for Public Health and the Environment, Netherlands	54
37)	University of Leuven, Belgium	54
38)	Johns Hopkins University, United States	53
39)	European Institute of Oncology, Italy	51
40)	Andalusian School of Public Health, Spain	50
40)	German Institute of Human Nutrition, Germany	50
41)	University of Padua, Italy	49
42)	University of Tromso, Norway	48
43)	Human Genetic Foundation (HuGeF), Italy	47
43)	Peter MacCallum Cancer Centre, Australia	47
43)	Stanford University, United States	47
44)	University of Michigan, United States	46
45)	Maastricht University Medical Center, Netherlands	45
45)	Mount Sinai Medical Centre, United States	45
45)	Health and Health Care Services Council, Spain	45
45)	University of Gothenburg, Sweden	45
45)	World Health Organisation, Worldwide	45
46)	Navarre Public Health Institute, Spain	44
47)	Charité Berlin, Germany	42
47)	Charles University, Czech Republic	42
47)	Fred Hutchinson Cancer Center, United States	42
47)	Ulm University, Germany	42
48)	Duke University, United States	41
49)	Massachusetts General Hospital, United States	40
50)	Universite Paris Descartes, France	39
50)	Hannover Medical School, Germany	39
50)	University of North Carolina, United States	39

Figures 3.6 and 3.7 explore the co-authorship network of host organisations. The complete network is a highly complex structure due to the large number of organisations and ties connecting those organisations. Specifically, the network involves >6,000 organisations connected by >95,000 co-authorships in publications. The complete network is depicted in Figure 3.6 (a).<sup>3</sup> Despite this complexity the complete co-authorship network is informative for the analysis of interdependencies in neoplasms research. For example, the largest component – i.e. the largest set of connected nodes (Wassermann and Faust 1994) – includes 97.4% of the nodes, which is notably high and suggests those organisations in the field are highly interdependent. Further evidence of the intensity of inter-organisational research activities is provided by the degree centrality measure, that is the number of ties connecting a node to other nodes in the network (Freeman 1979). On average an organisation is connected to 30.8 other organisations (with the maximum being 1,286 organisations).

The analysis of a core of the co-authorship network provides an additional informative perspective but can only be undertaken by subjectively imposing conditions (i.e. there is no objectively definable 'core'). We identify a core imposing the following conditions:

- a) Organisations that contributed to at least 0.1% (at least seven publications) of the UK research output are included in the set of nodes
- b) The strongest 5% of co-authorship ties are included as connections (connections are shown between two organisations if they are connected by co-authorship in at least five publications)

This imposing of these conditions is necessary to visualise the most central organisations. The core network is depicted in Figure 3.6 (b). It involves 575 organisations connected by 5,039 ties. We focus only on organisations in the largest component of the network. This reduces the network to 387 nodes, i.e. 188 organisations are working in smaller clusters isolated by imposing the above mentioned conditions. The set of 387 organisations is composed of 113 (~29%) UK organisations, 263 (~69%) non-UK organisations, and 11 (~2%) organisations located in multiple countries including UK (where multinational firms are placed).

Analysis of the core highlights one of the key features of UK research in neoplasms, which is the strong role international collaborations play. Despite the bias in sample collection created by focusing only on papers with UK authors (as defined by the sample strategy adopted to meet the main aims of this report) the centre of the network is dominated by international research host organisations. In the international core network, an organisation is on average connected with 17.5 other organisations (degree centrality) up to a maximum of 197 organisations. Figure 3.7 provides a more detailed picture of this core. The strong interdependency between UK organisations and international actors is also depicted in Figure 3.6 (c) which by removing the non-UK organisations from previous core networks, identifies the UK core network. In the UK core network

<sup>3</sup> Gephi 0.8.2 was used to produce the network figures.

an organisation is on average connected with 7.5 other organisations (degree centrality) up to 53 organisations.

Figure 3.6: Co-authorship network. The nodes' colours are assigned as in the followings: UK organisations (green), non-UK organisations (blue), organisation located in multiple countries including UK (yellow). The size of nodes is proportional to the  $\log_2$  of the number of publications the given actors contributed to.





Figure 3.7: Focus on the core co-authorship network in neoplasms. The nodes' colours are assigned as in the followings: UK organisations (green), non-UK organisations (blue), organisation located in multiple countries including UK (yellow). The size of nodes is proportional to the  $\log_2$  of the number of publications the given actors contributed to.



### 3.4.2 The interdependence of funding organisations

Publications in the sample acknowledged support from over 2,500 organisations. While 663 funders are based in the UK (excluding private sector organisations), 1,591 non-UK funders are acknowledged, as well as a further 307 private sector organisations (see Table 3.4).

**Table 3.4: Funding data and publications (N= 3,914)**

<b>Number of distinct funders</b>	
UK	663
Non-UK	1,579
Industrial actors	307
<b>Number of funders per publication</b>	
Mean	3.3
Standard Deviation	5.0
Min	1
Max	78
<b>Number of UK funders per publication (excluding industrial actors)</b>	
Mean	1.4
Standard Deviation	1.5
Min	0
Max	11
<b>Number of industrial funders per publication</b>	
Mean	0.3
Standard Deviation	1.5
Min	0
Max	50

Note. Industrial actors are considered as a separate category since they generally have multiple geographical locations.

Where publications acknowledge funding, only in 36% (1,420/3,914) of the cases the research depended on a single funder. Those papers acknowledging financial support had a mean of 3.3 funders.

To gain an insight into the reasons why papers acknowledge multiple funders, it is useful to draw on the case study interviews. Although only four individuals were interviewed, the resulting case studies follow research undertaken by Principal Investigators (PIs) over at least a decade each, thereby following multiple projects per investigator and giving an insight into the funding support behind several hundred papers. In a complex funding ecosystem, research is often not funded by a single organisation. The interviewees reveal three broad types of co-contribution:

1. Host + external funder - UK funders will generally not support the full economic cost of research and will require the host organisation to make a financial contribution. Host organisations will often meet this cost through cross-subsidising activities, for example with teaching revenues supporting research infrastructure and/or staff costs.
2. Sharing funding by cost type - funders contribute to different types of cost, perhaps at different times such as when one funder finances a facility (externally) and another provides for staff costs related to the particular

project. Additionally, others may provide significant support, as when industrial partners provide expensive drugs for a trial.

3. Joint funding - researchers or funders can anticipate the need for joint funding of a project or scheme in advance with costs being shared in a number of ways, such as by geography, institution or overall contribution. In other cases once a project is established, researchers may be opportunistic by working with other groups as projects progress if this allows projects to advance more efficiently. Joint publications are therefore also jointly funded by the authors' financial supporters.

These categories are not mutually exclusive, with some or all applying to a given publication. Interpreting the contribution of a given funder is challenging as publications often have multiple authors from multiple organisations, and acknowledge multiple funders. Indeed from the information provided in the acknowledgements sections of publications it is generally not possible to identify which mode of support a funder is being acknowledged for, or even which author or organisation a given funder is supporting. Resolving this without speaking to one or more of the research paper's authors is therefore not possible. A further limitation of the approach is that publications may (strategically or mistakenly) also acknowledge funders that have not supported a given paper.

Where the outputs of a research study depend on multiple sources of funding, the funders are described here as being interdependent, in that their funding support has required additional input from at least one other funder to yield the published output. It is important to acknowledge that this does not necessarily mean that no research would have been possible without all of the funders, but rather that the observed output would not have been possible in its exact form. One researcher interviewed said "I would strongly say that my research is not dependent on other people's funding at all" but said also that they did collaborate widely on papers for "scientific reasons". Another suggested that ad hoc collaborations were an efficient way of proceeding because it saved "re-inventing the wheel". Thus interdependency can be weak or strong.

An example of strong interdependency of funders that would fall within each of the three conditions above is described in Case study 1.

#### **Case Study 1: Interdependency of funders in large scale clinical oncology trials**

Tim Maughan is Professor of clinical oncology and Department Director of the MRC/ CR-UK Gray Institute for radiation oncology and biology, within the Department of Oncology at the University of Oxford. He is also honorary consultant at the Churchill Hospital, Oxford. Over the last decade, Professor Maughan has played a leading role in the design and execution of several large clinical trials of cancer treatments that have depended on funding from multiple sources. In particular his work has focused on advancing the stratification of therapeutic treatment by studying the effectiveness of different drug combinations against colorectal cancers, with the hope that in the future biomarker tests will be able to guide clinical treatment choices by molecular categorisation of tumour type.

Clinical research demands a much larger cost to answering a given research question than laboratory research. However, Maughan has been able to obtain

support for large and sophisticated multi-arm studies designed to answer different questions simultaneously. Phase 2 and Phase 3 trials designed by Maughan have been supported through combinations of CRUK, MRC and NIHR funding, as well as with contributions by industry and other charities.

A recent example is the COIN trial (results reported in Maughan et al 2011, and Adams et al. 2011) which compared three treatment regimes in patients with advanced colorectal cancer. Continuous or intermittent use of Oxaliplatin and fluoropyrimidine (in combination) were compared to assess whether breaks in chemotherapy reduced the toxic side effects suffered by patients. Another arm of the trial compared the use of cetuximab in combination with oxaliplatin and capecitabine to see if this was superior to the other regimes.

The COIN trial is an example of a large Phase III trial design that changed in form according to the availability of new research findings and collaborations even as it commenced. The initial idea for the COIN trial emerged from an NCRI study group – a group of experts that are funded to meet regularly to discuss research proposals. Maughan was encouraged by colleagues to design a study to explore the relative benefits of different drug combinations against advanced colorectal cancer, including to assess variants of a treatment protocol (Oxaliplatin with fluoropyrimidine) widely used outside the UK, but not yet approved by NICE.

The great expense of large trials such as COIN (with >1600 patients) means these are often prohibitively expensive without industrial support in other parts of Europe. However with the availability of government and charitable core funding it is possible to undertake independent academic investigator led trials in the UK. This has the advantage that the data is publicly owned and publication is unhindered by commercial interests. The core cost of the COIN trial was supported by a CRUK Clinical Trials Advisory and Awards Committee grant, with the MRC clinical trials unit providing infrastructural support and acting as the formal trial sponsor. Additionally the trial also relied on industry partners to supply drugs and additional funding.

Before the trial could commence the costs of Oxaliplatin had to be met. This drug was not yet NICE approved for NHS use, and so funding for this was underwritten by the NIHR. However NICE subsequently issued an approval before the trial commenced, and so this funding was not drawn on – the drug being purchased through routine NHS clinical provision. Several firms were invited to contribute to the study but some declined to join. However the team were successful in attracting Merck, a major German Pharmaceutical firm, to make a £500 per-patient contribution to trial costs and to supply around £10M worth of the MAb therapy, Cetuximab. Other contributions in the form of discounted drugs were made by Baxter, Wyeth, Sanofi. During the trial data was collected by staff funded through the National Cancer Research Networks

As the trial progressed, newly published data emerged suggesting that mutations in the KRAS gene might affect treatment outcomes in patients receiving epidermal growth factor receptor targeted antibodies such as Cetuximab. Arrangements had already been made to have a team at UCL hospitals undertaking biomarker testing for EGFR-status of tumours, and now plans were rapidly made to incorporate into the study the genotyping of patient tumours for KRAS status, which involved obtaining additional funding from Merck and CRUK, in the form of a Biomarkers and Imaging Discovery and Development Committee (BIDD) grant. This work was undertaken by a laboratory at Cardiff University where a doctoral research student, supported by local charity Cancer Research Wales, genotyped over 2000 tumour samples. The work was subsequently



validated by another laboratory in Leuven, in turn supported by the Institute for the promotion of Innovation through Science and Technology in Flanders.

The COIN trial made important contributions by showing that the addition of Cetuximab to oxaliplatin and fluoropyrimidine chemotherapy was not of benefit to patients regardless of tumour KRAS status, and that intermittent chemotherapy was not inferior to continuous chemotherapy, allowing oncologists to adjust treatments to reduce toxic side effects in selected patients with advanced colorectal cancer.

Figure 3.8 shows the interdependence of UK funders, where two or more UK funders are acknowledged in the same publication. Figure 3.8 reveals at least 250 UK-based public sector and charitable external funders that support more than one publication on neoplasms per year. The most commonly interdependent funders are also the largest – namely the MRC, Cancer Research UK and the UK's Departments of Health (including the NIHR). Figure 3.8 excludes private sector funders, non-UK funders and UK-based funders acknowledged in less than two publications in 2011. The majority of the funders shown are external to the host organisation undertaking the research, however a small proportion of these are host organisations that also appear to support neoplasms research through internal funds beyond the standard contribution to salary and infrastructure costs of staff needed to bring research council or charity grants up to full economic costs (although some authors do acknowledge such contributions, authors generally do not acknowledge their employer as a funder, but it is not possible to exclude these where they do occur).


By reading the symmetric matrix (in Figure 3.8 above) by row the top-3 'co-funders' for each funder can be identified (highlighted green), e.g. Wellcome Trust co-funds papers most often with MRC (86), Cancer Research UK (83) and the Departments of Health (75).

Beyond interdependencies at the national level, there is interdependence of national research systems and their funders, as explored in the previous section. This interdependence is further confirmed by assessing the numbers of UK publications that acknowledge non-UK funders: see Figure 3.9, which shows all funders acknowledged in more than 2% of publications in the sample. This reveals that of the top 17 funders of neoplasms papers with UK authors, nine are UK based and eight are non-UK.

Notably, the top five contains two non-UK funders: the NIH and the European Commission. The NIH is acknowledged almost as much as the MRC, while the contributions to UK publication output of the Swedish Cancer Society or Italian Association for Cancer Research is comparable to that of Leukaemia and Lymphoma Research, Breakthrough Breast Cancer or the Breast Cancer Campaign. However it must be recognised that these funders are not supporting UK researchers directly, but rather their co-authors in other countries. An exception is the European Commission which does directly support UK researchers through its funding programmes. With acknowledgements to the European Commission in 384 papers, this suggests that the European

Commission supports UK researchers in neoplasms more frequently than does the Wellcome Trust. However, this finding should be interpreted with caution because an unknown number of these acknowledgements will support non-UK collaborators of UK authors more often than is likely to be the case for the more UK-focused Wellcome Trust. Figure 3.9 also confirms the key importance to UK scientists of funding for non-UK co-authors in the USA, Italy Sweden, Australia, Germany and France.

**Figure 3.8: Co-funding of UK funders that were acknowledged in at least in two publications (excluding industry) and co-occurrence matrix for the funders that acknowledged in at least 2% of the publication sample**



Funder	1	2	3	4	5	6	7	8	9
1. Cancer Research UK	-	315	216	83	42	51	54	44	21
2. Departments of Health (including NHS and NIHR)	315	-	183	75	24	52	19	46	10
3. Medical Research Council (MRC)	216	183	-	86	41	15	7	43	25
4. Wellcome Trust	83	75	86	-	9	10	3	7	15
5. Leukaemia and Lymphoma Research	42	24	41	9	-	3	0	2	9
6. Breakthrough Breast Cancer	51	52	15	10	3	-	7	4	1
7. Breast Cancer Campaign	54	19	7	3	0	7	-	2	1
8. Engineering and Physical Science Research Council (EPSRC)	44	46	43	7	2	4	2	-	15
9. Biotechnology and Biological Sciences Research Council (BBSRC)	21	10	25	15	9	1	1	15	-
<b>Total number of publications supported</b>	<b>949</b>	<b>890</b>	<b>477</b>	<b>202</b>	<b>137</b>	<b>110</b>	<b>95</b>	<b>93</b>	<b>92</b>

These findings are highly contextual to neoplasms research and generalisations cannot be made outside the field of neoplasms because the sample of papers captured for this study excludes many papers that are funded by host organisations and external funders. Those funders that are more specialised on neoplasms will have a greater proportion of their activities included within the analysis. All tabulations of data should therefore be interpreted with this in mind.

This is a selective lens that focuses on neoplasms, and organisations' activities beyond neoplasms are excluded.

**Figure 3.9: UK (red), EU (blue), and non-EU (green) funding organisations acknowledged in at least 2% of the publication sample (N = 3,914). The chart excludes private actors.**




Table 3.5 and Figure 3.10 demonstrate that articles acknowledging external funding are more likely to involve more international organisations (as measured by the number of distinct countries in the list of host organisations). This suggests that external funders provide support for authors to collaborate internationally and that one consequence of such international collaboration is a leveraging of national research funding as UK authors' publications benefit from the financial support of their co-authors' funders.

**Table 3.5: Availability of funding data and number of countries**

Type of publication	Number of countries			
	Mean	Std.Dev.	Min	Max
Publication with funding data in acknowledgement sections	2.5	2.5	1	25
Publications with no acknowledgements sections or no funding data in acknowledgement sections	1.6	1.4	1	20

Notes. The t-test on mean ( $t=20.31, p<0.001$ ) confirmed that publications providing funding data in acknowledgement sections involves on average more countries than those that do not. This result is confirmed also when running the test on the sample of "Article" type of publication.

Figure 3.10: Numbers of publications and countries involved




Figure 3.11: Number of funders per publication and types of publications





Figure 3.11 shows that it is most common for papers acknowledging funders to be supported by one funder, however 64% of papers have more than one funder, with the mean number of funders acknowledged per paper being 3.3.

Industry plays a significant role in UK neoplasms research, with 698/3,914 publications acknowledging funders including a private organisation (17.8%). By comparison, industry co-authors less frequently, with 647/7,510 publications having a co-author at a private organisation (8.6%). However combining these categories reveals that industry supports 1,084/7,510 publications (14.4%). A minority (261) of industry-supported papers provides a co-author and acknowledged funding. Figure 3.12 shows the private organisations that most


frequently co-author publications with UK authors. The largest publisher is shown in green (Pfizer), the second largest in blue (AstraZeneca) and the third largest in orange (Novartis).

**Figure 3.12: Private organisation acknowledged in at least 1% of the publication sample (N = 3,914)**



As reported in Figure 3.13, on average ~17% of the publications supported by major UK funders involve industry – from a minimum of ~8% for Breast Cancer Campaign to a maximum of ~23% for MRC.

**Figure 3.13 Proportion of industry publications supported by major UK funders.**



### 3.5 Scientometric analysis: Complementarities in neoplasms research

Complementarities in research funding are regarded here as where the activities of funders and/or research host organisations support research in distinct areas rather than wholly overlapping (or being similar) in the activities that they support. For example, research grant funding can also be used to support projects that are complementary to each other by aiding the creation of multi-disciplinary groups, so broadening a research effort. A series of grants can also be used to lengthen the duration of a research effort, such that these are complementary in their use to develop a line of research towards application.

#### 3.5.1 Complementarities across regions

One of the most basic complementarities is revealed in the exploration of how hosts and funders are active across the geography of the UK. In order to divide geographies up into regions, the 'Nomenclature of territorial units for statistics' is adopted, using the Level 2 codes (NUTS-2 divides the UK into 36 regions, vs. only 12 for NUTS-1).<sup>4</sup> Table 3.7, Figure 3.13 and Figure 3.14 divide the UK into NUTS-2 regions. Table 3.7 demonstrates that all regions of the UK are active in neoplasms research to some extent.

**Table 3.7: UK regions (NUTS-2) and number of publications**

	NUTS-2 Code	Region	Number of publications
1)	UKI1 and UKI2	Inner London and Outer London	3124
2)	UKH1	East Anglia	720
3)	UKJ1	Berkshire, Buckinghamshire and Oxfordshire	713
4)	UKD3	Greater Manchester	540
5)	UKM2	Eastern Scotland	495
6)	UKG3	West Midlands	485
7)	UKE4	West Yorkshire	452
8)	UKM3	South Western Scotland	395
9)	UKD7	Merseyside	322
10)	UKK1	Gloucestershire, Wiltshire and Bristol/Bath area	313
11)	UKF1	Derbyshire and Nottinghamshire	307
12)	UKC2	Northumberland and Tyne and Wear	291
13)	UKJ3	Hampshire and Isle of Wight	286
14)	UKL2	East Wales	278
15)	UKE3	South Yorkshire	269
16)	UKF2	Leicestershire, Rutland and Northamptonshire	203
17)	UKN0	Northern Ireland	195
18)	UKM5	North Eastern Scotland	130
19)	UKJ2	Surrey, East and West Sussex	120
20)	UKK4	Devon	107
21)	UKD4	Lancashire	97
22)	UKD6	Cheshire	96
23)	UKE2	North Yorkshire	78
24)	UKL1	West Wales and The Valleys	69
25)	UKJ4	Kent	58
26)	UKE1	East Yorkshire and Northern Lincolnshire	57
27)	UKK2	Dorset and Somerset	54
28)	UKH2	Bedfordshire and Hertfordshire	47
29)	UKH3	Essex	41
30)	UKC1	Tees Valley and Durham	37
31)	UKG2	Shropshire and Staffordshire	30
32)	UKG1	Herefordshire, Worcestershire and Warwickshire	27
33)	UKF3	Lincolnshire	12
34)	UKK3	Cornwall and Isles of Scilly	12
35)	UKD1	Cumbria	7
36)	UKM6	Highlands and Islands	7

<sup>4</sup> [http://epp.eurostat.ec.europa.eu/portal/page/portal/nuts\\_nomenclature/introduction](http://epp.eurostat.ec.europa.eu/portal/page/portal/nuts_nomenclature/introduction)


Figure 3.14 shows how co-author ties generate a collaborative network that reflects some of the geospatial relationship of towns the UK, with remote, sparsely populated regions at the margins of the map. Figure 3.13 also shows that the UK is highly dependent on research in London, Cambridge and Oxford areas as 4,032/7,510 publications (~54% of the sample) were produced with at least one co-author in "Inner and Outer London", "East Anglia" or "Berkshire, Buckinghamshire and Oxfordshire". However, the remaining ~46% of the output has no co-author from a research host organisation from these regions. Vosviewer software identifies clusters within this co-authorship network, highlighting how authors in "Inner and Outer London", "East Anglia" or "Berkshire, Buckinghamshire and Oxfordshire" are more closely linked with "West Yorkshire" "Herefordshire, Worcestershire and Warwickshire" and "Surrey, East and West Sussex" than other parts of the country. See Figure 3.14. The Scottish regions also form a notably distinct cluster, as does the North West of England.

Table 3.8 shows funding by the funders acknowledged in at least 2% of the publications combined with region of the UK identified from host organisations' addresses. A strong limitation of the data is that publications do not consistently reveal which host organisations obtain support from specific funders in multi-host multi-funder papers. However, it is possible to demonstrate regions where no publications supported by a given funder have a host organisation in a particular region. In this way it is possible to show that eight NUTS-2 regions received funding from fewer than half of the top nine funders. These include "Cornwall & the Isles of Scilly" "Cumbria", "Devon", "Essex", "Kent", "Hertfordshire, Worstershire and Warwickshire", "Lincolnshire", "Tees Valley & Durham", and "West Wales and the Valleys".


Cancer Research UK, the Departments of Health and the MRC provide the most comprehensive geographic coverage by regional funding, which is unremarkable given the size of their funding portfolios. However, these funders and the Wellcome Trust are notable in focusing the most research funding in London, East Anglia and Berkshire, Buckinghamshire and Oxfordshire – the so-called 'Golden Triangle' of London, Cambridge and Oxford. While the smaller funders shown also generally have the core focus of their research on London, they more often have a secondary geographical focus outside the 'Golden Triangle'. For example Leukaemia and Lymphoma Research appears to focus in "Northumberland, and Tyne and Wear", and "West Yorkshire", while Breakthrough Breast Cancer supports research in "Greater Manchester" and "Eastern Scotland".

This suggests that there is complementarity between the large national funders that focus on the South East and smaller, perhaps more regionally oriented, charities that focus elsewhere as well as in London. Examples outside the top nine include Yorkshire Cancer Research, Scottish Funding Council, Cancer Research Wales, Northwest Cancer Research Fund and the Newcastle Healthcare Charity. There are also many smaller charities that also focus their funding efforts in the Golden Triangle, so this is not to say that small funders offset the focus demonstrated by the large funders.

Figure 3.14: Co-authorship between UK NUTS-2 regions. Network and relative clusters are produced using VOSviewer Version 1.5.4



(a) Network view



(b) Cluster view



**Table 3.8: UK funding organisations acknowledged in at least 2% of the publication sample by directly or indirectly supported regions (NUTS-2)**

Regions	Funders								
	Cancer Research UK	DH (including NHS and NIHR)	Medical Research Council (MRC)	Wellcome Trust	Leukaemia and Lymphoma Research	Breakthrough Breast Cancer	Breast Cancer Campaign	Engineering and Physical Science Research Council (EPSRC)	Biotechnology and Biological Sciences Research Council (BBSRC)
Tees Valley and Durham	6	6	3	1	0	0	0	0	0
Northumberland and Tyne and Wear	54	46	32	8	19	3	2	2	6
Cumbria	0	0	0	0	0	0	0	0	0
Greater Manchester	102	89	35	11	9	24	8	7	13
Lancashire	5	7	3	1	0	0	0	1	0
Cheshire	8	5	4	1	0	0	0	2	2
Merseyside	42	39	20	6	2	1	1	0	8
East Yorkshire and Northern Lincolnshire	2	6	4	1	1	0	0	1	1
North Yorkshire	5	7	4	1	7	0	0	1	1
South Yorkshire	40	42	14	3	4	6	12	6	5
West Yorkshire	88	60	40	10	18	1	6	2	7
Derbyshire and Nottinghamshire	38	32	19	1	1	3	9	4	5
Leicestershire, Rutland and Northamptonshire	24	28	15	5	7	1	5	0	1
Lincolnshire	0	0	1	0	0	0	0	0	0
Herefordshire, Worcestershire and Warwickshire	0	3	1	0	0	0	0	0	0
Shropshire and Staffordshire	2	2	0	0	0	0	1	1	1
West Midlands	85	54	45	11	15	1	7	7	5
East Anglia	224	177	115	70	19	8	22	5	8
Bedfordshire and Hertfordshire	1	2	2	0	1	0	1	1	0
Essex	2	1	0	0	0	0	0	0	0
Inner London and Outer London	518	613	274	113	62	78	41	47	26
Berkshire, Buckinghamshire and Oxfordshire	185	168	128	57	17	10	7	18	13
Surrey, East and West Sussex	14	16	7	3	2	1	1	1	1
Hampshire and Isle of Wight	50	35	17	5	16	2	7	1	4
Kent	3	4	0	0	0	0	1	0	0
Gloucestershire, Wiltshire and Bristol/Bath area	48	53	36	13	10	1	4	2	3
Dorset and Somerset	9	5	7	0	7	1	0	0	0
Cornwall and Isles of Scilly	1	2	1	0	0	0	0	0	0
Devon	20	27	10	3	0	1	0	0	0
West Wales and The Valleys	11	5	3	0	0	0	0	1	0
East Wales	39	36	23	9	14	2	2	4	5
Eastern Scotland	73	43	55	23	5	18	6	7	8
South Western Scotland	75	29	37	20	6	3	1	2	4
North Eastern Scotland	14	25	10	3	0	1	4	1	3

Around half of the organisations working on neoplasms in the UK produced work through international collaboration, while the remaining 576 worked alone or with national co-authors. Most such organisations (426) produced only one publication on neoplasms in 2011. This is a highly diverse group of organisations, including hospitals (157) government offices or organisations (34), industry (47) and charities (33). A further 152 – the majority of which were hospitals (116) – produced between 1 and 15 publications in 2011. This suggests there may also be a complementarity between institutions that have an international focus and those addressing national-level research agendas. However this requires further investigation to confirm.

It is possible that the national-level, low volume publishing organisations are producing distinct types of output to the high volume, highly international publishers. This remains to be investigated.

### 3.5.2 Funder complementarities at research host organisation level

Following from the discussion above, it is possible to explore the coverage of the UK research host organisations by the major funders to understand the number of distinct UK organisations directly or indirectly supported by them. As noted in Figure 3.1, it is not possible to distinguish between direct benefit (where a host organisation has funding) and indirect benefit (where host organisations and funders support a single publication). The funders shown in Table 3.9 supported (directly or indirectly) in total 430 UK organisations (out of 699 organisations involved in those publications with acknowledgment sections).

**Table 3.9: Number of research host organisations involved in papers supported by major UK funders**

Funder	Number of organisations
1) UK Departments of Health (inc. NHS, NIHR)	330
2) Cancer Research UK	259
3) Medical Research Council	175
4) Wellcome Trust	91
5) Breast cancer Campaign	68
6) Engineering and Physical Sciences Research Council	60
7) Leukaemia and Lymphoma Research	59
8) Biotechnology and Biological Sciences Research Council	49
9) Breakthrough Breast Cancer	48

### 3.5.3 Complementarities across MESH codes within neoplasms

Complementarity of funders and host organisations can be investigated by analysing the specific focus of the research that these organisations are pursuing. This allows the relative focus of research on neoplasms at national and organisational level to be studied, and identification of relatively neglected areas.

We use the MeSH descriptors under the 'parent' descriptor "Neoplasms" to profile the research of these organisations. Table 3.10 shows that the publications in our sample were classified by descriptors belonging to the sub-branches "Neoplasms by Site" and "Neoplasms by Histologic Type" which hold ~68% and ~43% of the sample respectively (see Table A2 in the appendix for more details on the MeSH classification system). Table 3.11 reports the descriptors of these 'sub-branches' at the next level of detail (the third MESH level) with the corresponding number of publications. The three areas with most publications are "Neoplasms, Glandular and Epithelial", "Digestive System Neoplasms", and "Urogenital Neoplasms".

**Table 3.10: “Neoplasms” MeSH Descriptors at level 2 (N=7,510).**

Descriptor	Tree number	Number of publications
Neoplasms by Site	C04.588	5,137
Neoplasms by Histologic Type	C04.557	3,252
Neoplastic Processes	C04.697	970
Cysts	C04.182	175
Neoplasms, Experimental	C04.619	158
Neoplastic Syndromes, Hereditary	C04.700	112
Precancerous Conditions	C04.834	109
Tumor Virus Infections	C04.925	106
Neoplasms, Multiple Primary	C04.651	56
Neoplasms, Radiation-Induced	C04.682	50
Paraneoplastic Syndromes	C04.730	44
Neoplasms, Second Primary	C04.692	40
Pregnancy Complications, Neoplastic	C04.850	37
Neoplasms, Hormone-Dependent	C04.626	24
Hamartoma	C04.445	23
Neoplasms, Post-Traumatic	C04.666	0

Note: More than one descriptor can be assigned to a publication. The publication count includes also the lower levels of the MeSH tree. 1,126 publications (14.99%) are classified as “Neoplasms” at the first level of the MeSH tree, i.e. no additional MeSH descriptors at second or lower level are reported.

**Table 3.11: “Neoplasms by Site” and “Neoplasms by Histologic Type” MeSH Descriptors at level 3.**

Descriptor	Tree number	No. of pubs
Neoplasms, Glandular and Epithelial	C04.557.470	1,633
Digestive System Neoplasms	C04.588.274	1,253
Urogenital Neoplasms	C04.588.945	1,017
Breast Neoplasms	C04.588.180	1,008
Head and Neck Neoplasms	C04.588.443	663
Neoplasms, Germ Cell and Embryonal	C04.557.465	652
Neoplasms, Nerve Tissue	C04.557.580	614
Endocrine Gland Neoplasms	C04.588.322	565
Thoracic Neoplasms	C04.588.894	533
Leukemia	C04.557.337	435
Nervous System Neoplasms	C04.588.614	373
Neoplasms, Connective and Soft Tissue	C04.557.450	328
Lymphoma	C04.557.386	302
Skin Neoplasms	C04.588.805	287
Bone Neoplasms	C04.588.149	236
Nevi and Melanomas	C04.557.665	229
Neoplasms, Plasma Cell	C04.557.595	132
Neoplasms, Vascular Tissue	C04.557.645	115
Neoplasms, Complex and Mixed	C04.557.435	62
Soft Tissue Neoplasms	C04.588.839	62
Eye Neoplasms	C04.588.364	61
Hematologic Neoplasms	C04.588.448	60
Abdominal Neoplasms	C04.588.33	46
Mammary Neoplasms, Animal	C04.588.531	23
Pelvic Neoplasms	C04.588.699	13
Neoplasms, Gonadal Tissue	C04.557.475	11
Lymphatic Vessel Tumors	C04.557.375	10
Histiocytic Disorders, Malignant	C04.557.227	5
Splenic Neoplasms	C04.588.842	5
Odontogenic Tumors	C04.557.695	1
Anal Gland Neoplasms	C04.588.83	1

Notes. More than one descriptor can be assigned to a publication. Publications to which multiple descriptors belonging to the same branch (at the third level of the MeSH tree) are assigned are not double counted. The third level of the MeSH tree allows classifying 6,174 publications (82.2%).

Major UK research host organisations (17) and funders (9) are profiled according to the most frequently occurring 25 MeSH descriptors in Figure 3.14 and Figure 3.15, respectively. These figures report two types of information for each major UK host organisation and funder. The radar chart on the left of each page depicts the proportion of research that a host organisations produced or a funder supported in a given neoplasm domain relatively to overall number of publications that they produced/supported in neoplasms. The radar chart on the right of the page normalises the organisations' profiles by comparing the proportion of publications a host organisation produced or a funder supported in a given neoplasm domain versus the expected value of publications in that domain. The expected value (number) of publications in the neoplasms domain is calculated as the average number of publications per organisation in that domain. This allows an organisation's research contribution by neoplasm domains in relation to the overall activity in those domains and to the organisation's output. For example, if a domain is indicated to have a value higher than 1, then the focal organisation is contributing to that domain more than expected.<sup>5</sup>

Figure 3.15 explores how the research of the major host organisation is distributed over the major neoplasm domains (as reported in Table 3.11). The Figure 3.15 indicates that major UK host organisations (except for Cardiff University and University of Southampton) contributed at least 20% of their research output to the "Neoplasms, Glandular and Epithelial" domain. At least 20% of the research output of University College London, Imperial College, Oxford University, University of Leeds, and University of Glasgow is focused on "Digestive System Neoplasms". Finally, the Institute of Cancer Research, University of Cambridge, Oxford University, Queen Mary University of London, and Cardiff University focused more than 20% of their research output on "Urogenital Neoplasms". Overall the top-9 major host organisations' research profiles are relatively similar. However the radar charts suggest that University of Edinburgh and University of Sheffield are particularly focused on "Breast Neoplasms" domains to which they contribute ~30% of their neoplasms research outputs. Other distinctive features include a relative focus at University of Liverpool on "Head and Neck Neoplasms" and at Cardiff University and University of Southampton on "Leukemia".

Additional information on the host organisations' research profile is provided by the radar charts on the right of each page in Figure 3.15, which show output relative to other organisations nationally. The charts reveal that while all UK major host organisations (except for Cardiff University and University of Southampton) contributed to the "Neoplasms, Glandular and Epithelial" domain with at least 20% of their research output in neoplasms, none of these organisations is contributing more than expected to this neoplasm domain, which is a major focus at the national level.

Similarly University College London, Imperial College, Oxford University, University of Leeds, and University of Glasgow undertake a high proportion of


---

<sup>5</sup> An alternative normalisation approach could consider the incidence ratio of different neoplasms on UK population. However, the available statistics do not fully match the MeSH classification making this type of normalisation possible only for certain types of neoplasms. This would provide partial statistics. We therefore deemed it more suitable to undertake a normalisation based on publication count.


their neoplasms research on "Digestive System Neoplasms". However, only Oxford University, University of Leeds, and University of Glasgow are contributing more than expected to this domain. Finally, the Institute of Cancer Research, University of Cambridge, Oxford University, Queen Mary University of London, and Cardiff University focus more than 20% of their research output in "Urogenital Neoplasms" and are also contributing more than expected to this type of neoplasm research.

The charts also reveal major contributions to relatively smaller neoplasms domains. For example, the Institute of Cancer Research, University of Leeds, University of Newcastle, University of Birmingham are contributing at least twice as much as is expected to "Neoplasms, Plasma Cell". In addition, University of Newcastle and University of Cardiff produced more publications than expected in "Leukemia".


**Figure 3.15a: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**



**Figure 3.15b: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**




**Figure 3.15c: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**






**Figure 3.15d: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**



**Figure 3.15e: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**



**Figure 3.15f: Major UK research host organisations in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of research host organisations’ total publications in different neoplasm domains. Right charts report whether research host organisations are more (>1.0) or less (<1.0) active in each domain than expected.**






Figure 3.16 shows that the top three external research funders (CR-UK, DH and MRC) also mainly focus on “Neoplasms, Glandular and Epithelial”, “Digestive System Neoplasms”, and “Urogenital Neoplasms”. The remaining funders have a more specialised research profile across the neoplasms domains. For instance, ~80% of the publications supported by Breakthrough Breast Cancer or Breast Cancer Campaign are classified as “Breast Neoplasms”. Leukaemia and Lymphoma Research support paper mainly related to “Leukemia” and “Lymphoma” domains. The Wellcome Trust and BBSRC are relatively more focused on “Neoplasms, Germ Cell and Embryonal” and “Neoplasms, Nerve Tissue” domains. While the top-3 funders’ research profiles are relatively similar in the neoplasms domains that they support, it is worth noting that relatively ‘minor’ neoplasm sites such as eye, bone, skin and soft tissue are neglected by these funders. However, the remaining major funders seem to complement this. For example, BBSRC and EPSRC are contributing more than expected to eye, bone, skin and soft tissue domains (see charts on the right in Figure 3.15).


**Figure 3.16a: Major UK funders acknowledged in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of funders’ total publications in different neoplasm domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**



**Figure 3.16b: Major UK funders acknowledged in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of funders’ total publications in different neoplasm domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**



**Figure 3.16c: Major UK funders acknowledged in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of funders’ total publications in different neoplasm domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**




The analysis also compares the major UK funders collectively (defined as those supporting at least 2% of the research output) with the remaining research funders that are more minor by funding activity in neoplasms research. To facilitate comparisons at the aggregate level, we first to chart the interdependence between different types of funders and set out the overall contributions by each set of funders individually and with other funders by group. To do so, we defines three categories of funder as in the followings:

- Major UK funders: UK funders acknowledged in at least 2% of the publications reporting acknowledgment sections

- Minor UK funders: UK funders acknowledged in less than 2% of the publications (however these are not necessarily small funders by size).
- Other Funders and Industry: all other funders not falling in the previous categories including industrial actors

A publication may be supported by one of these categories of funders or by combinations of these. We represent the possible combinations in Figure 3.17 and report the number of publications supported by each combination of funders.

**Figure 3.17: Conceptualising the co-funding**




Subset	Number of publications
A	697
B	426
C	1,344
D	483
E	166
F	433
G	365

The analysis reveals that 697 publications (17.8%) are exclusively supported by one or more UK major funders, 466 publications (10.9%) are exclusively supported by one or more UK minor funders, and 1,344 publications (34.3%) are exclusively supported by other funders and industry. Adopting the same radar chart approach used to profile the research produced by major UK host organisations or supported by the major UK funders, we profile the publications according to the combination of categories of funders that supported them. This analysis is reported in Figure 3.17.

Publications supported only by major UK funders (a) are mainly focused on "Neoplasms, Glandular and Epithelial", "Digestive System Neoplasms", "Urogenital Neoplasms", and "Breast Neoplasms" while "Head and Neck Neoplasms", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Endocrine Gland Neoplasms", and "Thoracic Neoplasms" are relatively neglected when compared to research outputs supported only by minor UK funders (b). This

finding is confirmed also when the observed number of publications is compared with the expected one (see right radar charts in Figure 3.18b). Interestingly, the subset of publications supported by UK minor funders and other funders including industry (e) is unevenly distributed across neoplasms domains when it is compared to the subset of publications supported by other funders' combinations (left charts). The combination of minor UK funder and other funders including industry is also disproportionately contributing to specific neoplasms domains (right charts) such as "Breast Neoplasms", "Neoplasms, Germ Cell and Embryonal", "Thoracic Neoplasms", "Bone Neoplasms", and "Nevi and Melanomas".

**Figure 3.18a: Funders acknowledged in "Neoplasms" area and distribution of publications across the different types of cancer. Left charts report the percentage of funders' total publications in different neoplasm domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**





**Figure 3.18b: Funders acknowledged in “Neoplasms” area and distribution of publications across the different types of cancer. Left charts report the percentage of funders’ total publications in different neoplasm domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**




Figure 3.19 summarizes how different categories of funders contribute to the neoplasms domains independently or in combination – based only publications reporting funding sources in the acknowledgement section. Results shows that the proportion of publications supported exclusively by major UK funders (blue) or minor UK funders (red) is very similar across a number of domains such as “Head and Neck Neoplasms”, “Neoplasms, Nerve Tissue”, “Thoracic Neoplasms”, and “Skin Neoplasms”. Major UK funders are more active than minor UK funders in domains such as “Digestive System Neoplasms”, “Urogenital Neoplasms”, “Breast Neoplasms”, “Neoplasms, Vascular Tissue”, “Soft Tissue, Neoplasms”, and “Pelvic Neoplasms”. As there are only nine major funders this suggests funding is relatively more concentrated in these domains. Publications supported exclusively by “Other Funders and Industry” (green) are relatively equally distributed across the different neoplasms domains (except for “Abdominal Neoplasms”, “Mammary Neoplasms, Animal” and “Pelvic Neoplasms”) showing that industrial funders and non-UK funders support on average ~33% of publications across the neoplasms domains.

**Figure 3.19: Funders acknowledged in “Neoplasms” area and distribution of publications across the different types of neoplasms (N=3,914)**





Figure 3.20 further explore this by combining the different categories in three overlapping groups, i.e. publications supported at least by one major UK funder (a+d+f+g), publications supported by at least one minor UK funder (b+d+e+g), and publications supported at least by one ‘other’ funder or industry (c+e+f+g). While the three groups have a relative similar research profile when compared in term of proportion of publications supported in a given neoplasms domains (top charts in Figure 3.20), the charts comparing the observed number of publication with the expected one in each domains provide evidence of the diversity of research profiles of the three groups. Publications supported by at least one UK minor funder seems to be more evenly spread across the neoplasms domains, i.e. the number of publications is close to the expected one in many domains, when

compared to the distribution of publications supported by at least one major UK funder. The analysis also shows that publications supported at least by one funder not falling to the other two groups or industry are concentrated more than expected in a number of neoplasms domains such as "Neoplasms, Plasma Cell", "Nevi and Melanomas", "Hematological Neoplasms", and "Abdominal Neoplasms".

**Figure 3.20: Comparing major and minor UK funders acknowledged in “Neoplasms”. Upper charts report the percentage of funders’ total publications in different neoplasm domains. Lower charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**



### 3.5.4 Complementarities across funding schemes

For the purpose of this study we identify complementary funders' schemes as being those that collectively support a wider range of research activity than individual funders, and by doing so facilitate researchers to obtain funding throughout their career for different types of research, rather than a narrower range of activity. In order to explore how funding schemes might be complementary, the top public funders in neoplasms were identified by publication counts, and data regarding the funding schemes they support gathered from their websites and their most recent annual reports.

The top funders were: Cancer Research UK, the UK Departments of Health (DH, subdivided into NHS and NIHR), the Medical Research Council (MRC), the National Institutes for Health (NIH, USA), The Wellcome Trust, Breast Cancer Campaign (BCC), Biotechnology and Biological Sciences Research Council (BBSRC), Yorkshire Cancer Research (YCR), Economic and Physical Sciences Research Council (EPSRC), Leukaemia and Lymphoma Research (LLR), European Union (EU, under Framework Programme 7 (FP 7) and European Commission Department of Health and Consumers (DG SANCO).

The data collected from these funders covered the purpose, duration and amount of the funding, in addition to an idea of the people who would be eligible to apply. A subjective interpretation has been made to develop a classification system in an attempt to overcome the issues associated with the diversity of terminology used by different funding bodies (see Table 3.12). The terminology used by funders to describe their schemes may vary from the description here.

**Table 3.12: Classification system to enable the categorisation of the different types of funding available from the top funders of UK research in neoplasms**

Type of funding	Purpose	Scale of award	Duration
<b>Fellowships</b>	To set up research groups, provide further training or to further academic career development. Anything after completion of doctoral studies	Usually covers salary for the duration	Can be anything from 1-6 years
<b>Studentships</b>	To fund academic development of fund further formal training (up to and including PhD training). Mainly stand-alone studentships (i.e. excluding studentships written into Programme or Project grant proposals).	Usually covers salary and tuition fees for the duration	3-4 years
<b>Projects</b>	To fund a defined piece of work with clearly state and achievable objectives	Some have no fixed limits but tend to range from £25,000 up to £1m per year	1-5 years
<b>Programmes</b>	To provide long term support for larger research groups that aim to answer an interrelated set of questions and utilise a multidisciplinary team	Often with no pre-defined funding limit but usually multi-million pound	5-7 years

Other types of funding categorised but not shown include funding specifically for infrastructure (sometimes including equipment and resources) or travel. The summary table of funding schemes offered by top funders is presented below (Table 3.13).

**Table 3.13: A summary overview of the different types of funding available from the top public funders of UK cancer research**

Funder	Type of project funding					
	Fellow-ships	Student-ships	Infra-structure	Programmes	Projects	Travel
Cancer Research UK	✓		✓	✓	✓	✓
DH (NHS)		✓				
NIHR	✓	✓			✓	
Medical Research Council (MRC)	✓	✓		✓	✓	
National Institutes of Health (NIH)	✓			✓	✓	✓
Wellcome Trust	✓	✓	✓	✓	✓	✓
Breast Cancer Campaign	✓	✓			✓	
Biotechnology and Biological Sciences Research Council (BBSRC)	✓	✓		✓	✓	✓
Yorkshire Cancer Research (YCR)	✓	✓		✓	✓	✓
Engineering and Physical Science Research Council (EPSRC)	✓	✓		✓	✓	✓
Leukaemia and Lymphoma Research	✓	✓		✓	✓	✓
European Commission (FP7)	✓		✓	✓	✓	
European Commission DG SANCO			✓		✓	✓

### PhD Studentships

PhD Studentships in cancer research represent a subset of the studentships categorised above. There are two reasons for this: 1) studentships in general was taken to include schemes such as internships for undergraduates, summer research placements, funding for masters programmes, 'in-practice' fellowships and funding for specific training for doctoral students, and 2) only those studentships that provided a full stipend and coverage of tuition fees are discussed further here. These studentships were available from seven of the top funders including BBSRC, BCC, EPSRC, LLR, MRC, NIHR and The Wellcome Trust. This shows that the UK funding system provides significant choice for prospective PhD students seeking funding.

Interestingly, the top two funders in the UK, Cancer Research UK and the DH (NHS division), do not appear on this list, principally because the NHS only provides bursaries for tuition fees, and not stipends to students and Cancer Research UK fund studentships within PI led projects rather than awarding direct-to-student funding..Of the studentships available, it notable that the three UK research councils offering studentships, the BBSRC, EPSRC and MRC, all offer a stream of funding available for research to be carried out in collaboration with industry partners. Termed CASE (Collaborative Awards in Science and Engineering) studentships, these provide students with research training experience and an opportunity to take their research into the private sphere.

## Early Career Researchers

For a more detailed analysis of the funding available for early career researchers, we take a subset of the fellowships category, as defined in Table 3.11. For these purposes we take the threshold for 'early' career funding opportunities to be any available to researchers who completed their PhD less than five years prior to application<sup>6</sup>. Included under this categorisation are fellowships open to post-doctoral researchers, where the funding is specifically aimed at early career researchers, or where there is no specification of career stage. Only fellowships supporting awardees salary are included.<sup>7</sup> Nine of the major funding bodies provide early career fellowships including the BBSRC, Cancer Research UK, EPSRC, EU (under FP7), LLR, MRC, NIHR, The Wellcome Trust and YCR. The UK funding system therefore benefits from a wide range of funding options for early career researchers.

One common characteristic of these fellowships is that there are many that are collaborative in nature and involve cooperation between more than one type of institution or funder, be it in terms of sector, discipline or geographic location. For instance, all three fellowships offered by BBSRC are funded in partnership with another funding body (the Food Standards Agency, Royal Society of Edinburgh and Royal Society/EPSC/NERC and Rolls Royce) with one requiring the establishment or strengthening of corporate ties between industry and academia. Other funders tend to encourage clinical/academia links with fellowships offering clinicians academic research training or lectureships (LLR, MRC and NIHR). In terms of encouraging research outside the biological and chemical sciences the MRC, Cancer Research UK and Wellcome show some focus towards social science disciplines such as health economics, population studies, biomedical informatics and public health, whereas the NIHR and Wellcome have fellowships in transitional/translational research areas, emphasising the shift from basic to clinical science. The EPSRC support a scheme focusing high risk research. In terms of fellowships that encourage geographic movement, the EU (FP7) presents several outgoing (and ingoing – although these were not specifically included in this analysis due to the lack of salary funding) fellowships in collaboration with Marie Curie, and the support of training networks, that allow networks to bring early career researchers in directly. In addition, Wellcome has a collaborative fellowship with the Massachusetts Institute of Technology (MIT) that allows researchers time in both a UK (host) institution and at MIT.

## Projects

Project grants represent the most common pathway to funding from the sample of funders we assessed: 12 of the 13 funding bodies analysed showed opportunities for project funding. The only funder that shows no availability of project funding was the NHS, which is likely explained by the responsibility for this type of funding for the DH being taken on by the NIHR. As with fellowships there are distinctions between the ways organisations approach the distribution of

<sup>6</sup> Fellowships aimed at clinicians with professional qualifications were not deemed to be 'early career'.

<sup>7</sup> This inclusion criterion, therefore excludes schemes such as the CRUK Career Establishment Award, which aims to help researchers develop an independent career in cancer research by establishing a research group, as it does not fund the award holders salary.

funding for projects. Since the period studied, Cancer Research UK has withdrawn the availability of project grants.

**Table 3.14: Summary of the different types of project funding available from the top public funders of UK cancer research**

Funder	Targeting of project funding schemes						
	International or EU collaboration	Industrial collaboration	Translational, feasibility or innovation	Specific research areas relating to cancer	New investigators	Linked to prior or additional research	High Risk or longer term projects
Cancer Research UK			✓	✓			
NIHR			✓	✓			
Medical Research Council (MRC)			✓	✓		✓	
National Institutes of Health (NIH)			✓	✓		✓	
Wellcome Trust		✓	✓	✓		✓	
Breast Cancer Campaign				✓			
Biotechnology and Biological Sciences Research Council (BBSRC)	✓	✓	✓		✓		
Yorkshire Cancer Research (YCR)			✓				
Engineering and Physical Science Research Council (EPSRC)		✓			✓		✓
Leukaemia and Lymphoma Research				✓			
European Commission (FP7)	✓	✓			✓	✓	✓
European Commission DG SANCO	✓						

The diverse range of project grants available from the top public cancer funders is summarised in Table 3.14. Whilst some of these categories are straightforward, others show a large amount of variation. For instance, funding for translational, feasibility or innovation purposes can range from translation of research from lab to clinic (BBSRC, MRC, Wellcome, YCR), drug discovery (Cancer Research UK, YCR) and innovation of medical technologies more broadly (NIHR) to pilot or feasibility studies (NIH). However, this category does not include grants specifically aimed at proving funding for clinical trials (discussed in a separate section below). In addition, the project funding categorised under specific research covers general funding for particular subtypes of cancer (as in the cases of BCC or LLR) and the various disciplinary approaches to cancer research (e.g. Cancer Research UK funds specific projects relating to tobacco advisory groups, population research and biomarkers; NIHR funds more patient-related research such as health services and delivery, public health, health technology assessment, efficacy and mechanism evaluation and patient benefit; and Wellcome funds initiatives towards sustaining health). Projects that are linked to prior or additional research has been indicated where a funding body sets out project grants for research projects that may lead to programme grants (MRC),



grants linked to a renewal of a previous project (NIH), strategic grants that add value to existing research groups<sup>8</sup> (Wellcome) or for the support for recently created teams (EU FP7). In addition to these variations within groups there are also distinct strategies for project funding that do not fit into any of the above categories. For instance, the NIH offer more general and exploratory options for the direction of their project funding, as well as projects that encourage cooperation between itself (the NIH) and the research groups. In addition the MRC have a stream of project funding that focuses on the development of methods for research.

### **Programmes**

Ten of the 13 funders support large, multidisciplinary programme grants. These are BBSRC, Cancer Research UK, EPSRC, EU (FP7), LLR, MRC, NIH, NIHR, Wellcome and YCR. Most of these programme grants lack specified directions, where most simply require a proposal that identifies an integrated but multidisciplinary research stream. Some do, however, specify particular research area interests, such as the Cancer Research UK Population Research Committee Programme Grants, the MRC Experimental Medicine Challenge Grant (focusing on disease pathophysiology), the NIH Specialised Centre, supporting specific disease areas, and the Wellcome/EPSRC Innovative Engineering for Health scheme which focuses on biomedical engineering. The LLR Specialist Programme grant and the NIHR Programme Development Grant also show a distinction from other initiatives, where the LLR scheme provides further support existing grant holders, and the NIHR supports the preparation of programme grants.

### **Clinical trials**

Schemes that explicitly support clinical trials are available from four of the 13 funding bodies in this analysis: Cancer Research UK, LLR, MRC and NIH. Cancer Research UK have three such grant options, ranging from small project grants for feasibility studies (allowing for £25,000 per annum to be obtained for a maximum of four years) to larger scale Phase III Clinical Trial Grants, which appreciate how costly and time consuming this later stage of development can be by offering £100,000 per annum for 10 years. The charity's New Agents Committee Trials Funds also claims to provide a process for selecting new treatments and diagnostics and allowing them to enter early clinical trials (offering £40,000 per annum for two years). LLR also offer Clinical Trial awards for Phase I/II trials of new therapy options, however the financial and duration limitations are not publicly disclosed. The MRC (in collaboration with the Technology Strategy Board (TSB)) offer £250,000 as a minimum for clinical projects under their Biomedical Catalyst: Developmental Pathway Funding Scheme. Finally the NIH offer a smaller amount, up to \$100,000 for 1-3 years to support the planning of clinical trials as part of their Clinical Trial Planning Grant Program.

---

<sup>8</sup> Note that this stream shows possible overlap with the type of funding provided by CRUK in their Senior Cancer Research Fellowship which supports the establishment or further development of an independent research group.

## Industry

There are several ways in which funders seem to be encouraging collaboration between academic and industrial research. One is through the industrial fellowships where researchers from industry are encouraged to bring their skills into an academic context (run by BBSRC). Other schemes involve encouraging partnerships between industry and academia (EPSRC/TSB and MRC), while some of these entail the expectation that the industrial partner will contribute some funding towards the collaboration (BBSRC). The EU (FP7) shows support for industry through their collaborative projects and Industry-Academia Partnerships and Pathways (under the Marie Curie Actions), that encourage industry/academia consortia, and support for industry directly through a Risk-Sharing Finance Facility and Small and Medium Size Enterprises (SMEs) initiatives.

## Non-UK-based funding bodies

The analysis major funders of UK neoplasm research identified five funding bodies based outside the UK<sup>9</sup>. The NIH (National Institutes of Health in the USA), was included in the main analysis due to the apparent wide-ranging coverage of their project and programme funding and its availability to institutions from other countries outside the USA, ranging from public or private, non-profit or for-profit. It is therefore justifiable to conclude that researchers based in the UK may be gaining access to funding streams from the NIH. The remaining foreign funding bodies, which include the Swedish Cancer Society (SCS), the Italian Association for Cancer Research (AIRC), German Cancer Aid (GCA) and Australia's National Health and Medical Research Council (NHMRC), generally limit the amount of funding available to UK researchers/institutions and focus on domestic institutions. For the NHMRC, the general rules of eligibility are that the chief (principal) researchers should be Australian citizens or have permanent residency, however other listed researchers on grants can be of any nationality.

In light of this there are two potential explanations for the inclusion of these foreign funding bodies in the top funders of UK cancer research. One is that the data shows a large amount of international collaboration, where UK researchers are working alongside non-UK researchers, and the funding patterns of all collaborating authors are being picked up by our methods. The other explanation is that researchers based in the UK may have dual institutional affiliations or have undertaken visits abroad and therefore have had some funding from non-UK/EU funding sources.

## Summary on complementarities of funding schemes

This analysis shows that the funding opportunities available to researchers from the funding bodies most active in supporting cancer research in the UK are both overlapping and complementary.

The most overlap is seen with fellowships (including those for early career researchers) and project grants. Studentships are also readily available from a number of these funders, with particular significance lying in the existence of an

---

<sup>9</sup> This is with exception of the European Union FP7 and DG SANCO (EC) which are included in the analysis.

emphasis, from the UK research councils, on collaborative studentships with industrial partners.

Funders of UK research are particularly complementary to each other in the area of project grants where there are a broad range of different types of scheme available to suit the diverse needs of researchers.

Where there is least opportunity for support is in the later stages of the development spectrum in the area of clinical trials and industrial funding, opportunities are less broad particularly where studies require large amounts of funding over longer term. Exceptions include the Cancer Research UK Phase III Clinical Trial Grants and the MRC/TSB Biomedical Catalyst Developmental Pathways Funding Scheme being the only later stage development funding available from these sources. This implies that, despite the relatively well-funded area of translational studies, there are limitations to the extent to which public funding can provide the necessary funding for bodies of research to be taken towards commercialisation, creating a bottleneck with a smaller number of funders. Furthermore, despite the support for industry-academia links, there seems relatively little direct support for industry research from public funding bodies.

### 3.5.5 Researchers use of complementary funding schemes over time

As described in the previous section, diverse funding schemes are available to UK researchers studying neoplasms. This section uses interviews to explore case studies of how researchers can use a series of funding schemes to develop a line of research over a period of years or even over a decade. As the examples discussed illustrate, this is often necessary to achieve significant breakthroughs. Such breakthroughs may depend on bringing together and sustaining multi-disciplinary teams or organisations with diverse missions, meaning that complementary types of funding scheme need to be accessed. Case studies drawing on the experiences of three scientists leading programmes of research are presented here, followed by discussion of common themes.

#### **Case study 2: Research on DNA-repair mechanisms leads to promising drug candidates**

Professor Steve Jackson heads a laboratory at The Gurdon Institute, University of Cambridge, exploring the molecular pathways controlling DNA repair. DNA repair mechanisms are of particular interest because drugs that inhibit the body's cells' ability to repair damaged genes are considered a promising avenue to inhibit cancer growth. Jackson's laboratory has spun out two biotech firms, KuDOS Pharmaceuticals and MISSION Therapeutics, to aid translation of this fundamental biological science into commercial drug programmes. KuDOS attracted more than £40 million in private sector investment mainly from Venture Capital, before it was acquired for over £120 million by AstraZeneca in 2005. The resulting drugs are now in clinical trials.

*What kinds of funding allowed Jackson's work to develop to the stage where it attracted large scale commercial investment?*

Jackson, originally from Nottingham, conducted his early work on DNA repair during a post-doc in the USA in the late 1980s where he was funded by a Lucille P. Markey Fellowship and the Howard Hughes Medical Institute as well as the Leukaemia Society of America. He was offered further funding to stay in the USA and might not have returned: "I would not come back to the UK just to be scratching around for smaller grants" Jackson said. One substantial opportunity Jackson pursued was an application for a Cancer Research Campaign programme grant, which he won. This gave Jackson five years of funding. Jackson recalls "[For] me having a starting point where you can hire 2-3 individuals and form a coherent group is important and that was fundamental for me to come back to the UK." Returning to the UK in 1991, Jackson's laboratory was founded and hosted in an institute jointly funded by the Wellcome Trust and the Cancer Research Campaign. In what was then a new funding model, these charities provided research infrastructure, but the hosted scientists had to find their own additional grant funding to support researchers' salaries and the direct costs of their projects. The five-year CRC programme grant allowed Jackson considerable flexibility, which retrospectively can be seen as having allowed him to exploit the emerging promise of DNA repair enzymes: "A lot of good science comes along as unexpected. So way back to 1990-1992, I had no idea that my lab was going to be focusing on DNA repair... since then...almost all my publications, nearly a couple of hundred, have been on DNA repair and I set up two companies. That was not planned. So I think best science and the best opportunities are often through doing cutting edge studies in a good environment with good people and following your nose as much anything else."

The CRC programme grant became a platform from which to expand the team from 3-4 to around eight scientists. Jackson suggests that "In order to get a grant you need to have preliminary data to have a compelling case for your proposal and [there is] momentum... if you have an existing grant ongoing ... data can be used as starting point for applying to further grants." These extra grants were necessary to expand the group to fully develop the emerging research lines. Through the early and mid-1990s, Jackson's laboratory had additional funding support from the Medical Research Council, the Leverhulme Trust, the A-T Medical Trust, the Kay Kendall Leukaemia Research Fund, European Union funding schemes, and CRC project grants. Each extra grant would cover at least one additional post-doc's salary. Jackson laments these bolt-on awards are more difficult obtain now that Cancer Research UK focuses on distributing Programme grants and no longer offers stand-alone project grants. This makes it difficult to expand existing groups and also it concentrates resources so that some investigators in less well established groups will not get an opportunity to investigate their novel ideas: "we spend £2000 a day just for reagents and that does not include the salaries. Proper cell and molecular biology science in [the] lab is expensive. UK universities would not be able to do science without external funding... and that is just a matter [of] how science is done now."

As DNA repair became a major area of interest for researchers in the field, Jackson's laboratory has collaborated widely. Co-authorship patterns on Jackson's papers show a particularly strong link with an MRC centre at the University of Sussex. Jackson notes that the MRC investment here was also leveraged in supporting research that led to the founding of KuDOS. However, perhaps

surprisingly the grants that have facilitated these interactions have generally not been formal collaborative grants. Jackson suggests “[this area of] science isn’t like assembling an airbus... where you can plan several years in advance... It is perhaps more preferable from the scientists’ point of view that scientists are funded in a manner so that they can afford to collaborate in a spontaneous way”. In this manner, dozens of funders can be identified as supporting Jackson’s publications mainly by funding his co-authors.

It took almost a decade of activity from Jackson’s first paper on DNA repair mechanisms in 1988 to the founding of KuDOS in 1997 and then several more years to the development of pharmaceutical candidates known as PARP inhibitors. During this time not only was much fundamental science explored through an international network, but also the build-up of skills and knowledge in a single location, allowed KuDOS to be founded. Multiple charities and government grants were important to support this work, and CRC continued to support Jackson’s work as an early investor in facilities for KuDOS. Jackson has also played an active role in stewarding the commercial R&D, although as Chief Scientific Officer of KuDOS and now MISSION, he is concerned not to allow industrial influence to shape the scientific agenda.

### **Case study 3: Controversial hypotheses yield results with long term support**

Fran Balkwill is a Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, where she leads the Centre for Cancer and Inflammation and the Cytokine and Cancer group. Balkwill’s research began at the Imperial Cancer Research Fund laboratories at Lincoln’s Inn Fields, London (now Cancer Research UK’s London Research Institute). Balkwill has long been interested in translational research, exploring the therapeutic potential of cytokines such as tumour necrosis factor (TNF) and interferons.

Until the early 1990s TNF was largely characterised as an anti-cancer agent (Balkwill 2009). However during this period it began to be appreciated, by Balkwill’s group and others that under certain circumstances TNF may actually encourage tumour growth. Balkwill recalls a “eureka moment” when she took inspiration from a talk about the application of anti-TNF to treat Rheumatoid Arthritis, in which clinical activity was first shown in 1994: “I heard Mark Feldmann talk about how anti-TNF inhibited inflammatory cytokine production, inhibited the leukocyte infiltrate into the joint, inhibited angiogenesis and inhibited matrix metalloproteinases, and I thought, well that’s what you want to do in the tumour microenvironment”. At the time this was a particularly controversial view as prior evidence dating back to the 19<sup>th</sup> century suggested that TNF would inhibit cancer and subsequent clinical findings leading to the approval of a TNF agent for the treatment of soft tissue sarcoma in 1999 (Balkwill 2009). Balkwill’s unconventional work in the TNF field was nonetheless supported by ICRF (support which continued when it became Cancer Research UK) and she persevered with a trajectory of work on anti-TNF molecules. Balkwill’s work has supported the

clinical testing of anti-TNFs as anti-cancer agents, such as infliximab (Remicade, developed by Centocor), found other cytokine drug targets such as IL-6 and the chemokine receptor CCR4 and developed more fundamental understanding of cancers by showing the potential of some cytokines to have a dual role in tumour development, thus revealing the complexity of the tumour microenvironment.

*What kind of funding allowed Balkwill's work to develop to produce clinically applicable knowledge?*

During the 20 years Balkwill spent at the ICRF at Lincoln Inn Fields in London there was little need to gain access to external funding. However, when Balkwill moved to the Barts Cancer Institute at Queen Mary University of London (then the ICRF Translational Oncology Laboratory) it was necessary to find diverse sources of funding to ensure her group of scientists and their work could be sustained. One of the first things Balkwill did at her new lab was to persuade a commercial partner, Centocor, to fund the preclinical and clinical studies of infliximab, in cancer patients, a stream of funded work that continued for nearly a decade. Balkwill continues to receive funding from diversity of public and private sources reflecting the different streams of research relating to anti-TNF and IL-6 molecules and their clinical applications, to understanding the underlying molecular mechanisms surrounding the activity of TNF and IL-6 as well understanding the cytokine network in the tumour microenvironment as a whole. She also sees it as vital to have diverse funding support and currently holds both a Cancer Research UK Programme grant and an ERC Advanced Researcher grant.

While such large grants are important for sustaining the group, sub-projects can still require additional support as interesting opportunities arise. Balkwill recalls "I had a Cancer Research UK PhD student who came up with an unexpected observation about a chemokine receptor (CCR4) in renal cancer. I got a Discovery Committee grant from Cancer Research UK for 2 years for target validation. During that time, we were able to access a small molecule inhibitor for CCR4 in a collaboration with AstraZeneca". It is hoped that this drug, previously a shelved Asthma drug-candidate can be repurposed if further grant support is forthcoming. Subsequently this avenue of research targeting CCR4 also has proved of interest to Affitech, a Danish biotech firm identified by CRT, who helped to form a licensing and R&D agreement which secured Queen Mary's University further research funding to support Affitech – Balkwill said "we've had now 2 years of very substantial industry funding from them for pre-clinical studies of anti-CCR4 antibodies".

#### **Case study 4: Gene hunting provides new cancer diagnostics**

Ian Tomlinson is a Professor of Molecular and Population Genetics, Group Head/PI and Consultant Clinical Geneticist based at the Wellcome Trust Centre for Human Genetics, Oxford. Tomlinson's research is particularly concerned with genetic predispositions to cancers such as colorectal and renal cancers. His research has revealed a series of genetic mutations in several genes related to rare hereditary cancers. During the period 1995 to 1998, as a post-doctoral researcher, Tomlinson carried out several studies to determine the genetic basis for Peutz-

Jeghers syndrome (PJS), a rare inherited disorder causing hyperpigmented patches of mucosa and gastrointestinal polyps that present elevated malignancy risk. Beginning with genetic linkage studies, Tomlinson worked to gain an insight into the pathway linking PJS with a predisposition to cancers, and to find the genetic locus of PJS (see Hemminki, Tomlinson et al. 1997). The discovery of this specific locus rapidly allowed for the development of improved cancer screening for PJS patients (Tomlinson and Houlston 1997).

Tomlinson's work on PJS was facilitated by two grants, from the European Commission and the other from the Cancer Research Campaign (CRC). These grants covered different aspects of the PJS but presented complementary research themes. Tomlinson recalls: "the actual aims of [the grants] were interrelated, as it happened, doing slightly different things within that disease but very much linked". In addition to the work on PJS, the group also received a small exploratory pump priming award working on breast tumours<sup>10</sup> from the Medical Research Council (MRC).

### **Cross cutting themes**

The above case studies illustrate how multiple grants and funders are often necessary to generate a breakthrough such as developing a new diagnostic or advancing a new class of drug molecule to the clinic.

In the past, Cancer Research UK has been able to sustain researchers in its own laboratories allowing them over decades to develop controversial hypotheses into applied therapeutic programmes, however this is beginning to change as across the UK scientists are required to raise external grants.

Three interviewees discuss the particular importance of Cancer Research UK programme grants as a basis from which to grow larger teams by gaining additional grants. Although more than one suggested their institution would encourage them to look for other funding rather than Cancer Research UK (due to lack of overheads paid), Cancer Research UK grants were suggested by two of the three to be a "mark of quality" for peer reviewers and that helped to attract further grants. Also it was noted that a "core" grant provided the opportunity to generate the data necessary to develop interesting proposals to win further grants. In this way a core grant can help an investigator to rapidly build on promising research to develop a stronger research line.

Having multiple grants at the same time is also important for hedging and providing for continuity of the group, as there is a constant battle to keep post-doctoral researchers funded. Tomlinson suggests a key aim is to avoid sharp peaks or troughs in group size and instead aim for "a gentle undulation". He noted "There's always a potential crisis looming two years down the road for certain members of the group. In Oxford we are quite lucky in that people with their own fellowships, for example, are not that uncommon....they help to even out the natural cycle of [larger] grants."

---

<sup>10</sup> Pump priming awards are generally given out to research aimed at developing new ideas with promising potential.

Jackson also emphasised the importance of individual laboratories having multiple sources of funding: "I think it is a sort of healthy way in running a lab where you have at least two funding bodies contributing" although he (and other interviewees) emphasised that they should not be funded twice to do the same work. Balkwill also suggested it was important not to be over-reliant on one funding source, *recalling "When I moved from CR-UK we probably had 11-12 people on Cancer Research UK grants, by the time it got to my previous one it was three... they just don't give that kind of money any more, it's also got so expensive". Balkwill was awarded a further Cancer Research UK Programme Grant in 2013 with four posts granted. Balkwill currently aims to have no more than 25-30% of her group reliant on one funding source.*

*How do interviewees see today's UK funding environment?*

All four interviewed scientists suggested that the UK funding system was better, from their perspective, than the USA. Jackson suggests scientists studying cancer in the UK have a good choice of funders, including charities, government research councils and European funding opportunities. The situation at the present time is better than the USA where key grant funders such as the NIH are having their budgets cut.

*Balkwill's perspective on the funding environment for cancer research in the UK is generally positive, exceeding the system much of the rest of Europe and the USA. In the latter case, part of the strength of the UK funding environment is the introduction of the European Research Council.*

Jackson also agreed that the UK funding environment remains strong while the US was experiencing funding cuts. Tomlinson observes that the access to funding in the UK is relatively healthy, with a more "streamlined" process of grant applications, than is the case in other countries, particularly the USA. However, Tomlinson also suggests that there are frequently significant changes in directions in the types of research receiving funding. These changes are, perhaps, inevitable, and he likens them to "fashion in science" or "oscillations in how exciting various sorts of research are perceived". Jackson is also concerned that politics is driving UK research councils to be more prescriptive, and focusing too much on seeking economic benefits: "The reality is that innovation and opportunities, and ensuing healthcare companies, in most cases come out from doing good science in a good environment not through translational science in a very applied institute."



### 3.6 Scientometric analysis: Diversity in neoplasm research


#### 3.6.1 Diversity of funders and host organisations across scientific disciplines

One of the questions posed in the proposal was 'Which funders support more interdisciplinary research?' We considered that this question did not sufficiently address any of the three overarching questions posed by Cancer Research-UK, and so we therefore address a different question more related to the main thrust of the analysis – namely, 'which funders support more diversity in research'.

We investigate the diversity of research that funders and research host organisations support using the ISI journal subject categories for the journals their publications are in as a proxy for the disciplines they contribute to. We analyse three dimensions of diversity (Rafols et al. 2012, Stirling 1998) as shown in Figure 3.21.

- **Variety:** the number of scientific disciplines a funder or research host organisation contributes to by supporting or producing publications. Higher numbers indicate higher variety.
- **Balance:** the distribution of the publications a funder or research host organisation supported or produced across the scientific disciplines. A value of 1 would indicate each subject category has the same number of publications.
- **Disparity:** the cognitive distance between the scientific disciplines a funder (host organisation) contributed to by supporting (producing) publications. A value of 1 indicates the highest disparity between supported publications' subject categories, and 0 indicates no disparity.

Figure 3.21: Conceptualisation of diversity measures (based on Rafols and Meyer 2010 and Stirling 1998).



We also consider an 'aggregate' indicator of diversity that considers both the proportion of publications in each discipline and the cognitive distance between those disciplines. This indicator is the Rao-Stirling diversity index (Stirling 2007), with a value closer to 1 indicating higher diversity.

We assessed the diversity of publications for the major funders and research host organisations that contributed to at least 2% of the UK neoplasm research output in 2011. Table 3.15 and Table 3.16 report the results respectively for funders (based on the 3,914 publications with funder acknowledgements) and research host organisations (based on 7,510 publications in the total sample).

In Table 3.15, Variety refers to the number of subject categories that publications appear in, counted in absolute terms (no threshold) and counting only those subject categories where >1% of an organisations' research output is published. When counting without threshold restrictions, the Departments of Health (including NHS and NIHR) and Cancer Research UK support the greatest variety of subject categories, although when a 1% threshold is imposed, the BBSRC and EPSRC support more diverse research. The BBSRC and EPSRC also perform well in terms of providing a balance in the support they give to publications across subject categories.

In terms of the disparity of publications supported, the Departments of Health and Cancer Research UK support the most disparate publications overall, but the most disparate are not supported often, so that when a threshold is imposed, BBSRC performs more strongly. The BBSRC is also the funder supporting the most diverse publications. Of the top nine funders, Leukaemia and Lymphoma Research and Breakthrough Breast Cancer support the least diverse publications.

Table 3.16 shows diversity measures for the 17 top research host organisations. University College London and Oxford University publish across the highest variety of journal subject categories, however the majority of these do not contribute to >1% of the host's output. The University of Sheffield and King's College London contribute >1% of their publications to the widest variety of subject categories.

The Universities of Birmingham, Liverpool and Cardiff are the most balanced in terms of their contributions to subject categories, whereas the Institute of Cancer Research is the least balanced.

Disparity in the types of subject categories published in is highest in absolute terms for University College London and King's College London, but when a 1% threshold is imposed, Liverpool and King's College London publish in the most disparate range of publications. The University of Liverpool is the most diverse of the top 17 research host organisations based on the Rao-Stirling diversity index, and the Institute for Cancer Research is the least diverse.

**Table 3.15: UK funding organisations acknowledged in at least 2% of the publication sample (N = 3,914) and diversity measures on the supported research (funders sorted by total number of publications)**

Organisation	Variety		Diversity Measures			Rao-Stirling diversity
	No threshold	1% threshold	Balance	Disparity		
				No threshold	1% threshold	
1) Cancer Research UK	75	16	0.682	0.818	0.623	0.557
2) Departments of Health (including NHS and NIHR)	<b>78</b>	19	0.701	<b>0.827</b>	0.687	0.612
3) Medical Research Council (MRC)	66	23	0.747	0.801	0.669	0.587
4) Wellcome Trust	44	19	0.783	0.726	0.622	0.537
5) Leukaemia and Lymphoma Research	28	15	0.683	0.639	0.543	0.437
6) Breakthrough Breast Cancer	24	13	0.712	0.629	0.468	0.407
7) Breast Cancer Campaign	29	18	0.756	0.721	0.663	0.518
8) Engineering and Physical Science Research Council (EPSRC)	42	25	0.871	0.765	0.633	0.554
9) Biotechnology and Biological Sciences Research Council (BBSRC)	41	<b>28</b>	<b>0.884</b>	0.789	<b>0.746</b>	<b>0.691</b>

Notes. The threshold refers to the proportion of publications in a given SC. Figures from Rafols and Meyer (2010) and Stirling (1998).

**Table 3.16: UK organisations contributing to at least 2% of the publication sample (N = 7,510) diversity measures on the produced research output (organisation sorted by total number of publications)**

Organisation	Variety		Diversity Measures			Rao-Stirling diversity
	No threshold	1% threshold	Balance	Disparity		
				No threshold	1% threshold	
1) <a href="#">Institute of Cancer Research, London</a> <i>(including the following organisation or name variations: Royal Marsden NHS Foundation Trust)</i>	52	19	0.667	0.765	0.669	0.537
2) <a href="#">University College London, London</a> <i>(including the following organisation or name variations: University College London Hospitals NHS Trust, UCL Cancer Institute, National Hospital for Neurology and Neurosurgery, Royal Free Hampstead NHS Trust)</i>	<b>83</b>	23	0.788	<b>0.829</b>	0.685	0.679
3) <a href="#">Imperial College, London</a> <i>(including the following organisation or name variations: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross Hospital)</i>	66	21	0.741	0.784	0.666	0.608
4) <a href="#">University of Cambridge, Cambridge</a> <i>(including the following organisation or name variations: Cancer Research UK Cambridge Research Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research Centre, Addenbrooke's University Hospital, Cambridge University Hospital NHS Trust)</i>	64	24	0.750	0.784	0.654	0.598
5) <a href="#">Oxford University, Oxford</a> <i>(including the following organisation or name variations: Gray Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, United Kingdom)</i>	74	21	0.736	0.818	0.676	0.618
6) <a href="#">King's College London, London</a> <i>(including the following organisation or name variations: King's College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's Hospital, Western General Hospital)</i>	69	27	0.787	0.822	0.750	0.672
7) <a href="#">University of Leeds, Leeds</a>	67	22	0.750	0.816	0.709	0.642

Organisation	Variety		Diversity Measures		Rao-Stirling diversity	
	No threshold	1% threshold	Balance	Disparity		
<i>(including the following organisation or name variations: Leeds Cancer Research UK Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary)</i>						
8) University of Manchester, <a href="#">Manchester</a>	58	24	0.755	0.790	0.709	0.609
<i>(including the following organisation or name variations: Cancer Research UK Paterson Institute, Christie Hospital)</i>						
9) Queen Mary University of London, <a href="#">London</a>	47	20	0.726	0.781	0.670	0.545
<i>(including the following organisation or name variations: St Bartholomew's Hospital)</i>						
10) University of Edinburgh, <a href="#">Edinburgh</a>	49	24	0.793	0.782	0.740	0.634
<i>(including the following organisation or name variations: Edinburgh Cancer Research Centre, Western General Hospital)</i>						
11) University of Glasgow, <a href="#">Glasgow</a>	57	26	0.784	0.770	0.721	0.615
<i>(including the following organisation or name variations: NHS Greater Glasgow and Clyde, Gartnavel General Hospital, Glasgow Royal Infirmary, Western Infirmary)</i>						
12) University of Newcastle, <a href="#">Newcastle Upon Tyne</a>	45	18	0.747	0.753	0.717	0.601
<i>(including the following organisation or name variations: Northern Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Freeman Hospital)</i>						
13) University of Birmingham, <a href="#">Birmingham</a>	53	23	<b>0.822</b>	0.780	0.694	0.631
14) University of Sheffield, <a href="#">Sheffield</a>	59	28	0.816	0.817	0.767	0.683
<i>(including the following organisation or name variations: Weston Park Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals NHS Trust)</i>						
15) Cardiff University, <a href="#">Cardiff</a>	52	24	0.817	0.775	0.741	0.647
<i>(including the following organisation or name variations: Velindre NHS Trust)</i>						
16) University of Southampton, <a href="#">Southampton</a>	40	24	0.805	0.783	0.741	0.641
<i>(including the following organisation or name variations: Southampton General Hospital)</i>						
17) University of Liverpool, <a href="#">Liverpool</a>	51	23	0.821	0.806	<b>0.790</b>	<b>0.716</b>

Notes. The threshold refers to the proportion of publications in a given SC. Figures from Rafols and Meyer (2010) and Stirling (1998).

### 3.6.2 Diversity of funders and host organisations across medical areas


We further explore the diversity of funders and research host organisations by analysing the variety of, and balance across, the domains of research they support or contributed to using MeSH qualifiers. MeSH qualifiers further qualify the meaning of MeSH descriptors, and unlike MeSH descriptors, which operate in a hierarchical tree structure, MeSH qualifiers can be used to categorise all publications with MeSH codes.

All MeSH qualifiers assigned to at least 10% of the publications in the total sample are reported in Figure 3.22. These show that pathology and genetics are the most frequently occurring, followed by surgery (green), diagnosis (blue) and drug therapy (orange).


Figure 3.23 profiles the major UK funders according to the most frequent MeSH qualifiers, i.e. those assigned to at least 10% of the publications in the total sample. As in the previous analyses on the MeSH descriptors, we report the proportion of publications each funder supported in a domain in relation to the overall number of publications the funder supported (above) and the comparison between the observed and the expected value of publication number (below) – the methodology used here is similar to that described in section 3.5.3. It is worth noting that the qualifiers represented in the radar charts describe on average ~90% of the publications supported by these organisations, but each radar chart does not completely cover the scope of outputs.

Major UK funders strongly focus on supporting studies in genetics and pathology which each account for between 20% and 40% of the publications they support. The exception is the EPSRC for which a very small proportion of the supported publications are assigned to genetics. However, more than 20% of the publications supported by EPSRC are in diagnostics while the remaining major UK funders supported a lower proportion of publications in this domain. Unlike the overall sample, major UK funders neglect surgery.


**Figure 3.22: Top MeSH qualifiers (at least ~10% of the publications) assigned to the descriptors included in the “Neoplasms” branch of the MeSH tree (more than one qualifier can be assigned to a publication; 817 publications have no assigned qualifiers)**



**Figure 3.23a: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**




**Figure 3.23b: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**





**Figure 3.23c: Major UK funders in “Neoplasms” area and proportion of publications across the top MeSH qualifiers (90.6% of the 3,914 publications with acknowledgements to funders are classified using the reported MeSH qualifiers). Upper charts report the percentage of funders’ total publications in different domains. Right charts report whether funders are more (>1.0) or less (<1.0) active in each domain than expected.**



### 3.7 Scientometric analysis: Additional perspectives

In addition to the main questions of the study – related to the interdependency, complementarity and diversity of UK funders and research host organisations, there was opportunity to explore the following questions:

- a) Which funders support rapidly cited works?
- b) Which funders support international collaborations or public/private collaborations?

#### 3.7.1 Funder, host organisations and highly-cited publications

In order to identify the most highly cited publications it is necessary to first control for the different propensity of authors working in different subject categories to cite recent publications. To achieve this, each subject category was considered individually to identify the top 5% and top 10% papers by citation (Table 3.17). Those papers acknowledging research funding were more highly represented in these top cited papers, suggesting that there is a significant correlation between research funding acknowledgement and citation (Table 3.18).

**Table 3.17: Citations and publications (N=7,510)**

<b>Number of highly-cited publications</b>	
<i>Top-5% cited within a subject category</i>	486 (6.5%)
<i>Top-10% cited within a subject category</i>	905 (12.0%)
<i>Top-5% cited normalised by citation rate in subject categories</i>	375
<i>Top-10% cited normalised by citation rate in subject categories</i>	751

Note. Since a journal may be assigned to more than one SC, an article is considered highly cited if ranks in the top-cited articles of at least one of the SCs assigned to its journal.

**Table 3.18: Funding acknowledgements and highly cited publications (citations count normalised within ISI WoS subject categories)**

Type of publication	Number of publications	Number of publications within the top-5% cited	Number of publications within the top-10% cited
Publication with funding data in acknowledgement sections	3,914	268 (6.8%)	532 (13.6%)
Publications with no acknowledgements sections or no funding data in acknowledgement sections	3,596	107 (3.0%)	219 (6.9%)

Notes. The test on proportion supported ( $\chi^2=59.2$ ,  $p<0.001$  and  $\chi^2=117.2$ ,  $p<0.001$ , respectively) shows that publications acknowledging funding sources are significantly more highly cited than those publications without such funding. Results do not change when one considers the top-5% and top-10% cited articles according to the citation count normalised by SCs or focusing the analysis on 'article' type of publication.

Table 3.19 shows which research host organisations have the highest citations in their papers. To avoid results that are sensitive to publications that are outliers with very high numbers of citations coming from organisations with very few publications, only those major UK host organisations, i.e. those contributing to at

least 2% of the publications sample, are considered. The results show that while the Institute for Cancer Research and Oxford University have the highest number of publications in the top 5% cited (57 and 46 respectively), when the results are normalised by the size of the publication output of the top organisations, Cardiff University and Queen Mary University have a higher proportion of their output in the top 5% cited (8.9% and 8.67% respectively vs. 8.15% for the Institute of Cancer Research and 8.39% for Oxford University).

Table 3.20 contains the results of the equivalent analysis for funders. It shows that although Cancer Research UK and the Departments of Health support more papers in the top 5% cited (60 and 59 respectively) than other funders, several funders support a proportionally higher percentage of highly cited publications including Breakthrough Breast Cancer (10%), Wellcome Trust (7.9%), MRC (7.8%) and BBSRC (7.6%) – compared with 6.3% for Cancer Research UK and 6.6% for DH. Notably, the EPSRC did not fund neoplasms research papers in the highly cited category in this period.

Figure 3.24 explores the relationship between the number of funders acknowledged in publications and the relative proportion of highly cited (top-5%) publications. As the number of funders increase the proportion of highly cited paper increases up to 6-7 funders when the relationships shows decreasing returns.<sup>11</sup> The results confirm prior research that suggests papers supported by more funders are more highly cited (Lewison and Dawson 1998).

**Table 3.19: UK organisations contributing to at least 2% of the publication sample (N = 7,510) and number of highly cited (top-5%) publications**

Organisation	Number of publications within the top-5% cited	Number of publications within the top-5% cited out the number of publications produced
1) Institute of Cancer Research, <b>London</b> <i>(including the following organisation or name variations: Royal Marsden NHS Foundation Trust)</i>	57	8.15%
2) Oxford University, <b>Oxford</b> <i>(including the following organisation or name variations: Gray Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, United Kingdom)</i>	46	<b>8.39%</b>
3) University of Cambridge, <b>Cambridge</b> <i>(including the following organisation or name variations: Cancer Research UK Cambridge Research Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research Centre, Addenbrooke's University Hospital, Cambridge University Hospital NHS Trust)</i>	41	7.37%
4) University of Leeds, <b>Leeds</b> <i>(including the following organisation or name variations: Leeds Cancer Research UK Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary)</i>	33	8.35%
5) Imperial College, <b>London</b> <i>(including the following organisation or name variations: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross Hospital)</i>	32	5.64%
6) University College London, <b>London</b> <i>(including the following organisation or name variations: University College London Hospitals NHS Trust, UCL Cancer Institute, National Hospital for Neurology and Neurosurgery, Royal Free Hampstead NHS Trust)</i>	30	4.76%
7) University of Manchester, <b>Manchester</b> <i>(including the following organisation or name variations: Cancer Research UK Paterson Institute, Christie Hospital)</i>	30	7.71%
8) King's College London, <b>London</b> <i>(including the following organisation or name variations: King's College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's Hospital, Western General Hospital)</i>	28	5.29%
9) Queen Mary University of London, <b>London</b>	28	<b>8.67%</b>

<sup>11</sup> A more detailed analysis that controls for additional variables is required to draw explanatory conclusions here. This is beyond the scope of the present study.

Organisation	Number of publications within the top-5% cited	Number of publications within the top-5% cited out the number of publications produced
(including the following organisation or name variations: St Bartholomew's Hospital)		
10) University of Edinburgh, <b>Edinburgh</b>	21	7.45%
(including the following organisation or name variations: Edinburgh Cancer Research Centre, Western General Hospital)		
11) Cardiff University, <b>Cardiff</b>	17	<b>8.90%</b>
(including the following organisation or name variations: Velindre NHS Trust)		
12) University of Glasgow, <b>Glasgow</b>	15	5.40%
(including the following organisation or name variations: NHS Greater Glasgow and Clyde, Gartnavel General Hospital, Glasgow Royal Infirmary, Western Infirmary)		
13) University of Sheffield, <b>Sheffield</b>	15	7.08%
(including the following organisation or name variations: Weston Park Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals NHS Trust)		
14) University of Southampton, <b>Southampton</b>	13	7.65%
(including the following organisation or name variations: Southampton General Hospital)		
15) University of Liverpool, <b>Liverpool</b>	12	7.23%
16) University of Newcastle, <b>Newcastle Upon Tyne</b>	12	4.94%
(including the following organisation or name variations: Northern Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Freeman Hospital)		
17) University of Birmingham, <b>Birmingham</b>	9	4.11%

Notes. Only organizations contributing to at least 2% of publications are considered. The rank changes marginally when one considers the top-10% cited articles according to the citation count within SCs or the top-5% and top-10% cited articles according to the citation count normalised by SCs.


**Table 3.20: UK funding organisations acknowledged in at least 2% of the publication sample (N = 3,914) and number of highly cited (top-5%) publications**

Organisation	Number of publications within the top-5% cited	Number of publications within the top-5% cited out the number of publications produced
1) Cancer Research UK	<b>60</b>	6.3%
2) Department of Health (including NHS and NIHR)	<b>59</b>	6.6%
3) Medical Research Council (MRC)	<b>37</b>	<b>7.8%</b>
4) Wellcome Trust	16	<b>7.9%</b>
5) Breakthrough Breast Cancer	11	<b>10.0%</b>
6) Biotechnology and Biological Sciences Research Council (BBSRC)	7	7.6%
7) Leukaemia and Lymphoma Research	7	5.1%
8) Breast Cancer Campaign	6	6.3%
9) Engineering and Physical Science Research Council (EPSRC)	0	0.0%

Notes. Only funder acknowledged in at least 2% of publications were considered. The rank changes marginally when one considers the top-10% cited articles according to the citation count within SCs or the top-5% and top-10% cited articles according to the citation count normalised by SCs.

We also investigated the citations patterns by following the conceptualisations of funders and publications adopted in Section 3.5. We report in Table 3.21 the number of highly cited papers by categories of funder and relative compositions. We considered both top-5% and top-10% highly cited paper as in the previous analysis. Those publications simultaneously supported by all types of funders (g) have a higher proportion of highly cited publications (~12% and ~22% when considering the top-5% and top-10% cited). Conversely, those publications supported only by minor funders (b) report a lower proportion of publications (~5.2% and ~10.3% when considering the top-5% and top-10% cited) of highly cited publications.

**Figure 3.24 Number of funders and relative proportion of highly cited (top-5%) publications.**



We analysed the proportion of highly cited papers by combining the different categories in three overlapping groups as in previous analyses, i.e. publications supported at least by one major UK funder (a+d+f+g), publications supported by at least one minor UK funder (b+d+e+g), and publications supported at least by one 'other' funder or industry (c+e+f+g). The results are reported in the lower part of Table 3.21. Publications supported by at least one minor UK funder are less likely to be highly cited papers (~7% and ~15% when considering the top-5% and top-10% cited) compared to those publications involving at least one major UK funder (~9% and ~17% when considering the top-5% and top-10% cited) and those publications involving at least one industrial actor or any other funders not falling in the previous categories (~11% and ~19% when considering the top-5% and top-10% cited).

**Table 3.21: Funders compositions and number of highly cited publications**

Publications supported by	Subset	Number of publications	Number of publications within the top-5% cited	Number of publications within the top-10% cited
Major UK funders	a	697 (17.8%)	60 (8.6%)	102 (14.6%)
Minor UK funders	c	426 (10.9%)	22 (5.2%)	44 (10.3%)
Other funders and industry	c	1,344 (34.3%)	139 (10.3%)	232 (17.3%)
Major-Minor UK funders	d	483 (12.3%)	26 (5.4%)	55 (11.4%)
Minor UK funder-Other funders and industry	e	166 (4.2%)	14 (8.4%)	32 (19.2%)

Publications supported by	Subset	Number of publications	Number of publications within the top-5% cited	Number of publications within the top-10% cited
Major UK funders - Other funders and industry	f	433 (11.1%)	47 (10.8%)	92 (21.2%)
Major and minor UK funders - Other funders and industry	g	365 (9.3%)	44 (12.0%)	80 (21.9%)
Major UK funders (extended)	a+d+f+g	1,978 (50.5%)	177 (8.9%)	329 (16.6%)
Minor UK funders (extended)	b+d+e+g	1,441 (36.8%)	106 (7.4%)	211 (14.6%)
Other funders (extended)	c+e+f+g	2,308 (59.0%)	245 (10.6%)	437 (18.9%)

In addition, we assess the citations of publications supported by industry (i.e. those publications with at least one author with an industrial affiliation or acknowledging at least one industrial funder. The results, reported in Table 3.22, show that industry supported publications are significantly over-represented in the top 5% and top 10% of highly cited publications compared to the sample of publications not involving industrial actors as funders or as host organisations.

**Table 3.22: Involvement of industrial actors and highly cited publications (citations count normalised within ISI WoS subject categories)**

Type of publication	Number of publications	Number of publications within the top-5% cited	Number of publications within the top-10% cited
Industry involvement	1,084 (14.4%)	104 (9.6%)	190 (17.5%)
No-industry involvement	6,426 (85.6%)	271 (4.2%)	561 (8.6%)

Notes. The test on proportion supported ( $chi^2=56.52, p<0.001$  and  $chi^2=79.76, p<0.001$ , respectively) that publications involving industry are significantly more cited than those not involving industrial actors. Results do not change focusing the analysis on 'scientific article' type of publication.

### 3.7.2 Funder, host organisations and intensity of international collaboration

The average number of countries that research host organisations collaborate with per publication is shown in Table 3.23. The results show that the University of Cambridge, Imperial College London and Oxford University support research that includes notably more international research links than other organisations.

Table 3.24 shows the results of the equivalent analysis for research funders, which show that the Wellcome Trust supports research that is notably more collaborative with international partners than that of other funders.

Table 3.25 reports the average number of countries and the relative standard deviation for the publication sample classified according to the conceptualisation of funders adopted in Section 3.5. Publications supported exclusively by major or

minor UK funders (a,b, and d) involves on average 1.3 countries. Publications supported by other funders or industrial actors involve on average a larger number of countries (3.6). As above, we investigated the involvement of international actors in publications by combining the different categories in three overlapping groups, i.e. publications supported at least by one major UK funder (a+d+f+g), publications supported by at least one minor UK funder (b+d+e+g), and publications supported at least by one 'other' funder or industry (c+e+f+g). The first two groups of publications involves on average 2 different countries per publications. This suggests that major UK funders are not more likely to support researchers to form international links compared to minor UK funders.

**Table 3.23: UK organisations contributing to at least 2% of the publication sample (N = 7,510) and international collaborations**

Organisation	Number of countries			
	Mean	Std.Dev.	Min	Max
1) University of Cambridge, <a href="#">Cambridge</a> <i>(including the following organisation or name variations: Cancer Research UK Cambridge Research Institute, Hutchison/MRC Research Centre, Cambridge Biomedical Research Centre, Addenbrooke's University Hospital, Cambridge University Hospital NHS Trust)</i>	3.4	3.9	1	25
2) Imperial College, <a href="#">London</a> <i>(including the following organisation or name variations: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Charing Cross Hospital)</i>	3.4	3.7	1	25
3) Oxford University, <a href="#">Oxford</a> <i>(including the following organisation or name variations: Gray Institute, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, United Kingdom)</i>	3.2	3.6	1	25
4) Institute of Cancer Research, <a href="#">London</a> <i>(including the following organisation or name variations: Royal Marsden NHS Foundation Trust)</i>	2.7	3.3	1	23
5) University of Newcastle, <a href="#">Newcastle Upon Tyne</a> <i>(including the following organisation or name variations: Northern Institute of Cancer Research, Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Freeman Hospital)</i>	2.6	4.1	1	25
6) University of Sheffield, <a href="#">Sheffield</a> <i>(including the following organisation or name variations: Weston Park Hospital, Sheffield Children's NHS Trust, Sheffield Teaching Hospitals NHS Trust)</i>	2.6	3.6	1	23
7) University of Leeds, <a href="#">Leeds</a> <i>(including the following organisation or name variations: Leeds Cancer Research UK Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary)</i>	2.5	3.0	1	25
8) University of Glasgow, <a href="#">Glasgow</a> <i>(including the following organisation or name variations: NHS Greater Glasgow and Clyde, Gartnavel General Hospital, Glasgow Royal Infirmary, Western Infirmary)</i>	2.4	3.2	1	25
9) King's College London, <a href="#">London</a> <i>(including the following organisation or name variations: King's College Hospital NHS Trust, Guy's and St Thomas NHS Trust, Guy's Hospital, Western General Hospital)</i>	2.4	2.9	1	23
10) University of Liverpool, <a href="#">Liverpool</a>	2.3	3.1	1	25
11) University of Manchester, <a href="#">Manchester</a> <i>(including the following organisation or name variations: Cancer Research UK Paterson Institute, Christie Hospital)</i>	2.3	2.5	1	20
12) Queen Mary University of London, <a href="#">London</a> <i>(including the following organisation or name variations: St Bartholomew's Hospital)</i>	2.2	2.4	1	18
13) Cardiff University, <a href="#">Cardiff</a> <i>(including the following organisation or name variations: Velindre NHS Trust)</i>	2.2	2.1	1	14
14) University of Edinburgh, <a href="#">Edinburgh</a> <i>(including the following organisation or name variations: Edinburgh Cancer Research Centre, Western General Hospital)</i>	2.2	2.2	1	17
15) University College London, <a href="#">London</a> <i>(including the following organisation or name variations: University College London Hospitals NHS Trust, UCL Cancer Institute, National Hospital for Neurology and Neurosurgery, Royal Free Hampstead NHS Trust)</i>	2.1	2.0	1	17
16) University of Birmingham, <a href="#">Birmingham</a>	2.0	1.7	1	14
17) University of Southampton, <a href="#">Southampton</a> <i>(including the following organisation or name variations: Southampton General Hospital)</i>	2.0	2.6	1	20

**Table 3.24: UK funding organisations acknowledged in at least 2% of the publication sample (N = 3,914) and international collaborations**

Organisation	Number of countries			
	Mean	Std.Dev.	Min	Max
1) Wellcome Trust	3.1	3.4	1	17
2) Medical Research Council (MRC)	2.6	2.9	1	20
3) Breakthrough Breast Cancer	2.5	3.1	1	20
4) Cancer Research UK	2.5	3.0	1	23
5) Breast Cancer Campaign	2.5	3.5	1	20
6) Department of Health (including NHS and NIHR)	2.2	2.8	1	23
7) Leukaemia and Lymphoma Research	1.6	0.9	1	5
8) Biotechnology and Biological Sciences Research Council (BBSRC)	1.6	0.8	1	4
9) Engineering and Physical Science Research Council (EPSRC)	1.5	0.8	1	4

**Table 3.25: Funders composition and international collaborations.**

Publications supported by	Subset	Number of publications	Mean number of countries per publication	Std.Dev. of the number of countries per publication
Major UK funders	a	697 (17.8%)	1.3	1.1
Minor UK funders	c	426 (10.9%)	1.3	0.9
Other funders and industry	c	1,344 (34.3%)	3.6	2.8
Major-Minor UK funders	d	483 (12.3%)	1.3	0.7
Minor UK funder-Other funders and industry	e	166 (4.2%)	2.7	2.3
Major UK funders -Other funders and industry	f	433 (11.1%)	2.9	2.8
Major and minor UK funders- Other funders and industry	g	365 (9.3%)	3.4	3.7
Major UK funders (extended)	a+d+f+g	1,978 (50.5%)	2.1	2.3
Minor UK funders (extended)	b+d+e+g	1,441 (36.8%)	2.0	2.3
Other funders (extended)	c+e+f+g	2,308 (59.0%)	3.4	2.6

### 3.8 Future research

This study has opened up some areas that may warrant further investigation. Firstly, it is clear that a high proportion of UK neoplasms research is supported by a large number of relatively small funders. The funding priorities of these funders and the ways in which they seek to complement the efforts of the larger funders is relatively unknown. Secondly, are such small funders a prominent contributor to other fields of biomedical research, or are they more strongly clustered in neoplasms? Finally, it is clear that a high proportion of UK research is in some way associated with international collaborations and funding from overseas. How would



cuts to the budget of UK or overseas funders impact the structure of the dense network or reduce the quality of scientific outputs?

### References for Chapter 3

- Freeman LC (1979) Centrality in social networks conceptual clarification. *Social Networks*, 1(3): 215–239.
- HERG, OHE, RAND Europe. (2008) *Medical research: what's it worth?* London: Medical Research Council, Wellcome Trust, Academy of Medical Sciences.
- Hopkins MM, Siepel J (2013) Just how difficult can it be counting up R&D funding for emerging technologies (and is tech mining with proxy measures going to be any better)? *Technology Analysis & Strategic Management*, 25(6): 655–685.
- Lewison G, Dawson G (1998) The effect of funding on the outputs of biomedical research. *Scientometrics*, 41(1-2): 17-27.
- Lewison G, Dawson G, Anderson J (1995) The behaviour of scientific authors in acknowledging their funding sources. *Proceedings of the fifth international conference of the international society for scientometrics and informetrics*.
- MacLean M, Davies C, Lewison G, Anderson J (1998) Evaluating the research activity and impact of funding agencies. *Research Evaluation*, 7(1): 7-16.
- Morgan Jones M, Grant J (2011) Complex trauma research in the UK. Product Page [http://www.rand.org/pubs/documented\\_briefings/DB613.html](http://www.rand.org/pubs/documented_briefings/DB613.html)
- Rafols I, Leydesdorff L, O'Hare A, Nightingale P, Stirling A (2012) How journal rankings can suppress interdisciplinarity. The case of innovation studies and business and management. *Research Policy*, 41(7): 1262–1282.
- Rafols I, Porter AL, Leydesdorff L (2010) Science overlay maps: A new tool for research policy and library management. *Journal of the American Society for Information Science and Technology*, 61(9): 1871–1887.
- Rotolo D, Rafols I, Hopkins M, Leydesdorff L (2013) Scientometric mappings as strategic intelligence for tentative governance of emerging science and technologies. Working Paper [http://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=2239835](http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2239835)
- Stirling A (1998) On the economics and analysis of diversity. *SPRU Electronic Working Papers*, 28.201
- Stirling A (2007) A General framework for analysing diversity in science, technology and society. *Journal of The Royal Society Interface*, 4(15): 707–719.
- UKCRC (UK Clinical Research Collaboration) (2012) *UK health research analysis 2009/10*. London: UKCRC.

Wassermann S, Faust K (1994) *Social Network Analysis: Methods and Applications*. Cambridge, MA: Cambridge University Press.

## 4. COMPLEMENTARITY/SUBSTITUTABILITY OF GOVERNMENT AND CHARITY FUNDING OF CANCER RESEARCH IN THE UK

### Key Points

- In a web-based survey of 401 members of the UK general public, we asked respondents how they would distribute a hypothetical £100 allocation of income tax amongst cancer research and other medical research charities under a range of different scenarios regarding changes in government spending on cancer research and other medical research.
- When respondents are asked to suppose that the government has cut (or has increased) funding for cancer research, the overall tendency is to give a larger (smaller) share of the allocation of income tax to cancer research charities. This suggests that, given the opportunity, respondents would try to counteract the hypothetical change in government funding of cancer research by allocating more (less) of their income tax to cancer research, were they given the opportunity. However, most respondents' preferred allocations did not vary much from scenario to scenario.
- The vast majority of respondents stated that their existing personal out-of-pocket donations to cancer research and/or other medical research charities would not be affected by changes in government funding levels or by being given the opportunity to allocate £100 of their income tax to these charities.
- Respondents' decisions about whether to donate to a cancer research charity are more likely to be driven by personal experience of cancer or by increases in their disposable income than by information about the level of government funding for cancer research.
- Recent additions to the literature suggest that government and charity funding of medical research may be complementary, with some empirical studies reporting that increases in government spending on a particular area may crowd in (rather than crowd out) private donations to charities operating in the same area.

### 4.1 Introduction

This chapter addresses the question: "If there was a cut in government funding for life sciences would other funders (private and public) be able to fill the gap and continue to support research activities?"

In our previous report for Cancer Research UK (OHE, 2011), we examined the likely consequences of a hypothetical reduction in the level of public funding for medical research. For that report we conducted a review of the peer-reviewed and grey literature, identifying 12 key papers that focused on the question of whether government and charity funding of medical research substitute for, or complement, one another.

The main finding of our 2011 review was that there are theoretical arguments supporting both “crowding out” effects – i.e. decreases in government funding lead to donors *increasing* their own contributions (Warr, 1982; Roberts, 1984; Bergstrom et al., 1986; Andreoni, 1990; Andreoni and Payne, 2003) and “crowding in” effects – i.e. decreases in government funding lead to donors *reducing* their own contributions (Rose-Ackerman, 1986; Payne, 2001; Heutel, 2009). However, no empirical evidence specific to the UK medical research environment was found.

The one relevant UK study we identified (Khanna and Sandler, 2000) suggested that government funding of research is more likely to crowd in than to crowd out charitable funding. But the evidence was weak and did not relate specifically to medical research charities. Outside of the UK, most of the studies were undertaken in the US and suggested that whether crowding in or crowding out prevails depends on the nature of the activity undertaken by the charity. For example, Payne (2001) reported evidence that government funding crowds in charity contributions for research universities but not for non-research universities.

Given the limited literature available at the time, we identified as top of the future research agenda: finding UK-specific evidence on the crowding in or crowding out effect of government funding vis-à-vis charitable funding of medical research.

## 4.2 Updated literature review

### 4.2.1 Objectives and scope

Our objective was to update the literature review we undertook for Cancer Research UK in 2011, adopting a similar search strategy to before (OHE, 2011) but limited to the period 2010 to 2013. However, we also identified a strand of the literature that had not previously been explored (experimental economics), so decided to include studies published prior to 2010 that had not been captured in the earlier review but were deemed to be relevant to the research question.

As before, the stated objectives of the review were to:

- identify the economic principles underpinning charity and government contributions to medical research (or research in general);
- investigate whether government and charitable funding of medical research (or research in general) complement and/or substitute each other within the UK research funding system.

### 4.2.2 Method

We used three approaches to identify additional literature:

1. Keyword searches of the major economics, medical and general databases, using an updated version of the search strategy used in our earlier review.
2. Searching for papers published since 2010 that cited one of more of the key papers identified in our earlier review, using Google Scholar’s “cited by” feature.
3. Searching for working papers and other unpublished literature using RePEc (Research Papers in Economics; <http://repec.org/>) and the websites of individuals and organisations who are active in this area of research.

We began with approach 1, examining the titles of the 12 key papers identified in our earlier review:

- Impure altruism and donations to public goods: a theory of warm-glow giving (Andreoni, 1990)
- Leadership giving in charitable fund-raising (Andreoni, 2006)
- Do government grants to private charities crowd out giving or fund-raising? (Andreoni and Payne, 2003)
- On the private provision of public goods (Bergstrom et al., 1986)
- Demand for collective goods in private non-profit markets: can fundraising expenditures help overcome free-rider behavior? (Weisbrod and Dominguez, 1986)
- Crowding out and crowding in of private donations and government grants (Heutel, 2009)
- Partners in giving: the crowding-in effects of UK government grants (Khanna and Sandler, 2000)
- Measuring the effect of federal research funding on private donations at research universities: is federal research funding more than a substitute for private donations? (Payne, 2001)
- A positive model of private charity and public transfers (Roberts, 1984)
- The informational value of sequential fundraising (Vesterlund, 2003)
- Pareto optimal redistribution and private charity (Warr, 1982)
- Do government grants to charity reduce private donations? (Rose-Ackerman, 1986)

We counted the number of times each potential keyword (e.g. "research") appeared in these titles, combining synonymous and related terms where appropriate (e.g. "charity", "charities", "charitable"). We identified the following nine keywords to be the most commonly used amongst the original key papers: private; donations; grants; government; charity/charities/charitable; research; giving; fund-raising/fundraising; crowd/crowding.

In addition, we included two further terms: "experimental" (in order to capture relevant papers in the experimental economics literature) and "medical research". This gave a total of 11 keywords.

We conducted a series of electronic searches of economics, medical and general databases in April 2013 using logical combinations of the 11 keywords. The keyword searches identified 346 potentially relevant English language records, 120 of which had been published since 2010.

We then proceeded to approach 2, using Google Scholar to identify papers published since 2010 that had cited the key papers from the original review:

- Andreoni (1990) – 777 citations since 2010
- Andreoni (2006) – 54 citations since 2010
- Andreoni and Payne (2003) – 105 citations since 2010
- Bergstrom et al. (1986) – 347 citations since 2010
- Weisbrod and Dominguez (1986) – 66 citations since 2010
- Heutel (2009) – 19 citations since 2010
- Khanna and Sandler (2000) – 41 citations since 2010

- Payne (2001) – 12 citations since 2010
- Roberts (1984) – 68 citations since 2010
- Rose-Ackerman (1986) – not a journal article therefore no citation statistics available via Google Scholar
- Vesterlund (2003) – 83 citations since 2010
- Warr (1982) – 86 citations since 2010

In total, the key papers (excluding Rose-Ackerman, 1986) were found to have been cited in 1,658 recent articles, although a number of these records were duplicates of each other and of the records identified using approach 1. Finally, using approach 3 we identified a small number working / occasional papers that had not (yet) been published in peer-review journals and had not been identified using approaches 1 and 2.

Including all of the identified records would have required reviewing up to 2,000 articles, which was infeasible given the scope of the study. We therefore restricted our attention to the first few pages of results from the searches (where the results were sorted by relevance). We also refined approach 2 by searching the results for the approach 1 keywords to identify the records that were most likely to be relevant to the research question. These steps reduced the results to 55 records.

We then screened each record by examining their titles and abstracts. Records were selected for the review if they were deemed to be directly relevant to the research question. We considered empirical studies, reviews and theoretical papers. Reference lists from included papers were checked to identify further relevant studies.

#### **4.2.3 Findings**

We organised the relevant studies into three broad categories:

- 1) studies that focused on or specifically mentioned funding for scientific or health-related research;
- 2) studies published since 2010 that did not specifically mention research but that focused on the relationship between government spending and private donations to charitable organisations; and
- 3) studies that used laboratory experiments to investigate private charitable donation behaviour.

##### ***4.2.3.1 Studies that mention funding for research***

The only study we identified that focused directly on funding for scientific research, and had not been included in our earlier review, was that of Diamond (1999). Diamond begins by noting evidence (from areas other than scientific research) that when the government increases its funding of a given activity, the private funding that had been supporting that activity diminishes. He hypothesises that the converse would also be true: as the government withdraws from funding an activity, private money will enter to partially fill the gap.

Diamond examines 43 years of US data on spending on basic research from four funding sources: the federal government, industry, universities and non-profit institutions. He finds evidence of crowding in, although the economic magnitude of

the effect is small, suggesting that donors view federal and private spending on basic research as complements rather than substitutes. If this is true both when the government increases *and* when it reduces spending levels, Diamond suggests that “private funding could not be expected to replace lost federal funding of science”.

We also identified an empirical study that distinguished health-related charities from other types of charities. In an examination of panel data covering all registered charities in Sweden between 1989 and 2003, Breman (2006) reported results that overall reject the crowding out hypothesis. She categorised the organisations depending on whether they are related to health (including health research), social services, international aid, or “other”; finding that for health and international aid organisations, zero crowding out cannot be rejected; whereas for social services and other organisations, zero crowding out can be rejected and there is evidence of crowding in.

#### **4.2.3.2 Studies published since 2010**

In a review of empirical studies of philanthropy, Bekkers and Wiepking (2011) identified eight factors driving charitable giving: awareness of need, solicitation, costs, benefits, altruism, reputation, psychological benefits, values, and efficacy. In the context of the impact of changes in government funding, altruism and psychological benefits are of particular interest. Purely altruistic motivation would lead to a crowding out effect, as donors reduce their own contributions as they learn about increases in contributions by others. However, there is evidence that charitable giving produces positive psychological consequences for the donor, often labelled “warm glow” or “joy of giving” effects.

In a UK study based on interviews with 60 “committed donors”, in general i.e. not limited to medical research charities, Breeze (2010) found that people tend not to give to the most urgent needs but rather to support causes that mean something to them. She reports the following criteria that commonly influence donors’ decision-making: their tastes, preferences and passions; their personal and professional backgrounds; their perceptions of charity competence; and their desire to have a personal impact. Regarding the fourth criterion, Breeze notes that the interviewees were “keen to avoid their donations becoming a substitute for government spending”, particularly in the area of welfare spending. Rather, they were keen for their contributions to complement rather than to replace the funding available for a particular cause – donors have “higher expectations for their contributions than ‘gap plugging’”.

Garrett and Rhine (2010) claim that the relationship between government spending and charitable giving depends on the specific categories of spending being studied. This suggests that it is difficult to make inferences about medical research funding using data that is not concerned primarily with medical research funding. The authors also note that no statistical relationship between government spending and charitable contributions would be expected if people are “rationally ignorant” about government activities, which is often likely to be the case.

Andreoni and Payne (2011) distinguish between “classic” and “fundraising” crowding out. Classic crowding out occurs when government grants to charities

lead donors to reduce their donations because the donors treat their voluntary private contributions as a substitute for their involuntary contributions through taxation. Fundraising crowding out occurs when the charities receiving the grants reduce their fundraising efforts, which results in reduced private donations. The latter is a feasible explanation for crowding out in situations where donors are largely unaware of changes in funding levels. Using a panel of charities in the US, the authors find that “crowding out attributable to classic crowd-out ranges from 30% to a slight crowd-in effect, while fundraising crowd-out ranges from 70% to over 100% of all crowd-out” (the percentages can be interpreted as follows: 30% crowd-out indicates that every \$1,000 government grant reduces private giving by \$300). This suggests that the actions of charities themselves are responsible for a large proportion of all observed crowding out.

A more recent study by Andreoni et al. (2013) examines the effect of grants on charities’ incomes in the UK. The authors use a sample of charities that applied for a grant from a National Lottery-funded programme. They find that grants do not crowd out other income, with evidence of crowd in for some of the smaller charities.

In an empirical study examining panel data from almost 30,000 charities in the US, Heutel (2012) reports the government grants to charities lead to a crowding in effect, with “a dollar increase in government grants leading to an increase in private donations between 10 and 30 cents”. He also finds that the rate of crowding in is larger for younger charities (the effect disappears for the oldest charities). This suggests the existence of a signalling effect as younger charities are less likely to be known by donors, so the signal value of a grant is higher. Heutel calls for further research on signalling effects.

In an empirical study examining the determinants of private donations to US-based non-government organisations engaged in international development cooperation, Herzer and Nunnenkamp (2012) find that government grants crowd in private donations in the long run. However, the authors note that private donors tend to be more familiar with local charities, whereas information asymmetries are likely to exist in the context of large and/or international organisations.

#### ***4.2.3.3 Experimental economics literature***

An alternative approach to testing the crowding out hypothesis is to use laboratory experiments. Eckel et al. (2005) conducted one such study in which respondents were randomly assigned to an allocation of real money (for example, US\$15 to the respondent and US\$5 to a charity chosen by the respondent from a list). Respondents were then invited to voluntarily allocate additional money to their chosen charity. One group of respondents was simply informed of the initial allocations between themselves and the charity. The other group was told that their initial allocation had been, say, US\$20 but that a tax had been levied on this, with the tax revenue being allocated to the charity. In the first group, the size of respondents’ voluntary contributions increased as the size of the initial allocation to the charity fell. In the second group, in which “fiscal illusion is eliminated”, the size of the voluntary contributions was not found to vary with the size of the initial allocation to the charity. Eckel et al. conclude that “forced contributions crowd out



private giving when the source of the funding of the forced transfers is apparent to the subjects”.

In another experimental study, Crumpler and Grossman (2008) allocated an endowment of US\$10 to respondents and asked them how they wished to divide the amount between themselves and a charity (again, chosen by the respondent from a list). The respondents were also told that the experimenter would be making a donation to the charity, but that the size of this donation would be reduced by however much the respondent chooses to allocate to the charity. Hence, the charity would receive US\$10 in all cases, so the respondents’ donations would be completely crowded out and a pure altruist would have no incentive to donate. The authors report that over half of the respondents made a donation, which indicates the existence of “warm glow” giving.

#### **4.2.3.4 Summary of the literature**

In summary, a number of recent studies have reported evidence of the crowding in effect, which suggests that an increase in government spending in a particular area may result in increased private donations to charities operating in that area. However, the majority of studies report US data and may not be relevant to the UK context. With their US focus, most of the studies examine the impact of direct government grants to charities themselves. There are very few studies that specifically examine funding for research, let alone medical research. Furthermore, most of the studies focus on increases in government spending, whereas given the current economic climate it would be more appropriate to consider the impact of cuts in spending. The lack of relevant UK evidence means that experimental or stated preference studies may be useful in terms of understanding the potential impact of cuts in government funding for cancer research.

### **4.3 Stated preference survey**

#### **4.3.1 Objective**

The aim of this stated preference study was to elicit the views of the general public about how a change in government spending on cancer research might affect people’s willingness to donate to cancer research charities. We sought to address a number of gaps in the existing literature on charitable behaviour, which lacks studies that use a stated preference design, and which contains no studies that focus specifically on medical research and charitable giving in the UK.

The survey was designed so as to answer the following key research questions:

- If given the opportunity to allocate £100 of the income tax they pay this year to one or more medical research charities, how would people choose to distribute the £100 between cancer research and other medical research charities?
- Would being given the opportunity to allocate £100 of their income tax to cancer and other medical research charities lead people to change their existing personal out-of-pocket donations to those types of charities?
- Would people’s preferred allocations of funds change if they were to learn that the government was cutting or increasing funding for cancer and/or other medical research?

## 4.3.2 Methods

### 4.3.2.1 Survey instrument

The main part of the survey comprised five hypothetical scenarios. In each scenario, respondents were asked to imagine that they had the opportunity to allocate £100 of the income tax they paid this year to one or more medical research charities. They were asked how they wished to allocate the £100 between cancer research charities and medical research charities concerned with diseases other than cancer. The recipients of the allocation would be unnamed charities of the respondents' choosing. The idea behind the scenarios was loosely based on the situation in Italy, where since 2006 taxpayers have been offered the opportunity to donate 0.5% of their income tax they pay to non-profit organisations of their choosing (Agenzia delle Entrate, n.d.).

After having been given the opportunity to allocate £100 in this way, the respondents were then asked if they would want to reduce or increase any personal donations that they already make out of their own pocket to cancer research and non-cancer medical research charities; and if so, by how much. Respondents were only asked about changes to their out-of-pocket personal donations if they had earlier claimed to have made financial donations to one or more medical research charities in the previous year (see below). These questions allowed us to test the extent to which having the opportunity to allocate some of their income tax to medical research charities might affect people's willingness to donate from their own (post-tax) resources.

Table 4.1 summarises the information provided to respondents in the five scenarios. The full survey is reproduced in the Appendix.

In scenario 1, no information was provided about research funding levels. In scenario 2, respondents were presented with rounded estimates of how much the government and charities actually spend on medical research in the UK each year (figures based on data in: NCRI, 2011; UKCRC, 2012). The actual levels of spending on medical research may be very different from what respondents would have been expecting. Comparing scenarios 1 and 2 allows us to test the hypothesis that some respondents would revise their choices of allocations when they become better informed about research funding levels.

In scenario 3, respondents were asked to imagine a hypothetical situation where the government has reduced its annual spending on cancer research from £150million (as in scenario 2) to £50million, and has spent the £100million difference on more research into diseases other than cancer. The crowding out hypothesis suggests that respondents would seek to make up the gap by increasing the amount they give to cancer research charities. Alternatively, respondents may view the government's decision to redirect resources away from cancer research towards other areas of medical research as a signal that cancer research is a relatively low priority for society (hence comparing scenarios 2 and 3 allows us to test the signalling hypothesis). If so, they may follow suit by reducing the amount they give to cancer research charities.

**Table 4.1: Summary of scenarios used in the survey**

Scenario	Spend on medical research in the UK each year				Description
	Funding from government		Funding from charities		
	Cancer research	Other medical research	Cancer research	Other medical research	
1	No information provided to respondent				Scenario included to capture respondents' preferences in absence of information about medical research funding levels
2	£150m	£2,350m	£350m	£650m	Realistic estimates of actual spending on medical research
3	£50m	£2,450m	£350m	£650m	Government reduces its spending on cancer research and spends that money instead on other medical research
4	£50m	£2,350m	£350m	£650m	Government reduces its spending on cancer research; spending on other medical research remains unchanged
5	£250m	£2,250m	£350m	£650m	Government increases its spending on cancer research and reduces its spending on other medical research by the same amount

Scenario 4 replicates scenario 3 except that the government does not increase its spending on other areas of medical research, so total annual government spending on medical research has been reduced by the same £100million that has been cut from spending on cancer research.

Finally, in scenario 5 the government has increased its annual spending on cancer research by £100million and has found that money by reducing its spending on research into diseases other than cancer by £100million. It was hypothesised that if a respondent reacts to hearing that the government has *reduced* its spending on cancer research by increasing (reducing) the share of the £100 allocation they give to cancer research charities, then they may react to hearing the government has *increased* its spending on cancer research by reducing (increasing) the share for cancer research charities.

Information about the levels of funding for research from charities remained constant throughout the scenarios, and was included to provide some context to the respondents.

The questions relating to the five scenarios were preceded by a small number of preliminary questions. First, respondents were presented with a list of well-known cancer research charities and were asked to indicate which of those charities, if any, they had given money to in the past year. An "Other" option was included to allow respondents to specify the name of a cancer research charity that they had given money to and was not included in the list. Respondents were then asked a similar question but about medical research charities focusing on diseases other

than cancer. When later faced with the five scenarios, respondents were only asked the questions about whether they would change their personal out-of-pocket donations to cancer research and/or other medical research charities if they had already claimed to give money to the relevant types of charities in these preliminary questions.

The respondents were then asked to guess: (1) how much the UK government currently spends on medical research each year, in millions of pounds; and (2) the percentage of total UK government spending on medical research each year that is on cancer research. It was assumed that respondents would not know the answers to either of these questions, but having information on their best guesses helps us to interpret any changes in their responses when moving from scenario 1 (no information on government spending provided) to scenario 2 (realistic estimates of government spending levels provided).

The respondents were then asked to indicate whether they thought that government funding of medical research had been going up, been going down, or remained about the same, over the last three years. They were then asked the same question, but focusing specifically on cancer research.

Following these preliminary questions, the respondents were presented with the five scenarios, as described above. Once they had completed the questions for these scenarios, they were invited to provide comments to support their answers if they so wished. Respondents who had claimed not to have given money to any cancer research charities in the previous year were asked what, if anything, might encourage them to donate to a cancer research charity.

The next question sought to elicit respondents' views more directly, asking them whether hearing that the government has reduced its spending on cancer research would make them more or less likely to donate to a cancer research charity, or to donate more or less than they already do. Alternatively, respondents could indicate that government spending decisions make no difference to their donation decisions.

Finally, the respondents were asked some background questions about the types of charity donations they had made in the last year (to any kind of charity, medical or otherwise); whether the level of their charity donations had been going up, been going down or remained about the same; and whether they had any personal experience of cancer.

#### **4.3.2.2 Administration of survey**

The questions were included in a self-completion web-based survey. The survey was administered on a sample of adult members of the UK general public, all of whom were members of a panel managed by Aurora MR, with whom the market research agency Accent partnered for this component of the research. We sought a sample that was representative of the general population in terms of age and gender. We also sought respondents from different socioeconomic grades, choosing to oversample those from the very highest grades (A and B) in order to obtain a large subsample comprising individuals who might be expected *a priori* to be more likely than average to be regular givers of large charity donations (or to become such givers in the future). Screen-in questions, combined with a

“minimum quota” approach, were used to ensure that the sample comprised individuals with the appropriate characteristics. Respondents were compensated for taking part by way of “reward points” which can be redeemed for gift vouchers.

Information about the scenarios was presented using a combination of text descriptions and diagrams (see Appendix). All responses were recorded via the web-based survey. In order to control for potential ordering effects, the respondents were randomly assigned to one of two blocks that determined the order in which the scenarios were presented to them. Respondents in the first block faced the scenarios in the same order as described above (12345); respondents in the second block were presented with the scenario describing an increase in the government’s funding for cancer research before proceeding to the scenarios describing reductions in the government’s funding for cancer research (12534).

#### **4.3.2.3 Piloting**

The study design was informed by a focus group, which was used to pilot a draft version of the survey and to seek feedback from general public participants. The focus group took place in Hammersmith, London in May 2013. It was moderated by a focus group leader from Accent, with assistance from a member of the study team (KS). Nine members of the general public took part, all of whom claimed to support the principle of giving to charity. The sample was well-balanced with respect to age (three participants under 30 years; three between 30 and 60 years; and three over 60 years) and gender (four males; five females).

The topic was introduced by the focus group leader. This was followed by a group discussion about different reasons for giving to charity, including medical research charities. The participants were then each handed a paper copy of the draft survey and were asked to complete it by hand without conferring with each other. All but one of the participants completed the survey within 15 minutes; the majority required less than 10 minutes. Feedback was sought on all aspects of the survey. The entire session was video recorded.

The comments were largely favourable, with participants describing the scenarios as interesting and easy to understand; and claiming that the survey was straightforward to complete without assistance. However, the participants also criticised the survey for being overly “wordy” and repetitive; and some participants questioned the plausibility of some of the scenarios.

The findings from the focus group informed the design of the final survey in a number of ways, in particular: the reduction of wordiness throughout the survey, with less repetition from scenario to scenario; the use of diagrams (rather than tables) to demonstrate the key pieces of information in the scenarios; the focus on financial donations only, rather than all types of giving (unpaid time, for example); the provision of examples of cancer and other medical research charities at the start of the survey; survey routing based on answers to previous question (e.g. only ask about changes to the respondent’s out-of-pocket donations to cancer research charities if the respondent has already claimed to give money to cancer research charities); removal of specific reference to the policy in Italy; and the use

of features to make the web-based survey more user-friendly than its pen-and-paper counterpart.

#### 4.3.3 Results

The survey was carried out in July 2013. Respondents who completed the survey in less than 3.5 minutes were excluded from the sample due to concerns about data quality (n=74), leaving a sample of 401 respondents. The median time taken by these 401 respondents to complete the survey was 6.025 minutes. Table 4.2 presents the background characteristics of the sample. By design, the sample was broadly representative of the general population with respect to age and gender (Office for National Statistics, 2011a), and comprised a larger proportion of individuals in the highest socioeconomic grades (National Readership Survey, 2013).

**Table 4.2: Sample background characteristics**

	Freq	%
<b>Total</b>	401	100
<b>Gender</b>		
Male	214	53.4
Female	187	46.6
<b>Age (years)</b>		
18 to 29	49	12.2
30 to 39	90	22.4
40 to 49	63	15.7
50 to 59	76	19.0
60 and over	123	30.7
<b>Social grade (refers to the occupation/responsibilities of the chief wage earner of the respondent's household)</b>		
A (higher managerial, administrative or professional)	23	5.7
B (intermediate managerial, administrative or professional)	144	35.9
C1 (supervisory or clerical and junior managerial, administrative or professional)	95	23.7
C2 (skilled manual workers)	52	13.0
D (semi-skilled and unskilled manual workers)	27	6.7
E (state pensioners, casual and lowest grade workers, unemployed with state benefits only)	60	15.0
<b>Types of charity donations made in the last year</b>		
Money – regular donation	127	31.7
Money – one-off donation	241	60.1
Money – other (charity events, auctions, etc.)	126	31.4
Non-financial (donation of unwanted goods, volunteering, etc.)	223	55.6
None of the above	45	11.2
<b>Over the last three years, what has happened to the level of your charity donations(s)?</b>		
Going up	66	16.5
Going down	56	14.0
About the same	279	69.6
<b>Personal experience of cancer (respondents could tick multiple boxes)</b>		
Yes, self	34	8.5
Yes, close friend or relative	275	68.6
No	87	21.7
No answer given	22	5.5

Just over half of the respondents (53.4%) said they had given money to Cancer Research UK in the previous year. Donations to Cancer Research UK were more common amongst respondents with personal experience of cancer and those from

the lower socioeconomic grades (although the question did not specify the size or regularity of the donations).

Figure 4.1 shows the distribution of answers given by respondents when asked: (1) how much the UK government spends on medical research each year, in millions of pounds; and (2) what proportion of the total UK government spending on medical research each year is spent on cancer research. The vast majority (96.3%) of respondents underestimated the total government spending on medical research (median guess = £24million; actual figure  $\approx$  £2,500million), and a similarly large majority overestimated the proportion of government spending on medical research that is spent on cancer research (median guess  $\approx$  30%; actual figure  $\approx$  6%) (actuals based on NCRI, 2011 and UKCRC, 2012). Over four-fifths of the respondents (82.5%) guessed that total government spending on medical research was less than or equal to £100million, with three evident peaks at £10million (12.9%), £50million (9.0%) and £100million (12.2%). The majority of respondents guessed that government funding of cancer research had either been going down (33.7%) or remained about the same (35.2%) over the past three years, with most of the remainder selecting the “don’t know” option.

**Figure 4.1: Distribution of guesses of levels of government spending**




Table 4.3 reports the aggregate response data for the five scenarios. In scenario 1, in which no information about actual levels of medical research funding was provided, the respondents were fairly equally split between giving the majority of the £100 allocation to cancer research charities (38.2%), giving the majority to non-cancer medical research charities (27.9%), and splitting the allocation equally between cancer research and non-cancer medical research charities (33.9%). In all of the subsequent scenarios, the proportion of respondents giving the majority of the allocation to cancer research charities was greater than in scenario 1. Respondents were mostly likely to give the majority of the allocation to cancer research charities in scenarios 3 and 4, when they were asked to imagine that the

government had reduced its spending on cancer research. One hundred and fifty-three respondents (38.2%) opted for the same split between cancer research and other medical research charities in all five scenarios, including 48 respondents (12.0%) who chose a 50:50 split on every occasion.

**Table 4.3: Aggregate response data for scenarios 1-5**

	Scenario				
	1 No info	2 Realistic estimates	3 ↓ cancer research; ↓ other medical research	4 ↓ cancer research	5 ↓ cancer research; ↓ other medical research
<b>Allocation to cancer research charities (out of notional £100 tax deducted sum)</b>					
<£50	27.9%	27.9%	26.9%	25.7%	29.4%
=£50	33.9%	22.2%	16.5%	19.7%	25.4%
>£50	38.2%	49.9%	56.6%	54.6%	45.1%
<b>Mean allocation to cancer research charities</b>	£53.60	£58.19	£63.15	£62.35	£56.47
<b>Change in personal out-of-pocket donations to cancer research charities<sup>1</sup></b>					
Would reduce	4.0%	1.8%	2.6%	2.2%	5.8%
Would increase	4.7%	9.1%	11.7%	9.5%	5.1%
Would not change	91.2%	89.1%	85.8%	88.3%	89.1%
<b>Mean change in personal out-of-pocket donation to cancer research charities<sup>2</sup></b>	-£0.10	+£1.12	+£1.54	+£1.51	-£0.21
<b>Change in personal out-of-pocket donations to other medical research charities<sup>3</sup></b>					
Would reduce	5.4%	8.3%	7.8%	5.4%	4.4%
Would increase	2.5%	2.0%	3.9%	3.9%	5.4%
Would not change	92.2%	89.7%	88.2%	90.7%	90.2%
<b>Mean change in personal out-of-pocket donations to other medical research charities</b>	-£0.52	-£0.78	-£0.37	+£0.09	+£0.02

<sup>1</sup> Questions asked only to respondents who had given money to one or more cancer research charities in the previous year

<sup>2</sup> Excludes outlier (individual who claimed that they would increase their personal donations by £250)

<sup>3</sup> Questions asked only to respondents who had given money to one or more non-cancer medical research charities in the previous year

On average, from the £100 of income tax they were able to allocate to medical research, respondents chose to give £58.19 to cancer research charities and £41.81 to other medical research charities in scenario 2, in which they were presented with realistic estimates of government spending levels. In the scenarios in which the government had reduced its spending on cancer research, the average amount from within the £100 of income tax to be allocated to medical research that would be given to cancer research charities increased by £4.96 and £4.16 (scenarios 3 and 4, respectively). In the scenario in which the government had increased its spending on cancer research, the average amount given to cancer research charities from within the £100 of income tax to be allocated fell by £1.72 per person, on average (scenario 5).



In all five scenarios, of the respondents who had earlier claimed to have given money to medical research charities in the previous year, the vast majority (ranging from 88.2% in scenario 3 to 92.2% in scenario 1) said that they would not change the level of their personal out-of-pocket charity donations even after being given the opportunity to give an extra £100 out of their income tax. These respondents were most likely to increase their out-of-pocket donations to cancer research charities in scenarios 3 and 4, when they were asked to assume that the government had reduced its spending on cancer research; and were most likely to increase their out-of-pocket donations to non-cancer medical research charities in scenario 5, when they were asked to assume that the government had increased its spending on cancer research and had found that money by reducing its spending on research into diseases other than cancer.

Sixty-eight point three per cent (274/401) of respondents said they had donated to cancer research charities in the last year. Among that group of respondents, Table 4.3 shows that the mean personal out-of-pocket donation to cancer research charities would be greater in scenario 4 than in scenario 2, but by just £0.39 per existing donor. If replicated across 68.3% of the total 50million UK adult population this would amount to extra out-of-pocket donations totalling £13million. Relative to the hypothetical £100m cut in government spending on cancer research in this scenario, this would imply a net £87million reduction in combined government and charity annual spending on cancer research.

Figure 4.2 shows the distributions of the allocations given to cancer research charities in each of the five scenarios. The tendency to choose an even split between cancer research and other medical research charities is greatest in scenario 1. After being provided with information about the levels of government spending on medical research (scenarios 2 to 5), many respondents switch to giving the entire allocation to cancer research charities. This tendency is strongest in the scenarios that describe cuts in government spending on cancer research. It is notable that the distributions for scenarios 2 and 5 are near-identical.

Across all scenarios, respondents with personal experience of cancer were less likely to choose even splits than those without personal experience of cancer. The differences in the population means between the experience/no experience groups are statistically significant in four of the five scenarios (ANOVA analysis). The differences in the distributions of the allocations between these groups are statistically significant in scenarios 3 and 4 (Kolmogorov-Smirnov test), where respondents with personal experience of cancer are more likely than those without personal experience of cancer to give a larger share of the allocation to cancer research. No statistically significant differences were found between the allocations of respondents in the highest socioeconomic grades and those of respondents in the lower grades.

Figure 4.2: Distributions of the allocations given to cancer research charities





Figure 4.3 shows the extent to which respondents changed their allocation choices from one scenario to another (for selected pairs of scenarios). Compared to scenario 2 (the scenario presenting realistic government spending estimates), respondents were more likely to give an *increased* share of the allocation to cancer research charities in scenarios 3 and 4 (the scenarios describing cuts to government funding for cancer research); and were slightly more likely to give a *reduced* share in scenario 5 (the scenario describing an increase in government funding for cancer research).

**Figure 4.3: Changes in allocations from one scenario to another (for selected pairs of scenarios)**



Comparing the preferred allocations in scenarios 2, 3 and 5: over three-quarters of the respondents either gave the same amount to cancer research charities in all three scenarios (49.4%) or gave a larger amount to cancer research charities in scenario 3 than in scenarios 2 or 5 (28.2%). This is shown in Table 4.4.

**Table 4.4: Comparison of scenarios 2, 3 and 5 – in which was the largest amount allocated to cancer research charities?**

Scenario(s) in which the largest amount was given to cancer research charities	Freq	%
Same allocation in all three scenarios	198	49.4%
Scenario 2	20	5.0%
Scenario 3	113	28.2%
Scenario 5	18	4.5%
Scenarios 2 and 3	30	7.5%
Scenarios 2 and 5	7	1.7%
Scenarios 3 and 5	15	3.7%

Figure 4.4 shows, for each of the five scenarios, the relationship between respondents' preferred allocations of the £100 of their income tax and the amount they say that being given the opportunity to allocate that £100 of their income tax would cause them to reduce or increase their personal out-of-pocket donations to cancer research charities (excluding those who would not change their personal donations and a small number of outliers who claimed that they would increase their personal donations by more than £100). Figure 4.5 shows the stated changes in personal out-of-pocket donations to non-cancer medical research charities.

Figure 4.4: Relationship between allocation and change in personal out-of-pocket donation to cancer research charities






Figure 4.5: Relationship between allocation and change in personal out-of-pocket donation to non-cancer medical research charities



The linear trend lines in Figures 4.4 and 4.5 respectively indicate that the larger a respondent's allocation to cancer research charities, the more likely that respondent is to *increase* their personal out-of-pocket donations to cancer research charities as a result of being given the opportunity to allocate some of their income tax; and the more likely they are to *reduce* their personal out-of-pocket donations to non-cancer medical research charities. The relationship between respondents' preferred allocations and the changes in their personal donations to cancer research charities appears to be strongest in scenarios 3 and 4.

The order in which the scenarios are presented in the survey appears to affect the way in which respondents' preferred allocations of the £100 of income tax vary across the scenarios. Figure 4.6 shows that respondents who were presented with scenario 5 prior to scenarios 3 and 4 (order 2) were more likely to choose the same allocation in scenarios 2 and 5 than those who were presented with scenario 5 last (order 1).

**Figure 4.6: Order effects**



When asked directly if they were to hear that the government had reduced its spending on cancer research whether that would make them more or less likely to donate to a cancer research charity (or to donate more or less than they already do), the majority of respondents (70.8%) claimed that government spending decisions make no difference to their decision about whether or not (or how much) to donate to a cancer research charity. Of the remainder, most claimed that it would make them more likely to donate, whereas only eight respondents (2.0%) claimed that it would make them less likely to donate. Table 4.5 provides a cross-tabulation of respondents' answers to this question and their answers to the question regarding scenario 4 when they were asked if they would change the level of their personal out-of-pocket donations to cancer research charities when faced with a situation whereby the government had reduced its spending on cancer research by £100million (the wording of this scenario most closely matches the wording of the direct attitudinal question).

The majority of respondents who claimed that government spending decisions make no difference to their decision about whether to donate to a cancer research

charity also stated that they would not wish to change the level of their existing out-of-pocket donations to cancer research charities were they to hear that the government had reduced its spending on cancer research.

**Table 4.5: Cross tabulation – question regarding scenario 4 about impact on personal out-of-pocket donations vs. direct attitudinal question**

		Direct attitudinal question			
		Less likely to donate	Makes no difference	More likely to donate	Total
Question regarding scenario 4 (impact on out-of-pocket donations)	Would reduce	0	2	4	6
	Would not change	6	171	65	242
	Would increase	1	8	17	26
<b>Total</b>		7	181	86	274

Note: Table refers only to the 274 respondents who had given money to cancer research charities in the previous year.

All respondents were invited to leave comments about their answers to scenario questions. The comments were coded and organised into categories by Accent. Table 4.6 shows the proportion of respondents who made each type of comment. Note that some respondents made comments that belong to multiple categories, so the numbers sum to more than 100%.

**Table 4.6: Summary of comments made by respondents about their answers**

Category of comment	%
No comment	80.5%
Other charities are just as important (general)	0.5%
Other medical research is just as/more important	3.0%
Surprised/disgusted at how little cancer research receives from government	2.2%
My personal donations would not be affected by changes to government policy/funding	3.0%
The government should prioritise funding for education/preventative measures	0.7%
People/I tend to donate to a cause they're connected to (e.g. family members affected)	2.2%
Would support a campaign for increased government funding for medical research	0.7%
Government funding for medical research should be as transparent as possible	0.5%
Ability to donate to charity is affected by low income/current economic climate	1.2%
My preference is to support lesser known charities	0.7%
Concerns over how funding for research is spent (e.g. ineffective, bureaucracy, poor results)	0.7%
The government allocations look out of proportion (unspecified)	0.5%
Generally critical of all cancer treatment/mainstream medicine	0.5%
Strongly opposed to animal testing	0.5%
Problems with the form of the survey - confusing, complicated, repetitive	2.7%
Lack of information/specialist knowledge to provide meaningful responses	1.2%
Other	1.7%

Respondents who had not earlier claimed to have given money to cancer research charities in the previous year were asked what might encourage them to do so. The responses were coded and organised into categories by a member of the study team (KHV). Table 4.7 shows the proportion of respondents who gave each type of response. Responses that suggested that having a larger disposable income would encourage donations to a cancer research charity were made predominantly by respondents in the lower socioeconomic grades, while responses that mentioned personal experience of cancer were made predominantly by those in the highest grades. None of the respondents who were asked this question gave a response that mentioned the level of government funding for cancer (or any other type of) research.

**Table 4.7: Summary of responses made by respondents when asked what would encourage them to donate to a cancer research charity**

Category of response	%
No response	56.7%
Personal experience of cancer (self, friends or family)	11.8%
Larger disposable income	10.2%
Greater levels of information and transparency	8.7%
Nothing (would encourage me to donate to a cancer research charity)	7.1%
Other	5.5%

#### 4.3.4 Discussion

This study has elicited the views of a sample of the UK general public about how (hypothetical) changes in government spending on cancer research might affect people's willingness to donate to cancer research charities. The main findings are as follows:

- Almost all respondents (96.3%) underestimate the amount that the government spends on medical research, and most overestimate the proportion of government spending on medical research that is for cancer research. When presented with actual government spending figures, the overall tendency is to give a larger share of the allocation (£100 of their income tax) to cancer research charities (at the expense of medical research charities concerned with diseases other than cancer).
- When respondents are asked to suppose that the government has *cut* funding for cancer research, the overall tendency is to give a *larger* share of the allocation to cancer research charities.
- When respondents are asked to suppose that the government has *increased* funding for cancer research, the overall tendency is to give a *smaller* share to the allocation to cancer research charities, although the impact is somewhat smaller than that of when the government has cut funding for cancer research.
- Notwithstanding the above findings, most respondents' preferred allocation splits did not vary much from scenario to scenario; and a sizeable minority (38.2%) of respondents chose the same allocation split in all five scenarios.
- In all five scenarios, the vast majority (88.2-92.2%) of respondents said that they would not take the opportunity to change the levels of their existing personal out-of-pocket donations to cancer research and/or other medical research charities, despite the fact that these charities would be receiving additional funding by way of the £100 allocation. For those respondents who said that they *would* change their personal donations, the larger their preferred allocation to cancer research charities, the more likely they are to increase their personal donations to cancer research charities.

Overall, the results from the scenario questions suggest that most people's private donation decisions are not (or only slightly) affected by information about government spending. This finding is further supported by the responses to the direct attitudinal question, in which approximately two-thirds of respondents claimed that hearing that the government had reduced its spending on cancer research would not affect their decision about whether to donate to a cancer research charity, or the size of their donation.

The open-ended comments made by respondents paint a similar picture. Few of the comments mentioned government funding for research as a factor affecting their decisions, with respondents claiming that personal experience of cancer, or increases in their disposable income, would be the main drivers behind any future decision to donate to a cancer research charity. Of the respondents who left a comment about their answers to the scenario questions, 15% took the opportunity to reiterate the fact their personal donations would not be affected by changes in government policy or funding levels.



Nevertheless, there are some respondents whose preferred allocations varied substantially from scenario to scenario. Overall, the results suggest that crowding out effects outweigh any possible crowding in or signalling effects. Of the respondents who amended their allocation splits upon being given new information about government spending levels, the majority tended to move in the opposite direction to the government – increasing the share for cancer research charities when government funding for cancer research is cut, and reducing the share for cancer research charities when government funding for cancer research is increased.

On average, when moving from scenario 2 (realistic estimates of government spending) to scenario 4 (£100million cut to in government funding for cancer research with no increase in government funding for other medical research), respondents increased the share of the £100 of income tax allocated to cancer research by £4.16. Given that the adult population of the UK is approximately 50million (Office for National Statistics, 2011b) and assuming that the wider population would behave in accordance with the stated preferences elicited in this study, then if the government were to cut funding for cancer research by £100million and gave each individual £100 of income tax to allocate to cancer research and other medical research charities of their choosing, then cancer research charities would between them receive £208million from such a policy. In other words the general public would rebalance tax spending back to cancer research, given the chance, if government were to cut its planned spending on cancer research. The direction of intent is clear. However not much can be read into the magnitude of the additional allocation to cancer research owing to the hypothetical nature of the exercise and the fact that the magnitude is likely to be strongly affected by the size of the amount that the individual is given discretion over to allocate.

In addition, since the mean change in personal out-of-pocket donation to cancer research charities is greater in scenario 4 than in scenario 2, cancer research charities might also expect to receive a small amount of further donations from the pockets of individuals who already give money to these types of organisations, should the government cut its spending on cancer research. Comparing scenario 4 with scenario 2, the additional £0.39 per person saying they already donate to cancer research charities, who make up 68.3% of our survey respondents (274/401), suggests that if replicated across 68.3% of the 50million UK adult population this would amount to extra out-of-pocket donations of £13million. This would not go far towards offsetting the hypothetical £100million cut in government spending on cancer research.

However, we would urge caution when scaling up in this way: in reality, even the better-informed members of the public would be unlikely to have access to information about government spending levels as presented in the scenarios. Furthermore, means tend to be skewed by extreme values (such as respondents who claim that they would give an additional £100 to cancer research charities after already having been given the opportunity to allocate £100 of income tax to those charities) that may not accurately reflect what would happen if the scenario were actually to occur. It is perhaps more telling that the median change in

personal out-of-pocket donations to both cancer research and other medical research charities was zero in all five scenarios.

It is not surprising that the respondents were largely uninformed about current levels of government spending on medical research. A recent survey of public views about science and biomedical research reported that, when asked which groups they are aware of that carry out medical research in the UK, only 6% mentioned the government, 18% the NHS, and 23% mentioned universities; and 16% said that they did not know (48% mentioned medical research charities) (Clemence et al., 2013).

Most respondents guessed that government spending on medical research is far more concentrated on cancer research than is actually the case. This may explain the large shares of the allocations given to cancer research at the expense of other medical research (in each of the scenarios, the mean amount given to cancer research charities was greater than £50 of the £100 to be allocated). However, the fact that cancer research was clearly the main subject of the survey (and the fact that respondents were informed that the study was funded by Cancer Research UK) is likely to have resulted in a focusing effect whereby respondents placed more importance on cancer than they otherwise might have done. In terms of the purpose of this study, however, the actual amounts given to cancer research charities in any given scenario are less important than the ways in which those amounts change from scenario to scenario.

After having been given the opportunity to allocate £100 of income tax to medical research charities of their choosing, very few respondents then said that they would take the opportunity to reduce the size of their existing personal out-of-pocket donations. Most existing donors to medical research charities said that they would not change the size of their personal donations. This is particularly the case in scenario 1, in which respondents were not given any information about government funding levels. This means that their answers regarding personal donations under scenario 1 would not have been driven by concerns that the government is spending too little (or too much) on medical research.

However, a drawback of stated preference studies is that they only elicit data on what respondents *say* that they would do/prefer – we do not know whether they would behave in the same way if the hypothetical scenarios were to actually happen. Survey respondents may exaggerate claims about their positive behaviour (i.e. giving to charity) either to appease or impress the researcher, or because they have a deluded view of themselves. Future research could combine the stated preference design with an experimental lab-based study in order to test whether people act on their claims when given real money to allocate.

#### References for Chapter 4

Agenzia delle Entrate. (n.d.) *5 per mille 2013 – Scheda informative*. (in Italian)  
Available at:  
<http://www.agenziaentrate.gov.it/wps/content/Nsilib/Nsi/Home/CosaDeviFare/Rich>

[iedere/Iscrizione+elenchi+5+per+mille+2013/Scheda+informativa+5xmille+2013](#)  
/ [Accessed 8 Aug 2013]

Andreoni, J. (1989) Giving with impure altruism: Applications to charity and Ricardian equivalence. *Journal of Political Economy*. 97(6), 1447-1458.

Andreoni, J. (1990) Impure altruism and donations to public goods: A theory of warm-glow giving. *The Economic Journal*. 100(401), 464-477.

Andreoni, J. (2006) Leadership giving in charitable fundraising. *Journal of Public Economic Theory*. 8(1), 1-22.

Andreoni, J. and Payne, A. (2003). Do government grants to private charities crowd-out giving or fund-raising? *The American Economic Review*. 93(3), 792-812.

Andreoni, J. and Payne, A.A. (2011) Is crowding out due entirely to fundraising? Evidence from a panel of charities. *Journal of Public Economics*. 95(5), 334-343.

Andreoni, J., Payne, A. and Smith, S. *Do grants to charities crowd out other income? Evidence from the UK*. CMPO Working Paper No. 13/301. Bristol: Centre for Market and Public Organisation.

Bekkers, R. and Wiepking, P. (2011) A literature review of empirical studies of philanthropy: Eight mechanisms that drive charitable giving. *Nonprofit and Voluntary Sector Quarterly*. 40(5), 924-973.

Bergstrom, T., Blume, L. and Varian, H. (1986) On the private provision of public goods. *Journal of Public Economics*. 29(1), 25-49.

Breeze, B. (2010) *How donors choose charities: Findings of a study of donor perceptions of the nature and distribution of charitable benefit*. CGAP Occasional Paper 1. Kent: Centre for Charitable Giving and Philanthropy.

Breman, A. (2006) *The economics of altruism, paternalism and self-control*. PhD thesis. Stockholm: Stockholm School of Economics.

Clemence, M., Gilby, N., Shah, J., et al. (2013) *Wellcome Trust Monitor Wave 2: Tracking public views on science, biomedical research and science education*. London: Wellcome Trust.

Diamond, A.M. (1999) Does federal funding "crowd in" private funding of science? *Contemporary Economic Policy*. 17(4), 423-431.

Eckel, C.C., Grossman, P.J. and Johnston, R.M. (2005) An experimental test of the crowding out hypothesis. *Journal of Public Economics*. 89(8), 1543-1560.

Garrett, T. and Rhine, R. (2010) Government growth and private contributions to charity. *Public Choice*. 143(1-2), 103-120.

Herzer, D. and Nunnenkamp, P. (2012) *Private donations, grants, commercial activities, and fundraising: Cointegration and causality for NGOs in international development cooperation*. Kiel Working Paper No. 1769. Kiel: Kiel Institute for the World Economy.

Heutel, G. (2009) *Crowding out and crowding in of private donations and government grants*. NBER Working Paper No. 15004. Boston: The National Bureau of Economic Research.

Heutel, G. (2012) *Crowding out and crowding in of private donations and government grants*. *Public Finance Review*. Published online. DOI: 10.1177/1091142112447525

Khanna, J. and Sander, T. (2000) *Partners in giving: The crowding-in effects of UK Government grants*. *European Economic Review*. 44(8), 1543-1556.

National Readership Survey (2013). *Lifestyle data 2012-2013*. Available at: <http://www.nrs.co.uk/lifestyle-data/> [Accessed 11 Aug 2013]

NCRI (National Cancer Research Institute) (2011) *Celebrating a decade of progress through partnership in cancer research*. London: NCRI.

Office for National Statistics. (2011a) *Census: neighbourhood statistics (England and Wales)*. Available at: <http://www.neighbourhood.statistics.gov.uk/dissemination/> [Accessed 11 Aug 2013]

Office for National Statistics. (2011b) *2011 Census: Population Estimates for the United Kingdom, 27 March 2011*. Available at@ [http://www.ons.gov.uk/ons/dcp171778\\_292378.pdf](http://www.ons.gov.uk/ons/dcp171778_292378.pdf) [Accessed 22 Aug 2013]

OHE (Office of Health Economics). (2011) *Exploring the interdependency between public and charitable medical research*. London: Cancer Research UK.

Payne, A. (2001) *Measuring the effect of federal research funding on private donations at research universities: Is federal research funding more than a substitute for private donations?* *International Tax and Public Finance*. 8(5-6), 731-751.

Roberts, R. (1984) *A positive model of private charity and public transfers*. *Journal of Political Economy*. 92(1), 136-148.

Rose-Ackerman, S. (1986) *Do government grants to charity reduce private donations?* In: *The Economics of Non-Profit Institutions*. New York and Oxford: Oxford University Press.

Shang, J. and Croson, R. (2009) *A field experiment in charitable contribution: The impact of social information on the voluntary provision of public goods*. *The Economic Journal*. 119(540), 1422-1439.

UKCRC (UK Clinical Research Collaboration) (2012) *UK health research analysis 2009/10*. London: UKCRC.

Vesterlund, L. (2001) *The informational value of sequential fundraising*. *Journal of Public Economics*. 87(3-4), 627-657.

Warr, P.G. (1982) *Pareto optimal redistribution and private charity giving*. *Journal of Public Economics*. 19(1), 131-138.

## APPENDIX TO CHAPTER 3

### A1.1 Identification of the publication sample

To map the UK cancer funding landscape it is necessary to take a snapshot of the research and funder organisational 'ecosystem' as a whole. To ensure comprehensive coverage a window of one full calendar year was selected based on the assumption that research active scientists would author at least one published paper per year and that even relatively small funding organisations would have been likely to have publications stemming from their work published during a given year. The year 2011 was selected so that at the outset of the project (in early 2013) the lag between publication of papers in journals and complete indexing by publication databases would minimally affect data collection, whilst allowing the study to be as up-to-date as possible. The sample aims to capture all papers with an electronic publication date for 2011.<sup>12</sup>

Delineating a broad topic such as cancer for scientometric analysis from first principles, without creating biases in data collection, is often challenging. In particular, approaches using ad hoc searches for keywords (e.g. in titles and abstracts of papers) or those that rely on author-defined keywords will often yield many false positives and false negatives (Leydesdorff et al. 2012). In order to benefit from prior expertise in building the sample, the Medical Subject Headings (MeSH) controlled vocabulary indexing system was used. MeSH classification is the basis of the US National Library of Medicine (NLM) of the National Institutes for Health (NIH) PubMed/MEDLINE collection where papers are classified in a standardised process by indexers according to the main themes and subject matter of the paper.<sup>13</sup> The coding system allows each paper to be categorised using sets of terms drawn from over 26,000 MeSH descriptors organised in a tree like branching structure.<sup>14</sup> The descriptors describe the disease and anatomical focus, the techniques used and any drugs or other molecules discussed in the paper. This coding system is such that very specific terms are located within broader topics.

To capture the study of cancer – itself a broad set of diseases – the highest available level in the tree-like MeSH coding system was used: "C04 – Neoplasms". MeSH notes the scope of the term neoplasm as: "New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms". The search therefore includes benign and malignant neoplasms. Table A2 (at the end of this section) shows a full list of the disease sub-categories captured within C04.

---

<sup>12</sup> The electronic date provided by PubMed/MEDLINE was used.

<sup>13</sup> For further details see [www.nlm.nih.gov/mesh](http://www.nlm.nih.gov/mesh)

<sup>14</sup> The tree is organized in 16 branches reported in the followings: "Anatomy", "Organisms", "Diseases", "Chemical and Drugs", "Analytical, Diagnostics and Therapeutic Techniques and Equipment", "Psychiatry and Psychology", "Phenomena and Processes", "Disciplines and Occupations", "Anthropology, Education, Sociology and Social Phenomena", "Technology, Industry and Agriculture", "Humanities", "Information Science", "Named Groups", "Health Care", "Publication Characteristics", and "Geographicals".

PubMed/MEDLINE returned 115,101 publications, to which examiners at NLM assigned as descriptor “Neoplasms” or relative sub-levels in the tree structure of the coding system, globally for year 2011.

### **A1.2. Data on authors’ addresses and identification of UK publications**

Although PubMed/MEDLINE provides the MeSH indexing system to retrieve papers, it does not provide the full data on affiliations or full addresses of all authors involved on a given publication. However this data is required to fulfil the aims of this study. We therefore matched the data from PubMed/MEDLINE in the above step with data from SCOPUS. The match was performed by using the PubMed/MEDLINE publication unique identifier, namely “PMID”, and the publication DOI. This match covered 98.1% of the global publication production.<sup>15</sup> All the data were then arranged into a relational database. We identified UK publications as those involving at least one author affiliated to a UK organisation. We specifically searched for UK in the “Affiliation” field provided by SCOPUS.<sup>16</sup> Records from PubMed/MEDLINE that were unmatched with SCOPUS records using PMID (1.9%) were manually screened and added to the dataset when a UK organisation was found involved in the given publication. The final dataset includes 7,922 UK publications.

### **A1.3. Data sample and scientific discipline coverage**

The 7,922 UK publications composing our sample were distributed across 1,480 journal titles. Due to publisher restrictions in electronic access to journal titles we were not able to access publications from 130 journals. However, access to full text of 7,510 publications was obtained. This provides coverage of 94.8% of the initial publication sample.

Figure A1 depicts a web of 224 scientific disciplines (shown as nodes) as defined by ISI Web of Science (WoS) ‘Subject Categories’ (SCs).<sup>17</sup> The network structure reflects the propensity of publications in the journals that make up each subject category to cite publications in journals in other subject categories (see Rafols, Porter, Leydesdorff 2010). The size of each node is proportional to the number publications that are published within each subject category. Leading nodes only are labelled. The smallest node size depicts nodes with no publications.

The broad range of scientific disciplines (135 of 224) demonstrates that the use of the C04 search does not exclude research in relevant domains.<sup>18</sup> Table 3.1 reports

<sup>15</sup> The lag in the indexing process of the two databases does not allow for a full match of the records. For example, when the matched was performed, SCOPUS did not provide the PMID for some of the records listed in PubMed/MEDLINE while the latter did not provide the DOI for of some records for which SCOPUS did.

<sup>16</sup> We build a query that searched for: “%United Kingdom%”, “% UK;”, “ U.K.;”, “ U.K.,” “U.K.”, “% UK,” “% UK.”, “%Scotland%”, “%England%”, “%Wales%”, “%Great Britain%”, “%Northern Ireland%”. The “%” represents the wild card/ jolly characters. The query returned a sample of 8,347 publications. Yet, this sample still included false positives (e.g. articles by authors at the “University of New South Wales”). These records were eliminated by manual screening returning a sample of 7,922 publications.

<sup>17</sup> The map was produced by using VOSviewer Version 1.5.4.

<sup>18</sup> The SCs not covered by the publication sample are reported in the followings: Agricultural Economics & Policy; Agricultural Engineering; Agriculture, Dairy & Animal Science; Agriculture, Multidisciplinary; Agronomy; Anthropology; Area Studies; Astronomy & Astrophysics; Automation & Control Systems; Business; Business, Finance; Computer Science, Cybernetics; Computer Science, Hardware & Architecture; Computer Science, Software Engineering; Construction & Building Technology;

the top-20 SCs in terms of number of publications. These SCs represent ~80% of the publication sample. Table 3.1 reveals that 33% of the sampled publications are published in specialist oncology journals. The other major categories are closely associated with clinical disciplines led by Surgery (2<sup>nd</sup>), Haematology (3<sup>rd</sup>), Radiology (4<sup>th</sup>), and Gastroenterology and Hepatology (7<sup>th</sup>), although basic sciences are well represented too such as Cell biology (5<sup>th</sup>), Biochemistry and Molecular Biology (6<sup>th</sup>) and Genetics and Heredity (11<sup>th</sup>).

Using the MeSH categorisation 'neoplasms' will inevitably miss some of those publications that might be deemed by researchers or funders to be associated with neoplasms. Coding is a subjective process and opinions may differ on whether a paper should be included or excluded. For example, a funder or researcher may consider studies of angiogenesis in healthy tissue to be relevant for understanding how tumours develop a blood supply, but if these papers are not considered to actually study cancerous tissue they may not be understood as within the study of neoplasms *per se*, and they will not be coded using the MeSH term 'C04'. The publications recovered by the searches employed in this study are therefore referred to as a 'sample', reflecting the fact that the search is exhaustive within the C04 field, but not comprehensive of neoplasms by other definitions.

**Table A1: ISI WoS Subject Categories (SCs) representing ~80% of the publication sample.**

ISI WoS Subject Categories	Number of publications
1) Oncology	2,405
2) Surgery	669
3) Hematology	432
4) Radiology, Nuclear Medicine and Medical Imaging	412
5) Cell Biology	405
6) Biochemistry and Molecular Biology	369
7) Gastroenterology and Hepatology	295
8) Medicine, General and Internal	287
9) Public, Environmental and Occupational Health	272
10) Pathology	247
11) Genetics and Heredity	242
12) Obstetrics and Gynecology	227
13) Clinical Neurology	203
14) Urology and Nephrology	193
15) Pharmacology and Pharmacy	169
16) Health Care Sciences and Services	163

Criminology & Penology; Crystallography; Cultural Studies; Demography; Electrochemistry; Energy & Fuels; Engineering, Aerospace; Engineering, Chemical; Engineering, Civil; Engineering, Geological; Engineering, Industrial; Engineering, Marine; Engineering, Mechanical; Engineering, Ocean; Engineering, Petroleum; Entomology; Environmental Studies; Ergonomics; Fisheries; Forestry; Geochemistry & Geophysics; Geography; Geography, Physical Geology; Geosciences, Multidisciplinary; History; History Of Social Sciences; Horticulture; Hospitality, Leisure, Sport & Tourism; Industrial Relations & Labour; Information Science & Library Science; International Relations; Law; Limnology; Management; Marine & Freshwater Biology; Materials Science, Ceramics; Materials Science, Characterization & Testing; Materials Science, Coatings & Films; Materials Science, Composites; Materials Science, Paper & Wood; Materials Science, Textiles; Mathematics; Mathematics, Applied; Mechanics; Metallurgy & Metallurgical Engineering; Meteorology & Atmospheric Sciences; Mineralogy; Mining & Mineral Processing; Oceanography; Operations Research & Management Science; Ornithology; Palaeontology; Physics, Fluids & Plasmas; Physics, Mathematical; Physics, Multidisciplinary; Physics, Nuclear; Physics, Particles & Fields; Planning & Development; Plant Sciences; Political Science; Psychology, Applied; Psychology, Educational; Psychology, Mathematical; Psychology, Psychoanalysis; Public Administration; Remote Sensing; Robotics; Social Sciences, Mathematical Methods; Soil Science; Spectroscopy; Telecommunications; Thermodynamics; Transportation; Transportation Science & Technology; Urban Studies; Water Resources; Women.

---

17)	Medicine, Research and Experimental	146
18)	Endocrinology and Metabolism	136
19)	Biology	129
20)	Dermatology	125

---

Note. A journal can be assigned to more than one SC.



Figure A1: Distribution of the publication sample over the ISI WoS SC – size of each node equal to  $\log_2$  of the number of publications in each SC; the map is based on 7,260 out 7,510 publications for which a SC can be identified.





Figure A2: SCOPUS classification of publications and coverage of funding data (N=7,510)



#### A1.4 Extraction of information on acknowledgements

The study relies on searches undertaken using automated software routines to read from the html code of publishers' web pages and where necessary to selectively download PDFs of the publications. The routines were designed to extract information under the following headings: (i) "Acknowledgements", (ii) "Funding", (iii) "Conflicts of Interest", (iv) "Financial Disclosure", (v) "Role of Funding Sources", (vi) "Financial Supports", (vii) "Competing Financial Interests", and (ix) "Statement of interests". We refer to all of the above wordings as 'acknowledgements' henceforth. The automated searches allowed the collection of acknowledgements from the majority of publications with manual checks of remaining papers. At completion the acknowledgements sections from ~83% of the publications in the sample were found, while the remaining ~17% of papers had no acknowledgement sections (see Figure A2).

#### A1.5 Identification of funders from acknowledgements in publications

Acknowledgements were manually read by the research team to establish whether they mentioned the support of funders. A detailed protocol established guidelines for interpretation and coding of funding data, which was undertaken manually by a team of coders.

All sources of funding were recorded where authors indicated financial support for work leading to a publication. Other forms of support (colleagues reading drafts, helpful comments) were not coded. Declarations of conflicts of interest stemming from historic support, unrelated to the current publication, were excluded where possible.

These searches revealed 3,914 publications (52.1%) that disclosed at least one funder in an acknowledgements section, and 2,286 (30.4%) that did not acknowledge funding support but did make other forms of acknowledgement. A further 1,310 (17.4%) of publications had no acknowledgement sections (see Figure A2).

#### A1.6 Why do so many publications not acknowledge research funding?

Around 48% of the 7510 publications in the sample do not directly disclose a source of funding. Prior studies of funding acknowledgements in UK biomedical research have found 39% of papers have no acknowledgement to a funder (Lewison et al. 1995), so this figure is high, but it is not unexpected for a large proportion of papers not to have acknowledgements to funders. There are several possible explanations for this:

- a) The publications required little or no financial support to produce.
- b) The publication required research funding but these details were omitted from the publication either by the author(s) or the publisher.
- c) The publications were supported by the author(s) employer, who is acknowledged indirectly through the author(s) affiliation.

Research by Lewison et al. (1995) would lead us to expect that in the majority of cases reason (c) would be the most common explanation.

Figure A2 shows of the sample of 7,510 publications divided according to their disclosure or funders as well as by publication type. Publication type is an important distinction to make since some publications rely on more laboratory work or other research-intensive activity than others. SCOPUS makes the distinction between "Articles" and what are

often less cost intensive publications to produce, such as "Reviews", "Letters", "Editorials" and "Notes".

The categorisation of publications by SCOPUS definition provides some evidence supporting explanation (a) as a higher proportion of publications with acknowledgements but no named funders are less cost intensive (37%) than is the case for those with acknowledgements (17%).

The NLM's MeSH descriptors for publication types allow further more detailed classification within the category of publications that SCOPUS defines as 'articles'. Again we searched for those publications that were perceived to be less cost intensive - such papers defined by MeSH descriptors as "Comments", "Case Reports", "Reviews", "Comparative Study", "Editorials", "Consensus Development Conferences", "Practical Guidelines", "English Abstract", and "Introductory Journal Articles". As with the SCOPUS typology above, the proportion of less cost intensive publications differs significantly between the subsamples of publications where acknowledgements contain funders and those that do not contain funders, with 27% of SCOPUS defined "Articles" with funding acknowledgements being classified as less cost intensive by MeSH descriptors while 67% of SCOPUS defined "Articles" without acknowledgement sections were of the less cost intensive types. This provides further evidence to support the high relevance of explanation (a).

To establish whether publications were omitting acknowledgements to funding sources due to explanations (b) and (c), it was necessary to directly investigate a sample of publications in more detail.

2,286/7,510 or 30.44% of the sample's publications have acknowledgements but no stated funders. Of these, 69% explicitly state they did not benefit from financial support. Of the remaining 31%, 89 were selected at random for investigation (over 10%). Of these, 14/89 (~16%) were deemed to be case reports and therefore it was assumed no funding (beyond the author's employer) was necessary to fund the publication. No further investigation was carried out for these publications. The remaining 75 were queried by e-mail to the corresponding author, and 28 responses obtained (37% response rate). Only 4/28 (14% of respondents) revealed contribution by funders other than authors' employers in publications. However 14/28 respondents suggested the research had been supported by their employer. We therefore cautiously conclude that explanation (c) is more frequently accurate than explanation (b).

Further enquires were needed for the distinct subset of publications in formats where some publishers do not permit author acknowledgements or in cases where authors may omit an acknowledgement section. 1,310/7,510 or 17.44% of the sample's publications contained no acknowledgement sections. Of these, 208 (~16%) were selected at random for investigation. 79/208 (38%) were classified as case reports and therefore it was assumed no funding (beyond the author's employer) was necessary to fund the publication. The remaining 129 were queried via email to the corresponding author, and 49 replies obtained (38% response rate). In 9/49 responses (18%), a funding contribution to the publication other than the authors' employers was revealed, although it is notable that 30/40 revealed a contribution by their employer. Again this suggests that explanation (b) is less frequently accurate while explanation (c) is more commonly accurate. This is consistent with the findings of Lewison et al. (1995).

## A1.7 Assumptions on funding disclosures and analytical implications

A high-level quantitative analysis such as that described here will necessarily make strong assumptions about the consistency of the data.

From the above investigations it is concluded that in the vast majority of cases UK-based authors are disclosing external funders appropriately and therefore that the majority of publications resulting from cost intensive research acknowledge external funding.

Publications that do not contain acknowledgements are likely to be the result of less costly research and/or paid for by the author(s) host institution or employer. It is also important to note (as discussed above) that when prompted by email, authors frequently acknowledge the financial contribution of their employer, but it is clearly not an established practice to acknowledge the host organisation in an acknowledgement section. One interviewee gave some insight into this norm: "I think in general the acknowledgements, as I'm sure you know... if your employer mostly fund[s] your work it seems a bit strange to thank them for giving you a job, which in a sense is true but it sounds a bit odd."

Where a paper contains no funding acknowledgements, it is therefore appropriate to assume that the authors' employer or host organisation is funding the work. Indeed even where there is an external funder acknowledged, the employer (or otherwise host) institution should be thought of, if not acknowledged, as a funder because, as explained in Chapter 2, the costs of research are borne by external funders and host organisations albeit to different extents. For example UK research councils reimburse research grant holders 80% of the full economic cost of research they undertake, while charities reimburse typically around 60%, with HEI support in England topping this up to 80% FEC (UKCRC 2012 p.20).

One major exception is that contributions by HEFCE, which distributes funding to researchers via their universities on the basis of quality performance of researchers in each institution as measured by exercises such as the Research Excellence Framework. Outputs stemming from HEFCE funding are not recorded because researchers rarely acknowledge this source of funding (even though 40 universities receive HEFCE funding for biological sciences alone).<sup>19</sup>

Taking the above limitations into account it is theoretically possible to undertake three analytical perspectives for the analysis of outputs from research funding support:

- 1) Publications supported fully or partially by one or more external funders
- 2) Publications fully or partially supported by one or more host organisations
- 3) Publications supported by a combination of host organisations and external funders

However, given that in some substantial cases external funders also fund host organisations, the third perspective is likely to produce results that are less robust and transparent than (1) and (2) individually. An exception is the case where industrial funding is concerned, due to higher transparency in the UK over recent years in the disclosure of industry support for research. The analysis presented in this study has for

---

<sup>19</sup> <http://www.hefce.ac.uk/whatwedo/rsrch/howfundr/mainstreamqr/>

the most part therefore will focused on either the contributions of host organisations, or the contributions of external funders.

### **A1.8 Standardisation of funders names, author affiliations and aggregation of related organisations**

Where funders are acknowledged, this may often be directly by name of organisation (in full or abbreviated form), section, funding scheme or even by grant number alone. To address the three above-discussed analytical perspectives, it was necessary to harmonise all funder names.<sup>20</sup> All funders were also geographically coded.

The same process was followed for the authors' affiliations (research host organisations). All authors routinely report at least one affiliation and related address details in each publication. This information allows publications to be organisationally and geographically classified. However, to count data consistently it is necessary to harmonise organisations' names and relative addresses. This is often challenging given that address details may describe teams/groups, departments, sites, organisations and clusters of organisations. Some detail levels may also be missing. For example, a researcher at the "Royal Free Hospital in London" may describe their affiliation as such or use the higher level affiliation, "University College London Hospitals NHS Trust". Furthermore individuals may not be consistent and individuals within the same organisation will often observe different practices. It is therefore appropriate to use higher level affiliation details for consistency, even though this results in the loss of some granularity of the data.

Manual identification of organisational linkages and aggregation to the highest level of organisational group was undertaken using Google-based web searches as well as the Cancer Research UK list of organisational groups for clusters of UK research institutions.

### **Table A2: MeSH Descriptors 2013 (source: PubMed/MEDLINE)**

Note: Each band denotes a distinct 3<sup>rd</sup> level heading. Codes within a band are subsections of the first code in the band

---

<sup>20</sup> The harmonisation process was manually conducted with the support of "The Vantage Point" software.

MeSH Heading	Tree Number
<b>Neoplasms</b>	<b>C04</b>
<b>Cysts</b>	<b>C04.182</b>
Arachnoid Cysts	C04.182.044
Bone Cysts	C04.182.089
Bone Cysts, Aneurysmal	C04.182.089.265
Jaw Cysts	C04.182.089.530
Nonodontogenic Cysts	C04.182.089.530.660
Odontogenic Cysts	C04.182.089.530.690
Basal Cell Nevus Syndrome	C04.182.089.530.690.150
Dentigerous Cyst	C04.182.089.530.690.310
Odontogenic Cyst, Calcifying	C04.182.089.530.690.605
Periodontal Cyst	C04.182.089.530.690.790
Radicular Cyst	C04.182.089.530.690.790.820
Branchioma	C04.182.117
Breast Cyst	C04.182.156
Bronchogenic Cyst	C04.182.195
Chalazion	C04.182.197
Choledochal Cyst	C04.182.198
Colloid Cysts	C04.182.199
Dermoid Cyst	C04.182.201
Epidermal Cyst	C04.182.254
Esophageal Cyst	C04.182.281
Follicular Cyst	C04.182.300
Ganglion Cysts	C04.182.347
Lymphocele	C04.182.430
Mediastinal Cyst	C04.182.444
Mesenteric Cyst	C04.182.473
Mucocele	C04.182.511
Ovarian Cysts	C04.182.612
Polycystic Ovary Syndrome	C04.182.612.765
Pancreatic Cyst	C04.182.640
Pancreatic Pseudocyst	C04.182.640.692
Parovarian Cyst	C04.182.668
Pilonidal Sinus	C04.182.710
Ranula	C04.182.766
Synovial Cyst	C04.182.867
Popliteal Cyst	C04.182.867.500
Tarlov Cysts	C04.182.872
Thyroglossal Cyst	C04.182.902
Urachal Cyst	C04.182.946
<b>Hamartoma</b>	<b>C04.445</b>
Hamartoma Syndrome, Multiple	C04.445.435
Proteus Syndrome	C04.445.435.500
Pallister-Hall Syndrome	C04.445.622
Tuberous Sclerosis	C04.445.810
<b>Neoplasms by Histologic Type</b>	<b>C04.557</b>
Histiocytic Disorders, Malignant	C04.557.227
Dendritic Cell Sarcoma, Follicular	C04.557.227.190
Dendritic Cell Sarcoma, Interdigitating	C04.557.227.199
Histiocytic Sarcoma	C04.557.227.380
Langerhans Cell Sarcoma	C04.557.227.500
Leukemia	C04.557.337
Enzootic Bovine Leukosis	C04.557.337.100
Leukemia, Experimental	C04.557.337.372
Avian Leukosis	C04.557.337.372.216
Leukemia L1210	C04.557.337.372.594
Leukemia L5178	C04.557.337.372.602
Leukemia P388	C04.557.337.372.782
Leukemia, Feline	C04.557.337.385
Leukemia, Hairy Cell	C04.557.337.415
Leukemia, Lymphoid	C04.557.337.428
Leukemia, B-Cell	C04.557.337.428.080
Leukemia, Lymphocytic, Chronic, B-Cell	C04.557.337.428.080.125
Leukemia, Prolymphocytic, B-Cell	C04.557.337.428.080.562
Leukemia, Biphenotypic, Acute	C04.557.337.428.100
Leukemia, Prolymphocytic	C04.557.337.428.565
Leukemia, Prolymphocytic, B-Cell	C04.557.337.428.565.745
Leukemia, Prolymphocytic, T-Cell	C04.557.337.428.565.750
Leukemia, T-Cell	C04.557.337.428.580
Leukemia, Large Granular Lymphocytic	C04.557.337.428.580.049
Leukemia-Lymphoma, Adult T-Cell	C04.557.337.428.580.100
Leukemia, Prolymphocytic, T-Cell	C04.557.337.428.580.125
Precursor Cell Lymphoblastic Leukemia-Lymphoma	C04.557.337.428.600
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	C04.557.337.428.600.600
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	C04.557.337.428.600.620
Leukemia, Mast-Cell	C04.557.337.440
Leukemia, Myeloid	C04.557.337.539
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	C04.557.337.539.250
Blast Crisis	C04.557.337.539.250.100
Leukemia, Myeloid, Accelerated Phase	C04.557.337.539.250.300

Leukemia, Myeloid, Chronic-Phase	C04.557.337.539.250.400
Leukemia, Myeloid, Acute	C04.557.337.539.275
Leukemia, Basophilic, Acute	C04.557.337.539.275.125
Leukemia, Eosinophilic, Acute	C04.557.337.539.275.300
Leukemia, Erythroblastic, Acute	C04.557.337.539.275.325
Leukemia, Mast-Cell	C04.557.337.539.275.440
Leukemia, Megakaryoblastic, Acute	C04.557.337.539.275.450
Leukemia, Monocytic, Acute	C04.557.337.539.275.484
Leukemia, Promyelocytic, Acute	C04.557.337.539.275.700
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	C04.557.337.539.300
Leukemia, Myelomonocytic, Acute	C04.557.337.539.520
Leukemia, Myelomonocytic, Chronic	C04.557.337.539.522
Leukemia, Myelomonocytic, Juvenile	C04.557.337.539.525
Sarcoma, Myeloid	C04.557.337.539.775
Leukemia, Plasma Cell	C04.557.337.595
Leukemia, Radiation-Induced	C04.557.337.650
Lymphatic Vessel Tumors	C04.557.375
Lymphangioma	C04.557.375.450
Lymphangioma, Cystic	C04.557.375.450.450
Lymphangiomyoma	C04.557.375.460
Lymphangioliomyomatosis	C04.557.375.460.465
Lymphangiosarcoma	C04.557.375.480
Lymphoma	C04.557.386
Composite Lymphoma	C04.557.386.150
Hodgkin Disease	C04.557.386.355
Immunoproliferative Small Intestinal Disease	C04.557.386.390
Lymphoma, Non-Hodgkin	C04.557.386.480
Burkitt Lymphoma	C04.557.386.480.100
Lymphoma, B-Cell	C04.557.386.480.150
Burkitt Lymphoma	C04.557.386.480.150.165
Lymphoma, AIDS-Related	C04.557.386.480.150.450
Lymphoma, B-Cell, Marginal Zone	C04.557.386.480.150.570
Lymphoma, Large B-Cell, Diffuse	C04.557.386.480.150.585
Lymphoma, Primary Effusion	C04.557.386.480.150.592
Lymphomatoid Granulomatosis	C04.557.386.480.150.600
Lymphoma, Follicular	C04.557.386.480.350
Lymphoma, Large-Cell, Anaplastic	C04.557.386.480.487
Lymphoma, Large-Cell, Immunoblastic	C04.557.386.480.493
Lymphoma, Mantle-Cell	C04.557.386.480.525
Lymphoma, T-Cell	C04.557.386.480.750
Enteropathy-Associated T-Cell Lymphoma	C04.557.386.480.750.099
Lymphoma, Extranodal NK-T-Cell	C04.557.386.480.750.199
Lymphoma, Large-Cell, Anaplastic	C04.557.386.480.750.399
Lymphoma, T-Cell, Cutaneous	C04.557.386.480.750.800
Lymphoma, Primary Cutaneous Anaplastic Large Cell	C04.557.386.480.750.800.507
Lymphomatoid Papulosis	C04.557.386.480.750.800.528
Mycosis Fungoides	C04.557.386.480.750.800.550
Pagetoid Reticulosis	C04.557.386.480.750.800.550.600
Sezary Syndrome	C04.557.386.480.750.800.775
Lymphoma, T-Cell, Peripheral	C04.557.386.480.750.825
Neoplasms, Complex and Mixed	C04.557.435
Adenolymphoma	C04.557.435.075
Adenoma, Pleomorphic	C04.557.435.090
Adenomyoepithelioma	C04.557.435.108
Adenomyoma	C04.557.435.110
Adenosarcoma	C04.557.435.135
Carcinoma, Adenosquamous	C04.557.435.250
Carcinosarcoma	C04.557.435.290
Carcinoma 256, Walker	C04.557.435.290.210
Composite Lymphoma	C04.557.435.295
Hepatoblastoma	C04.557.435.380
Mesenchymoma	C04.557.435.500
Mixed Tumor, Malignant	C04.557.435.525
Mixed Tumor, Mesodermal	C04.557.435.530
Mixed Tumor, Mullerian	C04.557.435.540
Myoepithelioma	C04.557.435.585
Wilms Tumor	C04.557.435.595
Denys-Drash Syndrome	C04.557.435.595.220
WAGR Syndrome	C04.557.435.595.950
Nephroma, Mesoblastic	C04.557.435.600
Pulmonary Blastoma	C04.557.435.675
Rhabdoid Tumor	C04.557.435.710
Sarcoma, Endometrial Stromal	C04.557.435.775
Thymoma	C04.557.435.850
Neoplasms, Connective and Soft Tissue	C04.557.450
Neoplasms, Adipose Tissue	C04.557.450.550
Angiolipoma	C04.557.450.550.100
Angiomyolipoma	C04.557.450.550.125
Lipoma	C04.557.450.550.400
Lipoblastoma	C04.557.450.550.400.500
Liposarcoma	C04.557.450.550.420



Liposarcoma, Myxoid	C04.557.450.550.420.425
Myelolipoma	C04.557.450.550.710
Neoplasms, Connective Tissue	C04.557.450.565
Chondroblastoma	C04.557.450.565.250
Chondroma	C04.557.450.565.265
Chondromatosis	C04.557.450.565.265.270
Chondrosarcoma	C04.557.450.565.280
Chondrosarcoma, Mesenchymal	C04.557.450.565.280.280
Endometrial Stromal Tumors	C04.557.450.565.325
Gastrointestinal Stromal Tumors	C04.557.450.565.370
Giant Cell Tumors	C04.557.450.565.380
Giant Cell Tumor of Bone	C04.557.450.565.380.380
Mastocytosis	C04.557.450.565.465
Mast-Cell Sarcoma	C04.557.450.565.465.124
Mastocytoma	C04.557.450.565.465.249
Mastocytoma, Skin	C04.557.450.565.465.249.500
Mastocytosis, Cutaneous	C04.557.450.565.465.500
Mastocytoma, Skin	C04.557.450.565.465.500.500
Urticaria Pigmentosa	C04.557.450.565.465.500.850
Mastocytosis, Systemic	C04.557.450.565.465.750
Leukemia, Mast-Cell	C04.557.450.565.465.750.500
Myofibroma	C04.557.450.565.540
Myxoma	C04.557.450.565.550
Carney Complex	C04.557.450.565.550.312
Neurothekeoma	C04.557.450.565.550.625
Myxosarcoma	C04.557.450.565.560
Neoplasms, Bone Tissue	C04.557.450.565.575
Fibroma, Ossifying	C04.557.450.565.575.400
Giant Cell Tumor of Bone	C04.557.450.565.575.420
Osteoblastoma	C04.557.450.565.575.600
Osteochondroma	C04.557.450.565.575.610
Osteochondromatosis	C04.557.450.565.575.610.615
Exostoses, Multiple Hereditary	C04.557.450.565.575.610.615.325
Osteoma	C04.557.450.565.575.625
Osteoma, Osteoid	C04.557.450.565.575.625.625
Osteosarcoma	C04.557.450.565.575.650
Osteosarcoma, Juxtacortical	C04.557.450.565.575.650.655
Sarcoma, Ewing	C04.557.450.565.575.650.800
Neoplasms, Fibrous Tissue	C04.557.450.565.590
Fibroma	C04.557.450.565.590.340
Fibroma, Desmoplastic	C04.557.450.565.590.340.345
Fibroma, Ossifying	C04.557.450.565.590.340.360
Fibromatosis, Abdominal	C04.557.450.565.590.340.400
Fibromatosis, Aggressive	C04.557.450.565.590.340.410
Fibrosarcoma	C04.557.450.565.590.350
Dermatofibrosarcoma	C04.557.450.565.590.350.320
Neurofibrosarcoma	C04.557.450.565.590.350.590
Histiocytoma	C04.557.450.565.590.425
Histiocytoma, Benign Fibrous	C04.557.450.565.590.425.350
Histiocytoma, Malignant Fibrous	C04.557.450.565.590.425.360
Myofibromatosis	C04.557.450.565.590.550
Neoplasms, Fibroepithelial	C04.557.450.565.590.595
Adenofibroma	C04.557.450.565.590.595.050
Cystadenofibroma	C04.557.450.565.590.595.050.500
Brenner Tumor	C04.557.450.565.590.595.150
Fibroadenoma	C04.557.450.565.590.595.350
Solitary Fibrous Tumors	C04.557.450.565.590.797
Solitary Fibrous Tumor, Pleural	C04.557.450.565.590.797.750
Sarcoma, Clear Cell	C04.557.450.565.800
Sarcoma, Small Cell	C04.557.450.565.825
Sarcoma, Synovial	C04.557.450.565.835
Neoplasms, Muscle Tissue	C04.557.450.590
Granular Cell Tumor	C04.557.450.590.350
Leiomyoma	C04.557.450.590.450
Angiomyoma	C04.557.450.590.450.125
Leiomyoma, Epithelioid	C04.557.450.590.450.455
Leiomyomatosis	C04.557.450.590.450.465
Leiomyosarcoma	C04.557.450.590.455
Myoma	C04.557.450.590.540
Rhabdomyoma	C04.557.450.590.540.700
Myosarcoma	C04.557.450.590.550
Rhabdomyosarcoma	C04.557.450.590.550.660
Rhabdomyosarcoma, Alveolar	C04.557.450.590.550.660.665
Rhabdomyosarcoma, Embryonal	C04.557.450.590.550.660.675
Sarcoma, Alveolar Soft Part	C04.557.450.590.775
Smooth Muscle Tumor	C04.557.450.590.800
Perivascular Epithelioid Cell Neoplasms	C04.557.450.692
Angiomyolipoma	C04.557.450.692.249
Lymphangioliomyomatosis	C04.557.450.692.500
Sarcoma	C04.557.450.795
Adenosarcoma	C04.557.450.795.135

Carcinosarcoma	C04.557.450.795.290
Carcinoma 256, Walker	C04.557.450.795.290.210
Chondrosarcoma	C04.557.450.795.300
Chondrosarcoma, Mesenchymal	C04.557.450.795.300.280
Desmoplastic Small Round Cell Tumor	C04.557.450.795.315
Endometrial Stromal Tumors	C04.557.450.795.332
Sarcoma, Endometrial Stromal	C04.557.450.795.332.500
Fibrosarcoma	C04.557.450.795.350
Dermatofibrosarcoma	C04.557.450.795.350.320
Neurofibrosarcoma	C04.557.450.795.350.590
Hemangiosarcoma	C04.557.450.795.390
Histiocytoma, Malignant Fibrous	C04.557.450.795.400
Leiomyosarcoma	C04.557.450.795.455
Liposarcoma	C04.557.450.795.465
Liposarcoma, Myxoid	C04.557.450.795.465.425
Lymphangiosarcoma	C04.557.450.795.480
Mixed Tumor, Mesodermal	C04.557.450.795.530
Myosarcoma	C04.557.450.795.550
Rhabdomyosarcoma	C04.557.450.795.550.660
Rhabdomyosarcoma, Alveolar	C04.557.450.795.550.660.665
Rhabdomyosarcoma, Embryonal	C04.557.450.795.550.660.675
Myxosarcoma	C04.557.450.795.560
Osteosarcoma	C04.557.450.795.620
Osteosarcoma, Juxtacortical	C04.557.450.795.620.655
Sarcoma, Ewing	C04.557.450.795.620.800
Phyllodes Tumor	C04.557.450.795.650
Sarcoma, Alveolar Soft Part	C04.557.450.795.775
Sarcoma, Clear Cell	C04.557.450.795.800
Sarcoma, Experimental	C04.557.450.795.830
Sarcoma 37	C04.557.450.795.830.760
Sarcoma 180	C04.557.450.795.830.780
Sarcoma, Avian	C04.557.450.795.830.800
Sarcoma, Yoshida	C04.557.450.795.830.850
Sarcoma, Kaposi	C04.557.450.795.850
Sarcoma, Myeloid	C04.557.450.795.853
Sarcoma, Small Cell	C04.557.450.795.870
Sarcoma, Synovial	C04.557.450.795.875
Neoplasms, Germ Cell and Embryonal	C04.557.465
Carcinoma, Embryonal	C04.557.465.200
Chordoma	C04.557.465.220
Germinoma	C04.557.465.330
Dysgerminoma	C04.557.465.330.300
Seminoma	C04.557.465.330.800
Gonadoblastoma	C04.557.465.420
Mesonephroma	C04.557.465.510
Endodermal Sinus Tumor	C04.557.465.510.350
Neuroectodermal Tumors	C04.557.465.625
Craniopharyngioma	C04.557.465.625.200
Neoplasms, Neuroepithelial	C04.557.465.625.600
Ganglioneuroma	C04.557.465.625.600.355
Glioma	C04.557.465.625.600.380
Astrocytoma	C04.557.465.625.600.380.080
Glioblastoma	C04.557.465.625.600.380.080.335
Optic Nerve Glioma	C04.557.465.625.600.380.080.667
Ependymoma	C04.557.465.625.600.380.290
Glioma, Subependymal	C04.557.465.625.600.380.290.390
Ganglioglioma	C04.557.465.625.600.380.350
Gliosarcoma	C04.557.465.625.600.380.400
Medulloblastoma	C04.557.465.625.600.380.515
Oligodendroglioma	C04.557.465.625.600.380.590
Optic Nerve Glioma	C04.557.465.625.600.380.795
Neurocytoma	C04.557.465.625.600.580
Neuroectodermal Tumors, Primitive	C04.557.465.625.600.590
Medulloblastoma	C04.557.465.625.600.590.500
Neuroectodermal Tumors, Primitive, Peripheral	C04.557.465.625.600.590.650
Neuroblastoma	C04.557.465.625.600.590.650.550
Esthesioneuroblastoma, Olfactory	C04.557.465.625.600.590.650.550.150
Ganglioneuroblastoma	C04.557.465.625.600.590.650.550.300
Pinealoma	C04.557.465.625.600.657
Retinoblastoma	C04.557.465.625.600.725
Neuroectodermal Tumor, Melanotic	C04.557.465.625.630
Neuroendocrine Tumors	C04.557.465.625.650
Adenoma, Acidophil	C04.557.465.625.650.025
Adenoma, Basophil	C04.557.465.625.650.075
Adenoma, Chromophobe	C04.557.465.625.650.095
Apudoma	C04.557.465.625.650.135
Carcinoid Tumor	C04.557.465.625.650.200
Malignant Carcinoid Syndrome	C04.557.465.625.650.200.500
Carcinoid Heart Disease	C04.557.465.625.650.200.500.205
Carcinoma, Neuroendocrine	C04.557.465.625.650.240
Carcinoma, Medullary	C04.557.465.625.650.240.315

Carcinoma, Merkel Cell	C04.557.465.625.650.240.325
Somatostatinoma	C04.557.465.625.650.240.695
Vipoma	C04.557.465.625.650.240.847
Melanoma	C04.557.465.625.650.510
Hutchinson's Melanotic Freckle	C04.557.465.625.650.510.385
Melanoma, Amelanotic	C04.557.465.625.650.510.515
Melanoma, Experimental	C04.557.465.625.650.510.525
Neurilemmoma	C04.557.465.625.650.595
Neuroma, Acoustic	C04.557.465.625.650.595.610
Neurofibromatosis 2	C04.557.465.625.650.595.610.500
Paraganglioma	C04.557.465.625.650.700
Paraganglioma, Extra-Adrenal	C04.557.465.625.650.700.705
Carotid Body Tumor	C04.557.465.625.650.700.705.220
Glomus Jugulare Tumor	C04.557.465.625.650.700.705.340
Glomus Tympanicum Tumor	C04.557.465.625.650.700.705.360
Pheochromocytoma	C04.557.465.625.650.700.725
Teratocarcinoma	C04.557.465.900
Teratoma	C04.557.465.910
Dermoid Cyst	C04.557.465.910.250
Struma Ovarii	C04.557.465.910.850
Trophoblastic Neoplasms	C04.557.465.955
Choriocarcinoma	C04.557.465.955.207
Choriocarcinoma, Non-gestational	C04.557.465.955.207.750
Trophoblastic Tumor, Placental Site	C04.557.465.955.207.875
Gestational Trophoblastic Disease	C04.557.465.955.416
Choriocarcinoma	C04.557.465.955.416.202
Trophoblastic Tumor, Placental Site	C04.557.465.955.416.202.875
Hydatidiform Mole	C04.557.465.955.416.812
Hydatidiform Mole, Invasive	C04.557.465.955.416.812.500
Neoplasms, Glandular and Epithelial	C04.557.470
Adenoma	C04.557.470.035
ACTH-Secreting Pituitary Adenoma	C04.557.470.035.012
Adenoma, Acidophil	C04.557.470.035.025
Adenoma, Basophil	C04.557.470.035.075
Adenoma, Bile Duct	C04.557.470.035.085
Adenoma, Chromophobe	C04.557.470.035.095
Adenoma, Islet Cell	C04.557.470.035.100
Insulinoma	C04.557.470.035.100.852
Adenoma, Liver Cell	C04.557.470.035.120
Adenoma, Oxyphilic	C04.557.470.035.140
Adenoma, Pleomorphic	C04.557.470.035.155
Adenoma, Sweat Gland	C04.557.470.035.175
Acrospiroma	C04.557.470.035.175.125
Poroma	C04.557.470.035.175.125.600
Hidrocystoma	C04.557.470.035.175.375
Syringoma	C04.557.470.035.175.800
Adenoma, Villous	C04.557.470.035.185
Adenomatoid Tumor	C04.557.470.035.200
Adenomatosis, Pulmonary	C04.557.470.035.210
Adenomatous Polyps	C04.557.470.035.215
Adenomatous Polyposis Coli	C04.557.470.035.215.100
Gardner Syndrome	C04.557.470.035.215.100.500
Adrenal Rest Tumor	C04.557.470.035.232
Apudoma	C04.557.470.035.250
Cystadenoma	C04.557.470.035.320
Cystadenoma, Mucinous	C04.557.470.035.320.225
Cystadenoma, Papillary	C04.557.470.035.320.230
Cystadenoma, Serous	C04.557.470.035.320.240
Growth Hormone-Secreting Pituitary Adenoma	C04.557.470.035.415
Mesothelioma	C04.557.470.035.510
Mesothelioma, Cystic	C04.557.470.035.510.515
Prolactinoma	C04.557.470.035.625
Carcinoma	C04.557.470.200
Adenocarcinoma	C04.557.470.200.025
Adenocarcinoma, Bronchiolo-Alveolar	C04.557.470.200.025.030
Adenocarcinoma, Clear Cell	C04.557.470.200.025.045
Adenocarcinoma, Follicular	C04.557.470.200.025.060
Carcinoma, Papillary, Follicular	C04.557.470.200.025.060.225
Adenocarcinoma, Mucinous	C04.557.470.200.025.075
Adenocarcinoma, Papillary	C04.557.470.200.025.085
Carcinoma, Papillary, Follicular	C04.557.470.200.025.085.225
Adenocarcinoma, Scirrhous	C04.557.470.200.025.095
Linitis Plastica	C04.557.470.200.025.095.410
Adenocarcinoma, Sebaceous	C04.557.470.200.025.105
Adrenocortical Carcinoma	C04.557.470.200.025.152
Carcinoid Tumor	C04.557.470.200.025.200
Malignant Carcinoid Syndrome	C04.557.470.200.025.200.500
Carcinoid Heart Disease	C04.557.470.200.025.200.500.205
Carcinoma, Acinar Cell	C04.557.470.200.025.215
Carcinoma, Adenoid Cystic	C04.557.470.200.025.220
Carcinoma, Ductal	C04.557.470.200.025.232

Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500
Carcinoma, Pancreatic Ductal	C04.557.470.200.025.232.750
Carcinoma, Endometrioid	C04.557.470.200.025.240
Carcinoma, Hepatocellular	C04.557.470.200.025.255
Carcinoma, Intraductal, Noninfiltrating	C04.557.470.200.025.275
Paget's Disease, Mammary	C04.557.470.200.025.275.625
Carcinoma, Islet Cell	C04.557.470.200.025.290
Gastrinoma	C04.557.470.200.025.290.500
Glucagonoma	C04.557.470.200.025.290.750
Carcinoma, Lobular	C04.557.470.200.025.305
Carcinoma, Mucoepidermoid	C04.557.470.200.025.340
Carcinoma, Neuroendocrine	C04.557.470.200.025.370
Carcinoma, Medullary	C04.557.470.200.025.370.315
Carcinoma, Merkel Cell	C04.557.470.200.025.370.325
Somatostatinoma	C04.557.470.200.025.370.695
Vipoma	C04.557.470.200.025.370.847
Carcinoma, Renal Cell	C04.557.470.200.025.390
Carcinoma, Signet Ring Cell	C04.557.470.200.025.415
Krukenberg Tumor	C04.557.470.200.025.415.410
Carcinoma, Skin Appendage	C04.557.470.200.025.420
Cholangiocarcinoma	C04.557.470.200.025.450
Choriocarcinoma	C04.557.470.200.025.455
Choriocarcinoma, Non-gestational	C04.557.470.200.025.455.750
Trophoblastic Tumor, Placental Site	C04.557.470.200.025.455.875
Cystadenocarcinoma	C04.557.470.200.025.480
Cystadenocarcinoma, Mucinous	C04.557.470.200.025.480.225
Cystadenocarcinoma, Papillary	C04.557.470.200.025.480.230
Cystadenocarcinoma, Serous	C04.557.470.200.025.480.240
Eccrine Porocarcinoma	C04.557.470.200.025.500
Klatskin's Tumor	C04.557.470.200.025.540
Paget Disease, Extramammary	C04.557.470.200.025.660
Pulmonary Adenomatosis, Ovine	C04.557.470.200.025.715
Carcinoma, Adenosquamous	C04.557.470.200.150
Carcinoma, Basal Cell	C04.557.470.200.165
Basal Cell Nevus Syndrome	C04.557.470.200.165.150
Carcinoma, Basosquamous	C04.557.470.200.170
Carcinoma, Ehrlich Tumor	C04.557.470.200.200
Carcinoma, Giant Cell	C04.557.470.200.220
Carcinoma in Situ	C04.557.470.200.240
Cervical Intraepithelial Neoplasia	C04.557.470.200.240.250
Prostatic Intraepithelial Neoplasia	C04.557.470.200.240.500
Carcinoma, Krebs 2	C04.557.470.200.255
Carcinoma, Large Cell	C04.557.470.200.260
Carcinoma, Lewis Lung	C04.557.470.200.280
Carcinoma, Papillary	C04.557.470.200.360
Carcinoma, Small Cell	C04.557.470.200.380
Carcinoma, Squamous Cell	C04.557.470.200.400
Bowen's Disease	C04.557.470.200.400.130
Carcinoma, Transitional Cell	C04.557.470.200.430
Carcinoma, Verrucous	C04.557.470.200.450
Buschke-Lowenstein Tumor	C04.557.470.200.450.500
Neoplasms, Adnexal and Skin Appendage	C04.557.470.550
Adenocarcinoma, Sebaceous	C04.557.470.550.105
Adenoma, Sweat Gland	C04.557.470.550.175
Acrospiroma	C04.557.470.550.175.125
Poroma	C04.557.470.550.175.125.600
Hidrocystoma	C04.557.470.550.175.375
Syringoma	C04.557.470.550.175.800
Carcinoma, Skin Appendage	C04.557.470.550.420
Neoplasms, Basal Cell	C04.557.470.565
Carcinoma, Basal Cell	C04.557.470.565.165
Basal Cell Nevus Syndrome	C04.557.470.565.165.150
Carcinoma, Basosquamous	C04.557.470.565.170
Pilomatrixoma	C04.557.470.565.625
Neoplasms, Cystic, Mucinous, and Serous	C04.557.470.590
Adenocarcinoma, Mucinous	C04.557.470.590.075
Carcinoma, Mucoepidermoid	C04.557.470.590.340
Carcinoma, Signet Ring Cell	C04.557.470.590.415
Krukenberg Tumor	C04.557.470.590.415.410
Cystadenocarcinoma	C04.557.470.590.480
Cystadenocarcinoma, Mucinous	C04.557.470.590.480.225
Cystadenocarcinoma, Papillary	C04.557.470.590.480.230
Cystadenocarcinoma, Serous	C04.557.470.590.480.240
Cystadenofibroma	C04.557.470.590.482
Cystadenoma	C04.557.470.590.485
Cystadenoma, Mucinous	C04.557.470.590.485.225
Cystadenoma, Papillary	C04.557.470.590.485.230
Cystadenoma, Serous	C04.557.470.590.485.240
Mucoepidermoid Tumor	C04.557.470.590.580
Pseudomyxoma Peritonei	C04.557.470.590.782
Neoplasms, Ductal, Lobular, and Medullary	C04.557.470.615

Carcinoma, Ductal	C04.557.470.615.132
Carcinoma, Ductal, Breast	C04.557.470.615.132.500
Carcinoma, Pancreatic Ductal	C04.557.470.615.132.750
Carcinoma, Intraductal, Noninfiltrating	C04.557.470.615.275
Paget's Disease, Mammary	C04.557.470.615.275.625
Carcinoma, Lobular	C04.557.470.615.305
Carcinoma, Medullary	C04.557.470.615.315
Paget Disease, Extramammary	C04.557.470.615.660
Papilloma, Intraductal	C04.557.470.615.670
Neoplasms, Fibroepithelial	C04.557.470.625
Adenofibroma	C04.557.470.625.050
Cystadenofibroma	C04.557.470.625.050.500
Brenner Tumor	C04.557.470.625.150
Fibroadenoma	C04.557.470.625.350
Neoplasms, Mesothelial	C04.557.470.660
Adenomatoid Tumor	C04.557.470.660.200
Mesothelioma	C04.557.470.660.510
Mesothelioma, Cystic	C04.557.470.660.510.515
Neoplasms, Neuroepithelial	C04.557.470.670
Ganglioneuroma	C04.557.470.670.355
Glioma	C04.557.470.670.380
Astrocytoma	C04.557.470.670.380.080
Glioblastoma	C04.557.470.670.380.080.335
Optic Nerve Glioma	C04.557.470.670.380.080.667
Ependymoma	C04.557.470.670.380.290
Glioma, Subependymal	C04.557.470.670.380.290.390
Ganglioglioma	C04.557.470.670.380.350
Gliosarcoma	C04.557.470.670.380.400
Medulloblastoma	C04.557.470.670.380.515
Oligodendroglioma	C04.557.470.670.380.590
Optic Nerve Glioma	C04.557.470.670.380.795
Neurocytoma	C04.557.470.670.580
Neuroectodermal Tumors, Primitive	C04.557.470.670.590
Medulloblastoma	C04.557.470.670.590.500
Neuroectodermal Tumors, Primitive, Peripheral	C04.557.470.670.590.650
Neuroblastoma	C04.557.470.670.590.650.550
Esthesioneuroblastoma, Olfactory	C04.557.470.670.590.650.550.150
Ganglioneuroblastoma	C04.557.470.670.590.650.550.300
Pinealoma	C04.557.470.670.657
Retinoblastoma	C04.557.470.670.725
Neoplasms, Squamous Cell	C04.557.470.700
Acanthoma	C04.557.470.700.040
Carcinoma, Papillary	C04.557.470.700.360
Carcinoma, Squamous Cell	C04.557.470.700.400
Bowen's Disease	C04.557.470.700.400.130
Carcinoma, Verrucous	C04.557.470.700.450
Buschke-Lowenstein Tumor	C04.557.470.700.450.500
Papilloma	C04.557.470.700.600
Papilloma, Inverted	C04.557.470.700.600.610
Neoplasms, Gonadal Tissue	C04.557.475
Gonadoblastoma	C04.557.475.395
Sex Cord-Gonadal Stromal Tumors	C04.557.475.750
Granulosa Cell Tumor	C04.557.475.750.656
Luteoma	C04.557.475.750.751
Sertoli-Leydig Cell Tumor	C04.557.475.750.847
Leydig Cell Tumor	C04.557.475.750.847.249
Sertoli Cell Tumor	C04.557.475.750.847.500
Thecoma	C04.557.475.750.875
Neoplasms, Nerve Tissue	C04.557.580
Meningioma	C04.557.580.520
Nerve Sheath Neoplasms	C04.557.580.600
Neurilemmoma	C04.557.580.600.290
Neurofibroma	C04.557.580.600.580
Neurofibroma, Plexiform	C04.557.580.600.580.585
Neurofibromatoses	C04.557.580.600.580.590
Neurofibromatosis 1	C04.557.580.600.580.590.650
Neurofibromatosis 2	C04.557.580.600.580.590.655
Neurofibrosarcoma	C04.557.580.600.580.795
Neurofibrosarcoma	C04.557.580.600.590
Neuroma	C04.557.580.600.610
Neurilemmoma	C04.557.580.600.610.595
Neuroma, Acoustic	C04.557.580.600.610.595.610
Neurofibromatosis 2	C04.557.580.600.610.595.610.500
Neurothekeoma	C04.557.580.600.625
Neuroectodermal Tumors	C04.557.580.625
Craniopharyngioma	C04.557.580.625.200
Neoplasms, Neuroepithelial	C04.557.580.625.600
Ganglioneuroma	C04.557.580.625.600.355
Glioma	C04.557.580.625.600.380
Astrocytoma	C04.557.580.625.600.380.080
Glioblastoma	C04.557.580.625.600.380.080.335

Optic Nerve Glioma	C04.557.580.625.600.380.080.667
Ependymoma	C04.557.580.625.600.380.290
Glioma, Subependymal	C04.557.580.625.600.380.290.390
Ganglioglioma	C04.557.580.625.600.380.350
Gliosarcoma	C04.557.580.625.600.380.400
Medulloblastoma	C04.557.580.625.600.380.515
Oligodendroglioma	C04.557.580.625.600.380.590
Optic Nerve Glioma	C04.557.580.625.600.380.795
Neurocytoma	C04.557.580.625.600.580
Neuroectodermal Tumors, Primitive	C04.557.580.625.600.590
Medulloblastoma	C04.557.580.625.600.590.500
Neuroectodermal Tumors, Primitive, Peripheral	C04.557.580.625.600.590.650
Neuroblastoma	C04.557.580.625.600.590.650.550
Esthesioneuroblastoma, Olfactory	C04.557.580.625.600.590.650.550.150
Ganglioneuroblastoma	C04.557.580.625.600.590.650.550.300
Pinealoma	C04.557.580.625.600.657
Retinoblastoma	C04.557.580.625.600.725
Neuroectodermal Tumor, Melanotic	C04.557.580.625.630
Neuroendocrine Tumors	C04.557.580.625.650
Adenoma, Acidophil	C04.557.580.625.650.025
Adenoma, Basophil	C04.557.580.625.650.075
Adenoma, Chromophobe	C04.557.580.625.650.095
Apudoma	C04.557.580.625.650.135
Carcinoid Tumor	C04.557.580.625.650.200
Malignant Carcinoid Syndrome	C04.557.580.625.650.200.500
Carcinoid Heart Disease	C04.557.580.625.650.200.500.205
Carcinoma, Neuroendocrine	C04.557.580.625.650.240
Carcinoma, Medullary	C04.557.580.625.650.240.315
Carcinoma, Merkel Cell	C04.557.580.625.650.240.325
Melanoma	C04.557.580.625.650.510
Hutchinson's Melanotic Freckle	C04.557.580.625.650.510.385
Melanoma, Amelanotic	C04.557.580.625.650.510.515
Melanoma, Experimental	C04.557.580.625.650.510.525
Neurilemmoma	C04.557.580.625.650.595
Neuroma, Acoustic	C04.557.580.625.650.595.610
Paraganglioma	C04.557.580.625.650.700
Paraganglioma, Extra-Adrenal	C04.557.580.625.650.700.705
Carotid Body Tumor	C04.557.580.625.650.700.705.220
Glomus Jugulare Tumor	C04.557.580.625.650.700.705.340
Glomus Tympanicum Tumor	C04.557.580.625.650.700.705.360
Pheochromocytoma	C04.557.580.625.650.700.725
Neoplasms, Plasma Cell	C04.557.595
Multiple Myeloma	C04.557.595.500
Leukemia, Plasma Cell	C04.557.595.500.500
Plasmacytoma	C04.557.595.600
Waldenstrom Macroglobulinemia	C04.557.595.925
Neoplasms, Vascular Tissue	C04.557.645
Angiofibroma	C04.557.645.100
Angiokeratoma	C04.557.645.115
Glomus Tumor	C04.557.645.350
Hemangioma	C04.557.645.375
Central Nervous System Venous Angioma	C04.557.645.375.185
Hemangioendothelioma	C04.557.645.375.370
Hemangioendothelioma, Epithelioid	C04.557.645.375.370.380
Hemangioma, Capillary	C04.557.645.375.380
Hemangioblastoma	C04.557.645.375.380.370
Hemangioma, Cavernous	C04.557.645.375.385
Hemangioma, Cavernous, Central Nervous System	C04.557.645.375.385.500
Kasabach-Merritt Syndrome	C04.557.645.375.617
Sturge-Weber Syndrome	C04.557.645.375.850
Hemangiopericytoma	C04.557.645.380
Hemangiosarcoma	C04.557.645.390
Meningioma	C04.557.645.520
Sarcoma, Kaposi	C04.557.645.750
Nevi and Melanomas	C04.557.665
Melanoma	C04.557.665.510
Hutchinson's Melanotic Freckle	C04.557.665.510.385
Melanoma, Amelanotic	C04.557.665.510.515
Melanoma, Experimental	C04.557.665.510.525
Nevus	C04.557.665.560
Dysplastic Nevus Syndrome	C04.557.665.560.260
Nevus, Halo	C04.557.665.560.580
Nevus, Intra-dermal	C04.557.665.560.590
Nevus, Pigmented	C04.557.665.560.615
Mongolian Spot	C04.557.665.560.615.530
Nevus, Blue	C04.557.665.560.615.550
Nevus of Ota	C04.557.665.560.615.585
Nevus, Spindle Cell	C04.557.665.560.615.625
Nevus, Epithelioid and Spindle Cell	C04.557.665.560.615.625.585
Nevus, Sebaceous of Jadassohn	C04.557.665.560.700
Odontogenic Tumors	C04.557.695

Ameloblastoma	C04.557.695.065
Cementoma	C04.557.695.210
Odontogenic Cyst, Calcifying	C04.557.695.605
Odontogenic Tumor, Squamous	C04.557.695.607
Odontoma	C04.557.695.610
<b>Neoplasms by Site</b>	<b>C04.588</b>
Abdominal Neoplasms	C04.588.033
Peritoneal Neoplasms	C04.588.033.513
Retroperitoneal Neoplasms	C04.588.033.731
Sister Mary Joseph's Nodule	C04.588.033.740
Anal Gland Neoplasms	C04.588.083
Bone Neoplasms	C04.588.149
Adamantinoma	C04.588.149.030
Femoral Neoplasms	C04.588.149.276
Skull Neoplasms	C04.588.149.721
Jaw Neoplasms	C04.588.149.721.450
Mandibular Neoplasms	C04.588.149.721.450.583
Maxillary Neoplasms	C04.588.149.721.450.601
Palatal Neoplasms	C04.588.149.721.450.692
Nose Neoplasms	C04.588.149.721.600
Orbital Neoplasms	C04.588.149.721.656
Skull Base Neoplasms	C04.588.149.721.828
Spinal Neoplasms	C04.588.149.828
Breast Neoplasms	C04.588.180
Breast Neoplasms, Male	C04.588.180.260
Carcinoma, Ductal, Breast	C04.588.180.390
Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483
Inflammatory Breast Neoplasms	C04.588.180.576
Digestive System Neoplasms	C04.588.274
Biliary Tract Neoplasms	C04.588.274.120
Bile Duct Neoplasms	C04.588.274.120.250
Common Bile Duct Neoplasms	C04.588.274.120.250.250
Gallbladder Neoplasms	C04.588.274.120.401
Gastrointestinal Neoplasms	C04.588.274.476
Esophageal Neoplasms	C04.588.274.476.205
Intestinal Neoplasms	C04.588.274.476.411
Cecal Neoplasms	C04.588.274.476.411.184
Appendiceal Neoplasms	C04.588.274.476.411.184.290
Colorectal Neoplasms	C04.588.274.476.411.307
Adenomatous Polyposis Coli	C04.588.274.476.411.307.089
Gardner Syndrome	C04.588.274.476.411.307.089.393
Colonic Neoplasms	C04.588.274.476.411.307.180
Adenomatous Polyposis Coli	C04.588.274.476.411.307.180.089
Gardner Syndrome	C04.588.274.476.411.307.180.089.500
Sigmoid Neoplasms	C04.588.274.476.411.307.180.800
Colorectal Neoplasms, Hereditary Nonpolyposis	C04.588.274.476.411.307.190
Rectal Neoplasms	C04.588.274.476.411.307.790
Anus Neoplasms	C04.588.274.476.411.307.790.040
Anal Gland Neoplasms	C04.588.274.476.411.307.790.040.040
Duodenal Neoplasms	C04.588.274.476.411.445
Ileal Neoplasms	C04.588.274.476.411.501
Jejunal Neoplasms	C04.588.274.476.411.523
Stomach Neoplasms	C04.588.274.476.767
Liver Neoplasms	C04.588.274.623
Adenoma, Liver Cell	C04.588.274.623.040
Carcinoma, Hepatocellular	C04.588.274.623.160
Liver Neoplasms, Experimental	C04.588.274.623.460
Pancreatic Neoplasms	C04.588.274.761
Adenoma, Islet Cell	C04.588.274.761.249
Insulinoma	C04.588.274.761.249.500
Carcinoma, Islet Cell	C04.588.274.761.500
Gastrinoma	C04.588.274.761.500.124
Glucagonoma	C04.588.274.761.500.249
Somatostatinoma	C04.588.274.761.500.500
Vipoma	C04.588.274.761.500.750
Carcinoma, Pancreatic Ductal	C04.588.274.761.750
Peritoneal Neoplasms	C04.588.274.780
Endocrine Gland Neoplasms	C04.588.322
Adrenal Gland Neoplasms	C04.588.322.078
Adrenal Cortex Neoplasms	C04.588.322.078.265
Adrenocortical Adenoma	C04.588.322.078.265.500
Adrenocortical Carcinoma	C04.588.322.078.265.750
Multiple Endocrine Neoplasia	C04.588.322.400
Multiple Endocrine Neoplasia Type 1	C04.588.322.400.500
Multiple Endocrine Neoplasia Type 2a	C04.588.322.400.505
Multiple Endocrine Neoplasia Type 2b	C04.588.322.400.510
Ovarian Neoplasms	C04.588.322.455
Granulosa Cell Tumor	C04.588.322.455.398
Hereditary Breast and Ovarian Cancer Syndrome	C04.588.322.455.431
Luteoma	C04.588.322.455.464
Meigs Syndrome	C04.588.322.455.531

Sertoli-Leydig Cell Tumor	C04.588.322.455.648
Thecoma	C04.588.322.455.765
Pancreatic Neoplasms	C04.588.322.475
Adenoma, Islet Cell	C04.588.322.475.249
Insulinoma	C04.588.322.475.249.500
Carcinoma, Islet Cell	C04.588.322.475.500
Gastrinoma	C04.588.322.475.500.124
Glucagonoma	C04.588.322.475.500.249
Somatostatinoma	C04.588.322.475.500.500
Vipoma	C04.588.322.475.500.750
Carcinoma, Pancreatic Ductal	C04.588.322.475.750
Paraneoplastic Endocrine Syndromes	C04.588.322.490
Parathyroid Neoplasms	C04.588.322.525
Pituitary Neoplasms	C04.588.322.609
ACTH-Secreting Pituitary Adenoma	C04.588.322.609.145
Nelson Syndrome	C04.588.322.609.145.500
Growth Hormone-Secreting Pituitary Adenoma	C04.588.322.609.292
Prolactinoma	C04.588.322.609.792
Testicular Neoplasms	C04.588.322.762
Sertoli-Leydig Cell Tumor	C04.588.322.762.500
Leydig Cell Tumor	C04.588.322.762.500.249
Sertoli Cell Tumor	C04.588.322.762.500.500
Thyroid Neoplasms	C04.588.322.894
Thyroid Nodule	C04.588.322.894.800
Eye Neoplasms	C04.588.364
Conjunctival Neoplasms	C04.588.364.235
Orbital Neoplasms	C04.588.364.659
Paraneoplastic Syndromes, Ocular	C04.588.364.738
Retinal Neoplasms	C04.588.364.818
Retinoblastoma	C04.588.364.818.760
Uveal Neoplasms	C04.588.364.978
Choroid Neoplasms	C04.588.364.978.223
Iris Neoplasms	C04.588.364.978.400
Head and Neck Neoplasms	C04.588.443
Esophageal Neoplasms	C04.588.443.353
Facial Neoplasms	C04.588.443.392
Eyelid Neoplasms	C04.588.443.392.500
Mouth Neoplasms	C04.588.443.591
Gingival Neoplasms	C04.588.443.591.402
Leukoplakia, Oral	C04.588.443.591.545
Leukoplakia, Hairy	C04.588.443.591.545.500
Lip Neoplasms	C04.588.443.591.550
Palatal Neoplasms	C04.588.443.591.692
Salivary Gland Neoplasms	C04.588.443.591.824
Parotid Neoplasms	C04.588.443.591.824.695
Sublingual Gland Neoplasms	C04.588.443.591.824.882
Submandibular Gland Neoplasms	C04.588.443.591.824.885
Tongue Neoplasms	C04.588.443.591.925
Otorhinolaryngologic Neoplasms	C04.588.443.665
Ear Neoplasms	C04.588.443.665.312
Laryngeal Neoplasms	C04.588.443.665.481
Nose Neoplasms	C04.588.443.665.650
Paranasal Sinus Neoplasms	C04.588.443.665.650.693
Maxillary Sinus Neoplasms	C04.588.443.665.650.693.575
Pharyngeal Neoplasms	C04.588.443.665.710
Hypopharyngeal Neoplasms	C04.588.443.665.710.485
Nasopharyngeal Neoplasms	C04.588.443.665.710.650
Oropharyngeal Neoplasms	C04.588.443.665.710.684
Tonsillar Neoplasms	C04.588.443.665.710.684.800
Parathyroid Neoplasms	C04.588.443.680
Thyroid Neoplasms	C04.588.443.915
Thyroid Nodule	C04.588.443.915.800
Tracheal Neoplasms	C04.588.443.925
Hematologic Neoplasms	C04.588.448
Bone Marrow Neoplasms	C04.588.448.200
Mammary Neoplasms, Animal	C04.588.531
Mammary Neoplasms, Experimental	C04.588.531.500
Nervous System Neoplasms	C04.588.614
Central Nervous System Neoplasms	C04.588.614.250
Brain Neoplasms	C04.588.614.250.195
Cerebral Ventricle Neoplasms	C04.588.614.250.195.205
Choroid Plexus Neoplasms	C04.588.614.250.195.205.200
Papilloma, Choroid Plexus	C04.588.614.250.195.205.200.500
Infratentorial Neoplasms	C04.588.614.250.195.411
Brain Stem Neoplasms	C04.588.614.250.195.411.100
Cerebellar Neoplasms	C04.588.614.250.195.411.211
Neurocytoma	C04.588.614.250.195.648
Pinealoma	C04.588.614.250.195.766
Supratentorial Neoplasms	C04.588.614.250.195.885
Hypothalamic Neoplasms	C04.588.614.250.195.885.500
Pallister-Hall Syndrome	C04.588.614.250.195.885.500.299



Pituitary Neoplasms	C04.588.614.250.195.885.500.600
Central Nervous System Cysts	C04.588.614.250.387
Arachnoid Cysts	C04.588.614.250.387.100
Colloid Cysts	C04.588.614.250.387.200
Meningeal Neoplasms	C04.588.614.250.580
Meningeal Carcinomatosis	C04.588.614.250.580.150
Meningioma	C04.588.614.250.580.500
Spinal Cord Neoplasms	C04.588.614.250.803
Epidural Neoplasms	C04.588.614.250.803.342
Cranial Nerve Neoplasms	C04.588.614.300
Optic Nerve Neoplasms	C04.588.614.300.600
Optic Nerve Glioma	C04.588.614.300.600.600
Paraneoplastic Syndromes, Nervous System	C04.588.614.550
Anti-N-Methyl-D-Aspartate Receptor Encephalitis	C04.588.614.550.112
Lambert-Eaton Myasthenic Syndrome	C04.588.614.550.225
Limbic Encephalitis	C04.588.614.550.450
Myelitis, Transverse	C04.588.614.550.550
Opsoclonus-Myoclonus Syndrome	C04.588.614.550.600
Paraneoplastic Cerebellar Degeneration	C04.588.614.550.650
Paraneoplastic Polyneuropathy	C04.588.614.550.700
Peripheral Nervous System Neoplasms	C04.588.614.596
Cranial Nerve Neoplasms	C04.588.614.596.240
Neuroma, Acoustic	C04.588.614.596.240.015
Optic Nerve Neoplasms	C04.588.614.596.240.240
Optic Nerve Glioma	C04.588.614.596.240.240.500
Pelvic Neoplasms	C04.588.699
Skin Neoplasms	C04.588.805
Acanthoma	C04.588.805.040
Sebaceous Gland Neoplasms	C04.588.805.578
Muir-Torre Syndrome	C04.588.805.578.500
Sweat Gland Neoplasms	C04.588.805.776
Soft Tissue Neoplasms	C04.588.839
Muscle Neoplasms	C04.588.839.500
Vascular Neoplasms	C04.588.839.750
Splenic Neoplasms	C04.588.842
Thoracic Neoplasms	C04.588.894
Heart Neoplasms	C04.588.894.309
Carney Complex	C04.588.894.309.500
Mediastinal Neoplasms	C04.588.894.479
Respiratory Tract Neoplasms	C04.588.894.797
Lung Neoplasms	C04.588.894.797.520
Bronchial Neoplasms	C04.588.894.797.520.109
Carcinoma, Bronchogenic	C04.588.894.797.520.109.220
Carcinoma, Non-Small-Cell Lung	C04.588.894.797.520.109.220.249
Small Cell Lung Carcinoma	C04.588.894.797.520.109.220.624
Multiple Pulmonary Nodules	C04.588.894.797.520.237
Pancoast Syndrome	C04.588.894.797.520.734
Pulmonary Blastoma	C04.588.894.797.520.867
Pulmonary Sclerosing Hemangioma	C04.588.894.797.520.933
Solitary Pulmonary Nodule	C04.588.894.797.520.966
Pleural Neoplasms	C04.588.894.797.640
Pleural Effusion, Malignant	C04.588.894.797.640.700
Solitary Fibrous Tumor, Pleural	C04.588.894.797.640.800
Tracheal Neoplasms	C04.588.894.797.760
Thymus Neoplasms	C04.588.894.949
Thymoma	C04.588.894.949.500
Urogenital Neoplasms	C04.588.945
Genital Neoplasms, Female	C04.588.945.418
Fallopian Tube Neoplasms	C04.588.945.418.365
Uterine Neoplasms	C04.588.945.418.948
Endometrial Neoplasms	C04.588.945.418.948.585
Carcinoma, Endometrioid	C04.588.945.418.948.585.124
Uterine Cervical Neoplasms	C04.588.945.418.948.850
Vaginal Neoplasms	C04.588.945.418.955
Vulvar Neoplasms	C04.588.945.418.968
Genital Neoplasms, Male	C04.588.945.440
Penile Neoplasms	C04.588.945.440.715
Prostatic Neoplasms	C04.588.945.440.770
Testicular Neoplasms	C04.588.945.440.915
Sertoli-Leydig Cell Tumor	C04.588.945.440.915.500
Leydig Cell Tumor	C04.588.945.440.915.500.249
Sertoli Cell Tumor	C04.588.945.440.915.500.500
Urologic Neoplasms	C04.588.945.947
Kidney Neoplasms	C04.588.945.947.535
Carcinoma, Renal Cell	C04.588.945.947.535.160
Wilms Tumor	C04.588.945.947.535.585
Denys-Drash Syndrome	C04.588.945.947.535.585.220
WAGR Syndrome	C04.588.945.947.535.585.950
Nephroma, Mesoblastic	C04.588.945.947.535.790
Ureteral Neoplasms	C04.588.945.947.940
Urethral Neoplasms	C04.588.945.947.945

Urinary Bladder Neoplasms	C04.588.945.947.960
Venereal Tumors, Veterinary	C04.588.945.956
<b>Neoplasms, Experimental</b>	<b>C04.619</b>
Carcinoma 256, Walker	C04.619.045
Carcinoma, Brown-Pearce	C04.619.124
Carcinoma, Ehrlich Tumor	C04.619.169
Carcinoma, Krebs 2	C04.619.214
Carcinoma, Lewis Lung	C04.619.230
Leukemia, Experimental	C04.619.531
Avian Leukosis	C04.619.531.216
Leukemia L1210	C04.619.531.594
Leukemia L5178	C04.619.531.602
Leukemia P388	C04.619.531.782
Liver Neoplasms, Experimental	C04.619.540
Mammary Neoplasms, Experimental	C04.619.590
Melanoma, Experimental	C04.619.600
Sarcoma, Experimental	C04.619.857
Sarcoma 37	C04.619.857.573
Sarcoma 180	C04.619.857.656
Sarcoma, Avian	C04.619.857.800
Sarcoma, Yoshida	C04.619.857.822
Tumor Virus Infections	C04.619.935
Avian Leukosis	C04.619.935.120
Epstein-Barr Virus Infections	C04.619.935.313
Burkitt Lymphoma	C04.619.935.313.165
Marek Disease	C04.619.935.489
Sarcoma, Avian	C04.619.935.800
<b>Neoplasms, Hormone-Dependent</b>	<b>C04.626</b>
<b>Neoplasms, Multiple Primary</b>	<b>C04.651</b>
Hamartoma Syndrome, Multiple	C04.651.435
Proteus Syndrome	C04.651.435.500
Multiple Endocrine Neoplasia	C04.651.600
Multiple Endocrine Neoplasia Type 1	C04.651.600.500
Multiple Endocrine Neoplasia Type 2a	C04.651.600.505
Multiple Endocrine Neoplasia Type 2b	C04.651.600.510
Tuberous Sclerosis	C04.651.800
<b>Neoplasms, Post-Traumatic</b>	<b>C04.666</b>
<b>Neoplasms, Radiation-Induced</b>	<b>C04.682</b>
Leukemia, Radiation-Induced	C04.682.512
<b>Neoplasms, Second Primary</b>	<b>C04.692</b>
<b>Neoplastic Processes</b>	<b>C04.697</b>
Anaplasia	C04.697.045
Cell Transformation, Neoplastic	C04.697.152
Blast Crisis	C04.697.152.110
Cell Transformation, Viral	C04.697.152.160
Cocarcinogenesis	C04.697.160
Neoplasm Invasiveness	C04.697.645
Leukemic Infiltration	C04.697.645.500
Neoplasm Metastasis	C04.697.650
Lymphatic Metastasis	C04.697.650.560
Neoplasm Micrometastasis	C04.697.650.695
Neoplasm Seeding	C04.697.650.830
Neoplasms, Unknown Primary	C04.697.650.895
Neoplastic Cells, Circulating	C04.697.650.900
Neoplasm Recurrence, Local	C04.697.655
Neoplasm Regression, Spontaneous	C04.697.670
Neoplasm, Residual	C04.697.700
<b>Neoplastic Syndromes, Hereditary</b>	<b>C04.700</b>
Adenomatous Polyposis Coli	C04.700.100
Gardner Syndrome	C04.700.100.392
Basal Cell Nevus Syndrome	C04.700.175
Birt-Hogg-Dube Syndrome	C04.700.212
Colorectal Neoplasms, Hereditary Nonpolyposis	C04.700.250
Lynch Syndrome II	C04.700.250.500
Muir-Torre Syndrome	C04.700.250.500.500
Dysplastic Nevus Syndrome	C04.700.305
Exostoses, Multiple Hereditary	C04.700.330
Hamartoma Syndrome, Multiple	C04.700.435
Hereditary Breast and Ovarian Cancer Syndrome	C04.700.517
Li-Fraumeni Syndrome	C04.700.600
Multiple Endocrine Neoplasia	C04.700.630
Multiple Endocrine Neoplasia Type 1	C04.700.630.500
Multiple Endocrine Neoplasia Type 2a	C04.700.630.505
Multiple Endocrine Neoplasia Type 2b	C04.700.630.510
Tuberous Sclerosis	C04.700.632
Wilms Tumor	C04.700.635
Denys-Drash Syndrome	C04.700.635.220
WAGR Syndrome	C04.700.635.950
Neurofibromatoses	C04.700.645
Neurofibromatosis 1	C04.700.645.650
Neurofibromatosis 2	C04.700.645.655

Peutz-Jeghers Syndrome	C04.700.705
<b>Paraneoplastic Syndromes</b>	<b>C04.730</b>
Paraneoplastic Endocrine Syndromes	C04.730.713
ACTH Syndrome, Ectopic	C04.730.713.317
Zollinger-Ellison Syndrome	C04.730.713.988
Paraneoplastic Syndromes, Nervous System	C04.730.856
Anti-N-Methyl-D-Aspartate Receptor Encephalitis	C04.730.856.112
Lambert-Eaton Myasthenic Syndrome	C04.730.856.225
Limbic Encephalitis	C04.730.856.437
Myelitis, Transverse	C04.730.856.543
Opsoclonus-Myoclonus Syndrome	C04.730.856.596
Paraneoplastic Cerebellar Degeneration	C04.730.856.650
Paraneoplastic Polyneuropathy	C04.730.856.700
Paraneoplastic Syndromes, Ocular	C04.730.900
<b>Precancerous Conditions</b>	<b>C04.834</b>
Aberrant Crypt Foci	C04.834.020
Erythroplasia	C04.834.288
Keratoses, Actinic	C04.834.450
Leukoplakia	C04.834.512
Leukoplakia, Oral	C04.834.512.513
Leukoplakia, Hairy	C04.834.512.513.500
Lymphomatoid Granulomatosis	C04.834.567
Preleukemia	C04.834.770
Uterine Cervical Dysplasia	C04.834.818
Xeroderma Pigmentosum	C04.834.867
<b>Pregnancy Complications, Neoplastic</b>	<b>C04.850</b>
Trophoblastic Neoplasms	C04.850.908
Gestational Trophoblastic Disease	C04.850.908.416
Choriocarcinoma	C04.850.908.416.186
Trophoblastic Tumor, Placental Site	C04.850.908.416.186.875
Hydatidiform Mole	C04.850.908.416.750
Hydatidiform Mole, Invasive	C04.850.908.416.750.500
<b>Tumor Virus Infections</b>	<b>C04.925</b>
Avian Leukosis	C04.925.120
Carcinoma, Merkel Cell	C04.925.216
Epstein-Barr Virus Infections	C04.925.313
Burkitt Lymphoma	C04.925.313.165
Marek Disease	C04.925.489
Sarcoma, Avian	C04.925.700
Warts	C04.925.744
Epidermodysplasia Verruciformis	C04.925.744.500

## Appendix to Chapter 4 - Screenshots from survey

### Introduction


Thank you for agreeing to take part in this research study which is conducted by Accent, on behalf of OHE (an economics research organisation). The purpose of the study is to find out how a change in Government support for medical research might affect your willingness to donate to medical research charities. The study is being funded by Cancer Research UK.

You will be asked to answer a series of questions involving hypothetical scenarios. There are no right or wrong (or better or worse) answers - we are simply seeking your views. You will also be asked some general questions about yourself and how you feel about giving to charity.

The results of the study will be written up in a report for Cancer Research UK, and may be published in academic journals and presented at conferences. You will not be identified in any reports or publications. The anonymised data collected during the course of the study may be used for additional or subsequent research and analysis.

This research is conducted under the terms of the MRS code of conduct and is completely confidential. If you would like to **confirm** Accent's credentials please call the MRS free on 0500 396999.

We will just ask you a couple of questions to check that you are eligible to take part in this research.





### Scoping questions

Are you:

Male

Female

Which of the following age groups do you fall into?

- Under 18
- 18-29
- 30-39
- 40-49
- 50-59
- 60 or over
- Do not wish to say



Please indicate to which occupational group the Chief Income Earner in your household belongs, or which group fits best.


This could be you: the Chief Income Earner is the person in your household with the largest income.

If the Chief Income Earner is **retired and has an occupational pension** please answer for their most recent occupation.

If the Chief Income Earner is **not in paid employment** but has been out of work for less than 6 months, please answer for their **most recent** occupation.

**PLEASE TICK ONLY ONE ANSWER**

- Semi or unskilled manual work.**  
(e.g. manual workers, all apprentices to be skilled trades, caretaker, park keeper, non-HGV driver, shop assistant)
- Skilled manual worker**  
(e.g. skilled bricklayer, carpenter, plumber, painter, bus/ ambulance driver, HGV driver, AA patrolman, pub/bar worker, etc)
- Supervisory or clerical/ junior managerial/ professional/ administrative**  
(e.g. office worker, student doctor, foreman with 25+ employees, salesperson, etc)
- Intermediate managerial/ professional/ administrative**  
(e.g. newly qualified (under 3 years) doctor, solicitor, board director in small organisation, middle manager in large organisation, principal officer in civil service/local government)
- Higher managerial/ professional/ administrative**  
(e.g. established doctor, solicitor, board director in a large organisation (200+ employees, top level civil servant/public service employee)
- Student
- Casual worker, not in permanent employment
- Housewife/Homemaker
- Retired and living on state pension
- Unemployed or not working due to long-term sickness
- Full-time carer of other household member



## Main Questionnaire

Thank you, I can confirm you are in scope for the survey. The questionnaire will take about 10 minutes to complete. You do not have to answer questions you do not wish to and you can terminate the interview at any point. For convenience you can stop and return to complete the questionnaire as many times as you wish, although once submitted you will not be able to enter again.



In the last year, to which of the following cancer research charities have you **given money**?

Please tick all that apply

- British Association for Cancer Research
- Cancer Research UK
- Children with Cancer UK
- Leukaemia & Lymphoma Research
- Marie Curie Cancer Care
- Ovarian Cancer Action
- Pancreatic Cancer Research Trust
- Prostate Cancer UK
- The Brain Tumour Charity
- Other, specify
- None of these



In the last year, to which of the following medical research charities have you **given money**?

Please tick all that apply

- Alzheimer's Research UK
- Arthritis Research UK
- British Heart Foundation
- Diabetes UK
- Motor Neurone Disease Association
- Parkinson's UK
- Scope
- Sense, the National Deafblind and Rubella Association
- The Multiple Sclerosis Society of Great Britain and Northern Ireland
- Other medical research charities (excluding cancer research charities), specify
- None of these




How much do you think the UK Government currently spends on medical research each year? Please note that we're interested in your best guess even if you don't know.

(in millions of pounds)



And, of the total amount that the UK Government is currently spending on medical research each year, what **percentage** do you think is spent on **cancer research**? Again, we're interested in your best guess.



Over the last three years, do you think that Government funding of **medical research**:

- Has been going up
- Has been going down
- Has remained about the same
- I don't know





And, over the last three years, do you think that Government funding of **cancer research**:

- Has been going up
- Has been going down
- Has remained about the same
- I don't know



## INTRO SCENARIOS

Now we would like you to imagine that you have the opportunity to allocate £100 of the income tax you pay this year to one or more medical research charities.

You could give none, some or all of the £100 to cancer research charities and the remainder (if any) to medical research charities (*of your choosing*) concerned with diseases other than cancer.

The following questions will ask you how you would distribute your £100 allocation under various scenarios.




How would you distribute your £100 allocation?

to cancer research charities

to non-cancer medical research charities

0




Having been given the opportunity to allocate £100 in this way, would you want to reduce or increase any personal donations that you currently make out of your own pocket to any **cancer research** charities?


Would *reduce* by £.... (type in)

Would *increase* by £.... (type in)

Would *not change*



Please consider the diagram below, which shows approximately how much the Government and charities currently spend on medical research in the UK each year.



In the light of that information, please consider again what you would do if you have the opportunity to allocate £100 of the income tax you pay this year to one or more medical research charities.



How would you distribute your £100 allocation?

to cancer research charities

to non-cancer medical research charities

0




Having been given the opportunity to allocate £100 in this way, would you want to reduce or increase any personal donations that you currently make out of your own pocket to any **cancer research** charities?

- Would *reduce* by £.... (type in)
- Would *increase* by £.... (type in)
- Would *not change*




Please consider the diagram below, which shows a scenario of what medical research spending in the UK might look like in the future. In this case, the Government has **reduced its spending on cancer research by £100 million** per year and is **spending that money instead on more research into diseases other than cancer**.



In the light of that information, please consider again what you would do if you have the opportunity to allocate £100 of the income tax you pay this year to one or more medical research charities.




Please consider the diagram below, which shows another scenario of what medical research spending might look like in the future. In this case, the Government has **reduced its spending on cancer research by £100 million** per year and is **NOT increasing its spending on any other area of medical research**, so total Government spending on medical research has been reduced by the same £100 million.



In the light of that information, please consider again what you would do if you have the opportunity to allocate £100 of the income tax you pay this year to one or more medical research charities.



Please consider the diagram below, which show another scenario of what medical research spending might look like in the future. In this case, the Government has **increased its spending on cancer research by £100 million** per year and has found that money by **reducing its spending on research into diseases other than cancer by £100 million**.



In the light of that information, please consider again what you would do if you have the opportunity to allocate £100 of the income tax you pay this year to one or more medical research charities.



If you have any comments that you would like to make about your answers to the previous questions, please enter them in the box below.

**WRITE IN:**

No comment



Which of the following statements best reflects your personal view?

- I would be **more likely** to donate to a cancer research charity, or to donate even more than I already do, if I were to hear that the Government has **reduced** its spending on cancer research
- I would be **less likely** to donate to a cancer research charity, or to donate less than I already do, if I were to hear that the Government has **reduced** its spending on cancer research
- Government spending decisions make **no difference** to my decision about whether or not to donate to a cancer research charity



Which of the following types of charity donation have you made in the last year? We are interested in your donations to **any** kind of charity, medical or otherwise. Please tick all boxes that apply.

Please tick all that apply

- Money - regular donation
- Money - one-off donation
- Money - other (charity events, auctions, etc.)
- Non-financial - e.g. donation of unwanted goods, volunteering
- None of the above



Over the last three years, has the level of your charity donation(s) been going up or going down, or has it remained about the same?

- Going up
- Going down
- About the same



Do you have personal experience of cancer or have a close friend or family member who has had cancer?

Please tick all that apply

- Yes, self
- Yes, friend or relative
- No
- I would rather not answer this question





We really appreciate the time that you have given us today. Would you be willing to be contacted again for clarification purposes or be invited to take part in other research for Office of Health Economics or Cancer Research UK?

- Yes, for both clarification and further research
- Yes, for clarification only
- Yes, for further research only
- No



## End of Survey

THANK YOU FOR YOUR HELP IN THIS RESEARCH

This research was conducted under the terms of the UK Market Research Society code of conduct and is completely confidential.

